U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 10-K
_____________________
(Mark One)
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the Fiscal Year Ended December 31, 2001
or
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Period From to |
Commission File Number: 000-32499
________________________
SELECT MEDICAL CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware | 23-2872718 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. employer identification number) |
4716 Old Gettysburg Road
P.O. Box 2034
Mechanicsburg, Pennsylvania 17055
(Address of principal executive offices and zip code)
(717) 972-1100
(Registrants telephone number, including area code)
_____________________
Securities registered pursuant to Section 12(b) of the Act: None
_____________________
Securities registered pursuant to Section 12(g) of the Act: Common Stock, par value $.01 per share
_____________________
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES X NO YES X NO
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. X
The aggregate market value of the registrants voting common stock held by non-affiliates, based on the closing sale price of $12.66 per share as reported on The Nasdaq National Market on February 28, 2002 was $252,259,261.
As of February 28, 2002, the number of outstanding shares of the Registrants Common Stock was 46,140,304.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of Registrants Proxy Statement to be filed with the Securities and Exchange Commission for the Registrants 2002 Annual Meeting are incorporated by reference into Part III.
SELECT MEDICAL CORPORATION
ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2001
INDEX
PART I | ||||
ITEM 1. | BUSINESS | 1 | ||
ITEM 2. | PROPERTIES | 20 | ||
ITEM 3. | LEGAL PROCEEDINGS | 20 | ||
ITEM 4. | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS | 21 | ||
PART II | ||||
ITEM 5. | MARKET FOR REGISTRANTS COMMON EQUITY AND RELATED STOCKHOLDER MATTERS | 21 | ||
ITEM 6. | SELECTED CONSOLIDATED FINANCIAL DATA | 22 | ||
ITEM 7. | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 25 | ||
ITEM 7A |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK |
38 | ||
ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 39 | ||
ITEM 9. |
CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE |
39 | ||
PART III | ||||
ITEM 10. | DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT | 39 | ||
ITEM 11. | EXECUTIVE COMPENSATION | 39 | ||
ITEM 12. |
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT |
39 | ||
ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS | 39 | ||
PART IV | ||||
ITEM 14. |
EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON
FORM 8-K |
40 |
PART I
Forward-Looking Statements
This discussion contains forward-looking statements relating to the financial condition, results of operations, plans, objectives, future performance and business of Select Medical Corporation. These statements include, without limitation, statements preceded by, followed by or that include the words believes, expects, anticipates, estimates or similar expressions. These forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements due to factors including the following:
| general economic, demographic and business conditions, both nationally and in regions where we operate; | ||
| the effect of existing or future governmental regulation and federal and state legislative and enforcement initiatives on our business including the Balanced Budget Act of 1997; | ||
| a change in government reimbursement for our services that would affect our revenue; | ||
| the failure of our long-term acute care hospitals to maintain their status as such, which could negatively impact our profitability; | ||
| private third party payors of our services may undertake cost containment initiatives that would decrease our revenue; | ||
| shortages in qualified nurses could increase our operating costs significantly; | ||
| future acquisitions may use significant resources and expose us to unforeseen risks; and | ||
| the effect of liability and other claims asserted against us. |
For a discussion of these and other factors affecting our business, see the section captioned Risk Factors under Item 1. Business.
ITEM 1. BUSINESS
Overview
We are the largest operator of specialty acute care hospitals for long term stay patients in the United States based on the number of facilities. We are also the second largest operator of outpatient rehabilitation clinics in the United States based on the number of clinics. As of December 31, 2001, we operated 64 specialty acute care hospitals in 22 states and 717 outpatient rehabilitation clinics in 31 states, the District of Columbia and seven Canadian provinces. We began operations in 1997 under the leadership of our current management team, including our co-founders, Rocco A. Ortenzio and Robert A. Ortenzio, both of whom have significant experience in the healthcare industry. Under this leadership, we have grown our business through strategic acquisitions and internal development initiatives. For the year ended December 31, 2001, we had net operating revenues of $959.0 million and EBITDA (defined as net income (loss) before interest, income taxes, depreciation and amortization and special charges, other income, minority interest, and extraordinary items) of $112.0 million. In 2001, we earned 54% of our net operating revenues from our specialty acute care hospitals and 46% from our outpatient rehabilitation business. In April 2001, we completed a $98.3 million initial public offering of our common stock, and in June 2001 we completed a $175 million offering of 9 1/2% senior subordinated notes.
Specialty Acute Care Hospitals
As of December 31, 2001, we operated 64 specialty acute care hospitals, 56 of which were certified by the federal Medicare program as long term acute care hospitals. The remaining eight hospitals are in the process of becoming certified as long term acute care hospitals.
1
These hospitals generally have 30 to 40 beds, and as of December 31, 2001, we operated a total of 2,307 available licensed beds. Our specialty acute care hospitals employ approximately 7,000 people, with the majority being registered or licensed nurses and respiratory therapists. In these specialty hospitals we treat patients with serious and often complex medical conditions such as respiratory failure, neuromuscular disorders, cardiac disorders, non-healing wounds, renal disorders and cancer.
Patients are admitted to our specialty acute care hospitals from general acute care hospitals in our markets. These general acute care hospitals are frequently not the optimum setting in which to treat these patients, because they require longer stays and a higher level of clinical attention than the typical acute care patient. Furthermore, general acute care hospitals reimbursement rates usually do not adequately compensate them for the treatment of this type of patient. The differences in clinical expertise and reimbursement rates provide general acute care hospitals and their physicians with incentives to discharge longer stay, medically complex patients to our facilities. As a result of these dynamics, we continually seek to increase our admissions by expanding and improving our relationships with the physicians and general acute care hospitals in our markets that refer patients to our facilities.
Below is a table that shows the distribution by medical condition of
patients in our hospitals for the year ended December 31, 2001.
Distribution
Medical Condition
of Patients
30
%
26
12
10
5
3
14
100
%
When a patient is referred to one of our hospitals by a physician, case manager, health maintenance organization or insurance company, a nurse liaison makes an assessment to determine the degree of care required and expected length of stay. This initial patient assessment is critical to our ability to provide the appropriate level of patient care. Based on the determinations reached in this clinical assessment, an admission decision is made by the attending physician.
Upon admission, an interdisciplinary team reviews a new patients condition. The interdisciplinary team comprises a number of clinicians, including the attending physician, a specialty nurse, a dietician, a pharmacist and a case manager. Upon completion of an initial evaluation by each member of the treatment team, an individualized treatment plan is established and implemented. The case manager coordinates all aspects of the patients hospital stay and serves as a liaison with the insurance carriers case management staff when appropriate. The case manager communicates progress, resource utilization, and treatment goals between the patient, the treatment team and the payor.
Each of our specialty hospitals has an onsite management team consisting of a chief executive officer, a director of clinical services and a director of provider relations. These teams manage local strategy and day-to-day operations, including oversight of per patient costs and average length of stay. They also assume primary responsibility for developing relationships with the general acute care providers and clinicians in our markets that refer patients to our specialty hospitals. We provide our hospitals with centralized accounting, payroll, legal, reimbursement, human resources, compliance, management information systems, billing and collecting services. The centralization of these services improves efficiency and permits hospital staff to spend more time on patient care.
2
Hospital within a Hospital Model
Of the 64 specialty hospitals we operated as of December 31, 2001, two are freestanding facilities and 62 are located in leased space within a host general acute care hospital. These leased spaces are separately licensed hospitals and are commonly referred to as a hospital within a hospital. As of December 31, 2001, we operated the largest number of specialty acute care hospitals operating with this hospital within a hospital model in the United States. We believe this model provides several advantages to patients, host hospitals, physicians and us.
| The host hospitals patients benefit from being admitted to a setting specialized to meet their unique medical needs without having the disruption of being transferred to another location. | ||
| In addition to being provided with a place to transfer high-cost, long-stay patients, host hospitals benefit by receiving payments from us for rent and ancillary services. | ||
| Physicians affiliated with the host hospital are provided with the convenience of being able to monitor the progress of their patients without traveling to another location. | ||
| We benefit from the ability to operate specialty hospitals without the capital investment often associated with buying or building a freestanding facility. We also gain operating cost efficiencies by contracting with these host hospitals for selected services at discounted rates. |
In addition, our specialty hospitals serve the broader community where they operate, treating patients from other general acute care hospitals in the local market. During the year ended December 31, 2001, 51% of the patients in our hospital within a hospital facilities were referred to us from general acute care hospitals other than the host hospitals.
Specialty Acute Care Hospital Strategy
Provide High Quality and Cost Effective Care
We believe that our patients benefit from our experience in addressing the complex medical needs of long term stay patients. A typical patient admitted to our specialty hospitals has multiple medical conditions and requires a high level of attention by our clinical staff. To effectively address the complex nature of our patients medical conditions, we have developed specialized treatment programs focused solely on their needs. We have also implemented specific staffing models that are designed to ensure that patients have access to the necessary level of clinical attention. These staffing models also allow us to allocate our resources efficiently, which reduces costs.
Our treatment and staffing programs benefit patients because they give our clinicians access to the regimens that we have found to be most effective in treating various conditions such as respiratory failure, non-healing wounds and neuromuscular disorders. In addition, we combine or modify these programs to provide a treatment plan tailored to meet a patients unique needs.
We continually monitor the quality of our patient care by several measures, including patient, payor and physician satisfaction, as well as clinical outcomes. Quality measures are collected monthly and reported quarterly and annually. In order to benchmark ourselves against other healthcare organizations, we have contracted with outside vendors to collect our clinical and patient satisfaction information and compare it to other healthcare organizations. The information collected is reported back to each hospital, to the corporate office, and directly to the Joint Commission on Accreditation of Healthcare Organizations. As of December 31, 2001, all but seven of our most recently opened hospitals had been accredited by the Joint Commission on Accreditation of Healthcare Organizations. See Government RegulationsLicensureAccreditation.
3
Reduce Costs
We continually seek to improve operating efficiency and reduce costs at our hospitals by standardizing operations and centralizing key administrative functions. These initiatives include:
| optimizing staffing based on our occupancy and the clinical needs of our patients; | ||
| centralizing administrative functions such as accounting, payroll, legal, reimbursement, compliance and human resources; | ||
| standardizing management information systems to aid in financial reporting as well as billing and collecting; and | ||
| participating in group purchasing arrangements to receive discounted prices for pharmaceuticals and medical supplies. |
Increase Higher Margin Commercial Volume
We typically receive higher reimbursement rates from commercial insurers than we do from the federal Medicare program. As a result, we work to expand relationships with insurers to increase commercial patient volume. Each of our hospitals has employees who focus on commercial contracting initiatives within their regions. Contracting professionals in our central office work with these hospital employees to ensure that our corporate contracting standards are met. Our goal in commercial contracting is to give discounted rates to those commercial payors that we expect to add significant patient volume to our hospitals.
We believe that commercial payors seek to contract with our hospitals because we offer patients quality, cost effective care. Although the level of care we provide is complex and staff intensive, we typically have lower operating expenses than a freestanding general acute care facilitys intensive care unit because of our hospital within a hospital operating model. General acute care hospitals incur substantial overhead costs in order to provide a wide array of patient services. We provide a much narrower range of patient services, and our hospitals within a hospital lease underutilized space within a general acute care hospital. These factors permit our hospitals to operate with lower overhead costs per patient than general acute care hospitals can. As a result of these lower costs, we offer more attractive rates to commercial payors. Additionally, we provide their enrollees with customized treatment programs not offered in traditional acute care facilities.
Develop New Specialty Acute Care Hospitals
Our goal is to open eight to ten new specialty acute care hospitals each year using our hospital within a hospital model. We seek to lease space from general acute care hospitals with leadership positions in the markets in which they operate. We have successfully contracted with various types of general hospitals, including for-profit, not-for-profit and university affiliated.
We have a dedicated development team with significant market experience. When we target a host hospital, the development team conducts an extensive review of all of its discharges to determine the number of referrals we would have likely received from it on a historical basis. Next, we review the host hospitals contracts with commercial insurers to determine the markets general reimbursement trends and payor mix. Ultimately, when we sign a lease with a new host hospital, the project is transitioned to our start-up team, which is experienced in preparing a specialty hospital for opening. The start-up team oversees facility improvements, equipment purchases, licensure procedures, and the recruitment of a full-time management team. After the facility is opened, responsibility for its management is transitioned to this new management team and our corporate operations group.
4
During 1999, 2000 and 2001, we had completed the development and opening
of the following 26 specialty acute care hospitals:
Hospital Name
City
State
Opening Date
Licensed Beds
SSH-Wilmington
Wilmington
DE
January 1999
35
SSH-Milwaukee
Milwaukee
WI
March 1999
34
SSH-Youngstown
Youngstown
OH
April 1999
31
SSH-Mesa
Mesa
AZ
September 1999
37
SSH-Battle Creek
Battle Creek
MI
October 1999
32
SSH-Omaha
Omaha
NE
October 1999
40
SSH-Gulfport
Gulfport
MS
January 2000
38
SSH-Denver
Denver
CO
February 2000
32
SSH-Tri-Cities
Bristol
TN
March 2000
25
SSH-St. Louis
St. Louis
MO
April 2000
33
SSH-Wichita
Wichita
KS
June 2000
35
SSH-San Antonio
San Antonio
TX
July 2000
34
SSH-Greensburg
Greensburg
PA
August 2000
31
SSH-Erie
Erie
PA
October 2000
35
SSH-North Dallas
Dallas
TX
November 2000
11
SSH-Fort Smith
Fort Smith
AR
December 2000
34
SSH-Birmingham
Birmingham
AL
February 2001
38
SSH-Jefferson Parish
New Orleans
LA
February 2001
34
SSH-Pontiac*
Pontiac
MI
June 2001
30
SSH-Camp Hill*
Camp Hill
PA
June 2001
31
SSH-Wyandotte*
Wyandotte
MI
September 2001
35
SSH-Charleston*
Charleston
WV
December 2001
32
SSH-Northwest Detroit*
Detroit
MI
December 2001
36
SSH-Scottsdale*
Scottsdale
AZ
December 2001
29
SSH-Bloomington*
Bloomington
IN
December 2001
30
SSH-Phoenix-Downtown*
Phoenix
AZ
December 2001
33
Total
845
* | As of December 31, 2001, certification as a long term acute care hospital pending, subject to successful completion of a start-up period and/or surveys by the applicable licensure or certifying agencies. See Governmental RegulationsLicensureCertification. |
Grow Through Acquisitions
In addition to our development initiatives, we intend to grow our network of specialty hospitals through strategic acquisitions. When we acquire a hospital or a group of hospitals, a team of our professionals is responsible for formulating and executing an integration plan. We have generally been able to increase margins at acquired facilities by centralizing administrative functions and implementing our standardized staffing models and resource management programs. Since our inception in 1997 we have acquired and integrated 37 hospitals which all share our centralized billing and purchasing programs and operate standardized management information systems.
Outpatient Rehabilitation
We are the second largest operator of outpatient rehabilitation clinics in the United States, based on the number of our clinics. As of December 31, 2001, we operated 622 clinics throughout 31 states and the District of Columbia and 95 clinics in seven provinces throughout Canada. Our outpatient rehabilitation division employs approximately 8,500 people. Typically, each of our clinics is located in a freestanding facility in a highly visible medical complex or retail location. In addition to providing therapy in our outpatient clinics, we provide rehabilitation management services and staffing on a contract basis to hospitals, schools, nursing facilities and home health agencies.
5
In our clinics and through our contractual relationships, we provide physical, occupational and speech rehabilitation programs and services. Our patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living. These impairments are often associated with accidents, sports injuries, strokes, heart attacks and other medical conditions. Our rehabilitation programs and services are designed to help these patients minimize physical and cognitive impairments and maximize functional ability. We also design services to prevent short-term disabilities from becoming chronic conditions. Our rehabilitation services are provided by our professionals including licensed physical therapists, occupational therapists, certified athletic trainers, psychiatrists, speech-language pathologists, respiratory therapists, exercise physiologists and physical rehabilitation counselors.
Outpatient rehabilitation patients are generally referred or directed to our clinics by a physician, employer or health insurer who believes that a patient, employee or member can benefit from the level of therapy we provide in an outpatient setting. We believe that our services are attractive to healthcare payors who are seeking to provide the most cost-effective level of care to their members. In our outpatient rehabilitation division, approximately 91% of our net operating revenues come from rehabilitation management services and commercial payors, including healthcare insurers, managed care organizations and workers compensation programs. The balance of our reimbursement is derived from Medicare and other government sponsored programs.
We have grown our outpatient rehabilitation business through acquisitions and new development. Our most significant outpatient acquisition was the purchase of the Physical Rehabilitation and Occupational Health Division of NovaCare, Inc. in November of 1999 through which we added approximately 500 outpatient rehabilitation clinics.
Outpatient Strategy
Increase Market Share
Our goal is to be a leading provider of outpatient rehabilitation services in our local markets. Having a strong market share in our local markets allows us to benefit from heightened brand awareness, economies of scale and increased leverage when negotiating payor contracts. To increase our market share, we seek to expand the services and programs we provide and generate loyalty with patients and referral sources by providing high quality care and strong customer service.
| Expand Rehabilitation Programs and Services. We assess the healthcare needs of our markets and implement programs and services targeted to meet the demands of the local community. In designing these programs we benefit from the knowledge we gain through our national network of clinics. This knowledge is used to design programs that optimize treatment methods and measure changes in health status, clinical outcomes and patient satisfaction. Our programs and services include, among others, back care and rehabilitation; work injury management and prevention; sports rehabilitation and athletic training; and health, safety and prevention programs. Other services that vary by location include aquatic therapy, speech therapy, neurological rehabilitation and post-treatment care. | ||
| Provide High Quality Care and Service. We believe that by focusing on quality care and offering a high level of customer service we develop brand loyalty in our markets. This loyalty allows us to retain patients and strengthen our relationships with the physicians, employers, and health insurers in our markets who refer or direct additional patients to us. We are focused on providing a high level of service to our patients throughout their entire course of treatment. To measure satisfaction with our service we have developed surveys for both patients and physicians. Our clinics utilize the feedback from these surveys to continuously refine and improve service levels. |
6
Optimize the Profitability of Our Payor Contracts
Before we enter into a new contract with a commercial payor, we evaluate it with the aid of our contract management system. We assess potential profitability by evaluating past and projected patient volume, clinic capacity, and expense trends. Each contract we enter into is continually re-evaluated to determine how it is affecting our profitability. We create a retention strategy for each of the top performing contracts and a re-negotiation strategy for contracts that do not meet our defined criteria.
Grow Through New Development and Disciplined Acquisitions
We intend to open new clinics in our current markets where we believe that we can benefit from existing referral relationships and brand awareness to produce incremental growth. From time to time, we also intend to also evaluate acquisition opportunities that may enhance the scale of our business and expand our geographic reach. Potential acquisitions are closely evaluated and we seek to buy only those assets that are complementary to our business and that are expected to give us a strong return on our invested capital.
Maintain Strong Employee Relations
We believe that the relationships between our employees and the referral
sources in their communities are critical to our success. Our referral
sources, such as physicians and healthcare case managers, send their patients
to our clinics based on three factors: the quality of our care, the service we
provide and their familiarity with our therapists. We seek to retain and
motivate our therapists by implementing a performance-based bonus program, a
defined career path with the ability to be promoted from within, timely
communication on company developments, and internal training programs. We also
focus on empowering our employees by giving them a high degree of autonomy in
determining local market strategy. This management approach reflects the
unique nature of each market in which we operate and the importance of
encouraging our employees to assume responsibility for their clinics
performance.
Sources of Net Operating Revenues
The following table presents the approximate percentages by source of net
operating revenue received for healthcare services we provided for the periods
indicated.
Year ended December 31,
Net Operating Revenues by Payor Source
2001
2000
1999
51.4
%
51.2
%
34.6
%
37.3
35.1
48.1
10.2
12.4
15.7
1.1
1.3
1.6
100.0
%
100.0
%
100.0
%
(a) | Includes commercial healthcare insurance carriers, health maintenance organizations, preferred provider organizations, workers compensation and managed care programs. | |
(b) | Includes self payors, Canadian revenues, contract management services and non-patient related payments. |
Non-Government Sources
A majority of our net operating revenues come from private payor sources. These sources include insurance companies, workers compensation programs, health maintenance organizations, preferred provider organizations, other managed care companies, and employers, as well as by patients
7
directly. Patients are generally not responsible for any difference between customary charges for our services and amounts paid by Medicare and Medicaid programs, insurance companies, workers compensation companies, health maintenance organizations, preferred provider organizations, and other managed care companies, but are responsible for services not covered by these programs or plans, as well as for deductibles and co-insurance obligations of their coverage. The amount of these deductibles and co-insurance obligations has increased in recent years. Collection of amounts due from individuals is typically more difficult than collection of amounts due from government or business payors. To further reduce their healthcare costs, an increasing number of insurance companies, health maintenance organizations, preferred provider organizations, and other managed care companies are negotiating discounted fee structures or fixed amounts for hospital services performed, rather than paying healthcare providers the amounts billed. If an increased number of insurance companies, health maintenance organizations, preferred provider organizations, and other managed care companies succeed in negotiating discounted fee structures or fixed amounts, our results of operations may be negatively affected.
Government Sources
Medicare is a federal program that provides medical insurance benefits to persons age 65 and over, some disabled persons, and persons with end-stage renal disease. Medicaid is a federal-state funded program, administered by the states, which provides medical benefits to individuals who are unable to afford healthcare. All of our hospitals are certified as providers of Medicare, and our outpatient rehabilitation clinics regularly receive Medicare payments for their services. Additionally, our specialty hospitals participate in six state Medicaid programs. Amounts received under the Medicare and Medicaid programs are generally less than the customary charges for the services provided. In recent years, changes made to the Medicare and Medicaid programs have further reduced payment to healthcare providers. Since an important portion of our revenues comes from patients under the Medicare program, our ability to operate our business successfully in the future will depend in large measure on our ability to adapt to changes in the Medicare program. See Government RegulationsOverview of U.S. and State Government Reimbursements.
Government Regulations
General
The healthcare industry is required to comply with many laws and regulations at the federal, state and local government levels. These laws and regulations require that hospitals and outpatient rehabilitation clinics meet various requirements, including those relating to the adequacy of medical care, equipment, personnel, operating policies and procedures, maintenance of adequate records, compliance with building codes and environmental protection. These laws and regulations are extremely complex and, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. If we fail to comply with applicable laws and regulations, we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in the Medicare, Medicaid and other federal and state healthcare programs.
Licensure
Facility Licensure . Our healthcare facilities are subject to state and local licensing regulations ranging from the adequacy of medical care to compliance with building codes and environmental protection laws. In order to assure continued compliance with these various regulations, governmental and other authorities periodically inspect our facilities.
Some states still require us to get approval under certificate of need regulations when we create, acquire or expand our facilities or services. If we fail to show public need and obtain approval in these states for our facilities, we may be subject to civil or even criminal penalties, lose our facility license or
8
become ineligible for reimbursement if we proceed with our creation or acquisition of the new facility or service.
Professional Licensure and Corporate Practice. Healthcare professionals at our hospitals and outpatient rehabilitation clinics are required to be individually licensed or certified under applicable state law. We take steps to ensure that our employees and agents possess all necessary licenses and certifications.
In some states, business corporations such as ours are restricted from practicing therapy through the direct employment of therapists. In those states, in order to comply with the restrictions imposed, we either contract to obtain therapy services from an entity permitted to employ therapists, or we manage the physical therapy practice owned by licensed therapists through which the therapy services are provided.
Certification. In order to participate in the Medicare program and receive Medicare reimbursement, each facility must comply with the applicable regulations of the United States Department of Health and Human Services relating to, among other things, the type of facility, its equipment, its personnel and its standards of medical care, as well as compliance with all applicable state and local laws and regulations. All of our hospitals participate in the Medicare program. In addition, we provide the majority of our outpatient rehabilitation services through clinics certified by Medicare as rehabilitation agencies or rehab agencies.
Accreditation. Our hospitals receive accreditation from the Joint Commission on Accreditation of Healthcare Organizations, a nationwide commission which establishes standards relating to the physical plant, administration, quality of patient care and operation of medical staffs of hospitals. As of December 31, 2001, all but seven of our most recently opened hospitals had been accredited by the Joint Commission on Accreditation of Healthcare Organizations. Typically, we wait until our hospitals have been in operation for at least six months before applying for accreditation.
Overview of U.S. and State Government Reimbursements
Medicare. The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services and the Centers for Medicare & Medicaid Services. For the year ended December 31, 2001, we received approximately 37.3% of our revenue from Medicare.
Long Term Acute Care Hospital Medicare Reimbursement. Our long-term acute care hospitals receive cost reimbursement, subject to a maximum cap. In contrast, Medicare inpatient costs for short-term acute care hospitals are reimbursed based upon a fixed payment amount per discharge using diagnosis related groups, commonly referred to as DRGs. The DRG payment under a prospective payment system is based upon the national average cost of treating a Medicare patients condition. Although the average length of stay varies for each DRG, the average stay for all Medicare patients subject to prospective payment system is approximately six days. Thus, a prospective payment system creates an economic incentive for general short-term acute care hospitals to discharge medically complex Medicare patients as soon as clinically possible. We believe that the incentive for short-term acute care hospitals to discharge medically complex patients as soon as clinically possible creates a substantial referral source for our long term acute care hospitals.
Prior to qualifying as an exempt long-term acute care hospital, a new long-term acute care hospital initially receives payment under the acute care DRG-based reimbursement system. The long-term acute care hospital must continue to be paid DRGs for a minimum of six months while meeting
9
certain Medicare long-term acute care hospital requirements, the most significant requirement being an average length of stay of more than 25 days. A hospital within a hospital facility must also establish itself as a hospital separate from its host by, among other things, obtaining separate licensure and certification, and limiting the services it purchases directly from its host to 15% of its total operating costs, or limiting the number of patient admissions from its host to 25% of total admissions.
Once the hospital qualifies for exempt status, long-term acute care hospitals currently are paid on the basis of Medicare reasonable costs per case subject to limits. Under cost-based reimbursement, costs accepted for reimbursement depend on a number of factors, including necessity, reasonableness, related-party principles and relatedness to patient care. Qualifying costs under Medicares cost-reimbursement system typically include all operating costs and also capital costs that include interest expense, depreciation, amortization, and rental expense. Non-qualifying costs include marketing costs.
The cost reimbursement received by a long-term acute care hospital is subject to per-discharge payment limits. During a long-term acute care hospitals initial operations, Medicare payment is capped at the average national target rate established by the Tax Equity and Fiscal Responsibility Act of 1982, commonly known as TEFRA. After the second year of operations, payment is subject to a target amount based on the lesser of the hospitals cost-per-discharge or the national ceiling in the applicable base year. Legislation enacted in December 2000, the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000, increases the target amount by 25 percent and the national ceiling by 2 percent for cost reporting periods beginning after October 1, 2000.
Congress has required the Secretary of the Department Health and Human Services to submit to Congress by October 1, 1999 a proposal to establish a prospective payment system for long-term acute care hospitals. This requirement was later extended until October 1, 2001, but no proposal has yet been submitted. Current law provides that a prospective payment system is to be effective for cost reporting periods beginning on or after October 1, 2002. When developing the prospective payment system, the December 2000 legislation requires the Secretary to examine the feasibility and impact of basing payment on the existing (or refined) short term acute hospital DRGs and the most recently available hospital discharge data. The Secretary is required to implement a prospective payment system using the existing short term acute hospital DRGs that have been modified where feasible, unless a different prospective payment system is implemented by October 1, 2002.
Outpatient Rehabilitation Services Medicare Reimbursement. We provide the majority of our outpatient rehabilitation services in our rehabilitation clinics. Through our contract services agreements, we also provide outpatient rehabilitation services in the following settings:
| schools; | ||
| physician-directed clinics; | ||
| hospitals; and | ||
| skilled nursing facilities. |
Essentially, all of our outpatient rehabilitation services are provided in rehabilitation agencies and are not provided through rehabilitation hospitals.
Prior to January 1, 1999, outpatient physical therapy, occupational therapy, and speech-language pathology services, which we refer to as outpatient therapy services, were reimbursed on the basis of the lower of 90% of reasonable costs or actual charges. Beginning January 1, 1999, outpatient rehabilitation services were reimbursed on a fee schedule, subject to annual limits. These outpatient rehabilitation providers receive a fixed fee for each procedure performed, which is adjusted by the geographical area in which the facility is located.
10
In November 1999, the Balanced Budget Refinement Act provided some relief to providers by unbundling speech-language pathology services from other outpatient rehabilitation services. The following lists the current annual limits per Medicare beneficiary by services offered:
| $1,500 for outpatient physical therapy services, | ||
| $1,500 for speech-language pathology services, and | ||
| $1,500 for outpatient occupational health services. |
A moratorium has since been placed on these limits for the years 2000 through 2002 pending a review by the Secretary of the Department of Health and Human Services of the clinical needs of these patients and the appropriate level of limitations.
The Secretary of the U.S. Department of Health and Human Services is required to report the results of this review to Congress, together with any relevant legislative recommendations, potentially including revised coverage policies as an alternative to the therapy caps. The Secretary is also required to study therapy utilization patterns and report the findings to Congress. The December 2000 legislation also requires the Secretary to study the implications of eliminating the in the room supervision requirement for Medicare payment for physical therapy assistants who are supervised by physical therapists and the implications of this requirement on the physical therapy cap.
Historically, outpatient rehabilitation services have been subject to scrutiny by the Medicare program for, among other things, medical necessity for services, appropriate documentation for services, billing for group therapy, and Medicare billing practices by skilled nursing facilities. In addition, payment for rehabilitation services furnished to patients of skilled nursing facilities has been affected by the establishment of a Medicare prospective payment system and consolidated billing requirement for skilled nursing facilities. The resulting pressure on skilled nursing facilities to reduce their costs by negotiating lower payments to therapy providers, such as our contract therapy services, and the inability of the therapy providers to bill the Medicare program directly for their services have tended to reduce the amounts that rehabilitation providers can receive for services furnished to many skilled nursing facility residents.
Long Term Acute Care Hospital Medicaid Reimbursement. The Medicaid program is designed to provide medical assistance to individuals unable to afford care. The program is governed by the Social Security Act of 1965 and administered and funded jointly by each individual state government and the Centers for Medicare & Medicaid Services. Most state Medicaid payments are made under a prospective payment system or under programs that negotiate payment levels with individual hospitals. In addition, Medicaid programs are subject to statutory and regulatory changes, administrative rulings, interpretations of policy by the state agencies and certain government funding limitations, all of which may materially increase or decrease the level of program payments to our hospitals. Medicaid payments accounted for about 1.7% of our long term acute care net operating revenues for the year ended December 31, 2001.
Workers Compensation. Workers compensation programs accounted for approximately 18.5% of our revenue from outpatient rehabilitation services for the year ended December 31, 2001. Workers compensation is a state-mandated, comprehensive insurance program that requires employers to fund or insure medical expenses, lost wages and other costs resulting from work-related injuries and illnesses. Workers compensation benefits and arrangements vary on a state-by-state basis and are often highly complex. In some states, payment for services covered by workers compensation programs are subject to cost containment features, such as requirements that all workers compensation injuries be treated through a managed care program, or the imposition of payment caps. In addition, these workers compensation programs may impose requirements that affect the operations of our outpatient rehabilitation services.
11
Canadian Reimbursement
The Canada Health Act governs the Canadian healthcare system, and provides for federal funding to be transferred to provincial health systems. Our Canadian outpatient rehabilitation clinics receive funding primarily through workers compensation benefits, which are administered by provincial workers compensation boards. The workers compensation boards assess employers fees based on their industry and past claims history. These fees are then distributed independently by each provincial workers compensation board as payments for healthcare services. Therefore, the payments each of our rehabilitation clinics receive for similar services can vary substantially because of the different payment regulations in each province. For the year ended December 31, 2001, we derived about 3.9% of our total net operating revenues from our operations in Canada.
Other Healthcare Regulations
Fraud and Abuse Enforcement. Various federal laws prohibit the submission of false or fraudulent claims, including claims to obtain payment under Medicare, Medicaid and other government healthcare programs. Penalties for violation of these laws include civil and criminal fines, imprisonment and exclusion from participation in federal and state healthcare programs. In recent years, federal and state government agencies have increased the level of enforcement resources and activities targeted at the healthcare industry. In addition, the federal False Claims Act allows an individual to bring lawsuits on behalf of the government, in what are known as qui tam or whistleblower actions, alleging false or fraudulent Medicare or Medicaid claims or other violations of the statute. The use of these private enforcement actions against healthcare providers has increased dramatically in the recent past, in part because the individual filing the initial complaint is entitled to share in a portion of any settlement or judgment.
From time to time, various federal and state agencies, such as the Department of Health and Human Services, issue a variety of pronouncements, including fraud alerts, the Office of Inspector Generals Annual Work Plan and other reports, identifying practices that may be subject to heightened scrutiny. These pronouncements can identify issues relating to long-term acute care hospitals or outpatient rehabilitation services or providers. For example, the Office of Inspector Generals 2002 Work Plan describes the governments intention to study providers use of satellite units and the hospital within a hospital model for furnishing long term acute care hospital services and the effectiveness of the Centers for Medicare & Medicaid Services payment safeguards relating to such services. We monitor these issuances to ensure that our resources are focused on compliance with areas targeted for enforcement.
We endeavor to conduct our operations in compliance with applicable laws, including healthcare fraud and abuse laws. If we identify any practices as being potentially contrary to applicable law, we will take appropriate action to address the matter, including, where appropriate, disclosure to the proper authorities.
Remuneration, Fraud and Anti-dumping Measures. The federal anti-kickback statute prohibits some business practices and relationships under Medicare, Medicaid and other federal healthcare programs. These practices include the payment, receipt, offer or solicitation of money in connection with the referral of patients covered by a federal or state healthcare program. Violations of the anti-kickback law may be punished by a criminal fine of up to $50,000 or imprisonment for each violation, civil monetary penalties of $50,000 and damages of up to three times the total amount of remuneration, and exclusion from participation in federal or state health care programs.
Section 1877 of the Social Security Act, commonly known as the Stark Law, prohibits referrals for designated health services by physicians under the Medicare and Medicaid programs to other healthcare providers in which the physicians have an ownership or compensation arrangement unless an exception applies. Sanctions for violating the Stark Law include civil monetary penalties of up
12
to $15,000 per prohibited service provided, assessments equal to twice the dollar value of each such service provided and exclusion from the Medicare and Medicaid programs. The statute also provides a penalty of up to $100,000 for a circumvention scheme. In addition, many states have adopted or may adopt similar anti-kickback or anti-self-referral statutes. Some of these statutes prohibit the payment or receipt of remuneration for the referral of patients, regardless of the source of the payment for the care.
Medicare-participating hospitals are also subject to the Emergency Medical Treatment and Active Labor Act, an anti-dumping statute commonly referred to as EMTALA. If a patient with an emergency condition enters a hospital with an emergency department, this federal law requires the hospital to stabilize a patient suffering from this emergency condition or make an appropriate transfer of the patient to a facility that can handle the condition. There are severe penalties under EMTALA if a hospital refuses to screen or appropriately stabilize or transfer a patient or if the hospital delays appropriate treatment in order to first inquire about the patients ability to pay. Although none of our hospitals operate emergency departments, the government has interpreted EMTALA broadly to cover situations in which any type of hospital inpatient is transferred in an unstable condition.
Provider-based Status. The designation provider-based refers to circumstances in which a subordinate facility ( e.g. , a separately-certified Medicare provider, a department of a provider or a satellite facility) is treated as part of a provider for Medicare payment purposes. In these cases, the services of the subordinate facility are included on the main providers cost report and overhead costs of the main provider can be allocated to the subordinate facility, to the extent that they are shared. We operate seven long term acute care hospitals that are treated as provider-based satellites of certain of our other facilities, and we provide rehabilitation management and staffing services to hospital rehabilitation departments that may be treated as provider-based.
Health Information Practices. In addition to broadening the scope of the fraud and abuse laws, the Health Insurance Portability and Accountability Act also mandates, among other things, the adoption of standards for the exchange of electronic health information in an effort to encourage overall administrative simplification and enhance the effectiveness and efficiency of the healthcare industry. Among the standards that the Department of Health and Human Services will adopt pursuant to the Health Insurance Portability and Accountability Act are standards for the following:
| electronic transactions and code sets; | ||
| unique identifiers for providers, employers, health plans and individuals; | ||
| security and electronic signatures; | ||
| privacy; and | ||
| enforcement. |
Although the Health Insurance Portability and Accountability Act was intended ultimately to reduce administrative expenses and burdens faced within the healthcare industry, we believe the law will initially bring about significant and, in some cases, costly changes. The Department of Health and Human Services has finalized two rules to date mandating the use of new standards with respect to certain healthcare transactions and health information. The first rule requires the use of uniform standards for common healthcare transactions, including healthcare claims information, plan eligibility, referral certification and authorization, claims status, plan enrollment and disenrollment, payment and remittance advice, plan premium payments and coordination of benefits.
Second, the Department of Health and Human Services has finalized new standards relating to the privacy of individually identifiably health information. These standards not only require our compliance with rules governing the use and disclosure of protected health information, but they also
13
require us to impose those rules, by contract, on any business associate to whom such information is disclosed. Rules governing the security of health information and setting standards for electronic signatures have been proposed but have not yet been issued in final form.
The Department of Health and Human Services finalized the new transaction standards on August 17, 2000, with a compliance date of October 16, 2002. In December 2001, Congress enacted a law that delays the effective date until October 16, 2003 for entities that submit a plan for being compliant by that date. We have not yet determined whether we will seek to delay our effective date. The privacy standards under the Health Insurance Portability and Accountability Act were issued on December 28, 2000, and became effective on April 14, 2001. We will be required to comply with them by April 14, 2003. Once the security regulations are issued in final form, we will have approximately two years to be fully compliant. Sanctions for failing to comply with the Health Insurance Portability and Accountability Act include criminal penalties, civil sanctions, and exclusion from the Medicare program.
We are evaluating the effect of the Health Insurance Portability and Accountability Act and have developed a task force to address the Health Insurance Portability and Accountability Act regulations as they have been adopted to date and as additional standards are adopted in the coming months. At this time, we anticipate that we will be able to fully comply with those Health Insurance Portability and Accountability Act requirements that have been adopted. However, we cannot at this time estimate the cost of such compliance, nor can we estimate the cost of compliance with standards that have not yet been finalized by the Department of Health and Human Services. Although the new and proposed health information standards are likely to have a significant effect on the manner in which we handle health data and communicate with payors, based on our current knowledge, we believe that the cost of our compliance will not have a material adverse effect on our business, financial condition or results of operations.
Employees
As of December 31, 2001 we employed approximately 15,900 people throughout the United States and Canada. A total of approximately 9,900 of our employees are full-time and the remaining approximately 6,000 are part-time employees. Outpatient, contract therapy and physical rehabilitation and occupational health employees totaled approximately 8,500 and inpatient employees totaled approximately 7,000. The remaining employees were in corporate management and administration.
Competition
We compete primarily on the basis of pricing and quality of the patient services we provide. Our specialty acute care hospitals face competition principally from general acute care hospitals in the communities in which we operate. General acute care hospitals usually have the capability to provide the same services we provide. Our hospitals also face competition from large national operators of similar facilities, such as Kindred Healthcare, Inc.
Our outpatient rehabilitation clinics face competition principally from locally owned and managed outpatient rehabilitation clinics in the communities they serve. Many of these clinics have longer operating histories and greater name recognition in these communities than our clinics, and they may have stronger relations with physicians in these communities on whom we rely for patient referrals. In addition, HealthSouth Corporation, which operates more outpatient rehabilitation clinics in the United States than we do, competes with us in a number of our markets.
14
Compliance Program
Our Compliance Program
In late 1998, we voluntarily adopted our code of conduct, which is the basis for our company-wide compliance program. Our written code of conduct provides guidelines for principles and regulatory rules that are applicable to our patient care and business activities. These guidelines are implemented by a compliance officer, a director of compliance who assists the compliance officer, a compliance committee and sub-committees, and employee education and training. We also have established a reporting system, auditing and monitoring programs, and a disciplinary system as a means for enforcing the codes policies.
Operating Our Compliance Program
We focus on integrating compliance responsibilities with operational functions. We recognize that our compliance with applicable laws and regulations depends upon individual employee actions as well as company operations. Our corporate executives, with the advice of outside experts, designed the programs of the compliance committee. We have adopted an operations team approach to compliance. We use facility leaders in our compliance sub-committees for employee-level implementation of our code of conduct. This approach is intended to enforce our company-wide commitment to operate in accordance with the laws and regulations that govern our business.
Compliance Committee
Our compliance committee is made up of members of our senior management and in-house counsel. The compliance committee meets on a quarterly basis and reviews the activities, reports and operation of our compliance program. In addition, the compliance sub-committees meet on a regular basis and review compliance for each of our business divisions.
Compliance Issue Reporting
In order to facilitate our employees ability to report known, suspected or potential violations of our code of conduct, we have developed a system of anonymous reporting. This anonymous reporting may be accomplished through our toll-free compliance hotline or our compliance post office box. The compliance officer and the compliance committee are responsible for reviewing and investigating each compliance incident in accordance with the compliance departments investigation policy.
Compliance Monitoring and Auditing/Comprehensive Training and Education
Monitoring reports and the results of compliance for each of our business divisions are reported to the compliance committee on a quarterly basis. We train and educate our employees regarding the code of conduct, as well as the legal and regulatory requirements relevant to each employees work environment. New and current employees are required to sign a compliance certification form certifying that the employee has read, understood, and has agreed to abide by the code of conduct.
Policies and Procedures Reflecting Compliance Focus Areas
We review our current policies and procedures for our compliance program, and we intend to continue to review them on an annual basis in order to improve operations and to ensure compliance with requirements of standards, laws and regulations and to reflect the on-going compliance focus areas which have been identified by the compliance committee.
15
Internal Audit
In addition to and in support of the efforts of our compliance department, we have established during 2001 an internal audit function led by our full time internal auditor.
Risk Factors
Our business involves a number of risks, some of which are beyond our control. The risk and uncertainties we describe below are not the only ones we face. Additional risks and uncertainties that we do not currently know or that we currently believe to be immaterial may also adversely affect our business.
If there are changes in the rates or methods of government reimbursements for our services, our net operating revenues and net income could decline.
Approximately 37.3% of our net operating revenues for the year ended December 31, 2001 came from the highly regulated federal Medicare program. The methods and rates of Medicare reimbursements may change at any time. Our specialty acute care hospitals operate as Medicare-designated long term acute care hospitals. As long term acute care hospitals, they receive reimbursements from Medicare based on the actual costs incurred during the treatment of a patient, subject to a cap. Many other types of healthcare providers, including general acute care hospitals, receive reimbursements from Medicare under prospective payment systems. These systems reimburse providers fixed amounts, subject to adjustments, based on each patients expected cost of treatment. Congress has directed the Secretary of the U.S. Department of Health and Human Services to develop a prospective payment system applicable to long term acute care hospitals. The Secretary is currently developing such a prospective payment system. The Secretary has not announced the details of the prospective payment system, but is expected to do so in the near future. The application of a prospective payment system to long term acute care hospitals could reduce the level of reimbursement we receive from the Medicare program for our services and negatively affect our profit margins.
Our outpatient rehabilitation clinics receive payments from the Medicare program under a fee schedule. These payments were to be subject to annual limits, originally $1,500 per patient, effective January 1, 1999. Congress has imposed a moratorium on these limits through 2002. The Secretary of the U.S. Department of Health and Human Services is required to review this annual limit and make a proposal to Congress to revise the payment system for outpatient rehabilitation. Any changes adopted by Congress, which could include reduced annual limits or a new payment system, could have an adverse effect on our outpatient rehabilitation business.
If our hospitals fail to maintain their exemption from the Medicare prospective payment system or fail to qualify as hospitals separate from their host hospitals, our profitability may decline.
As of December 31, 2001, 56 of our 64 hospitals were certified as Medicare long term acute care hospitals, and the remaining eight were in the process of becoming certified as Medicare long term acute care hospitals. If our hospitals fail to meet or maintain the standards for certification as long term acute care hospitals, such as average minimum length of patient stay, they will not receive cost-based reimbursement but will instead receive predetermined payments applicable to general acute care hospitals under the prospective payment system. Such predetermined payments would likely result in our hospitals receiving less Medicare reimbursement than they currently receive for their patient services. Moreover, nearly all of our hospitals are subject to additional Medicare criteria because they operate as separate hospitals located in space leased from, and located in, a general acute care hospital, known as a host hospital. This is known as a hospital within a hospital model. These additional criteria include limitations on services purchased from the host hospital and other requirements concerning separateness from the host hospital. If several of our hospitals were to lose their cost-based
16
reimbursement status or failed to comply with the separateness requirements, our profit margins would likely decrease. See Government RegulationsOverview of U.S. and State Government ReimbursementsLong Term Acute Care Hospital Medicare Reimbursement.
Future cost containment initiatives undertaken by private third party payors may limit our future net operating revenues and profitability.
Initiatives undertaken by major insurers and managed care companies to contain healthcare costs affect the profitability of our specialty acute care hospitals and outpatient rehabilitation clinics. These payors attempt to control healthcare costs by contracting with hospitals and other healthcare providers to obtain services on a discounted basis. We believe that this trend may continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, our profit margins may decline, or we may lose patients if we choose not to renew our contracts with these insurers at lower rates.
We conduct business in a heavily regulated industry, and changes in regulations or violations of regulations may result in increased costs or sanctions that reduce our net operating revenues and profitability.
The healthcare industry is subject to extensive federal, state and local laws and regulations relating to:
| facility and professional licensure, including certificates of need; | ||
| conduct of operations, including financial relationships among healthcare providers, Medicare fraud and abuse, and physician self-referral; | ||
| addition of facilities and services; and | ||
| payment for services. |
Recently, there have been heightened coordinated civil and criminal enforcement efforts by both federal and state government agencies relating to the healthcare industry, including the specialty acute care hospital and outpatient rehabilitation clinic businesses. The ongoing investigations relate to, among other things, various referral practices, cost reporting, billing practices, physician ownership and joint ventures involving hospitals. In the future, different interpretations or enforcement of these laws and regulations could subject our current practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services and capital expenditure programs, and increase our operating expenses. If we fail to comply with these extensive laws and government regulations, we could become ineligible to receive government program reimbursement, suffer civil or criminal penalties or be required to make significant changes to our operations. In addition, we could be forced to expend considerable resources responding to an investigation or other enforcement action under these laws or regulations. See Government Regulations.
If we fail to cultivate new or maintain established relationships with the physicians in our markets, our net operating revenues may decrease.
Our success is, in part, dependent upon the admissions and referral practices of the physicians in the communities our hospitals and our outpatient rehabilitation clinics serve, and our ability to maintain good relations with these physicians. Physicians referring patients to our hospitals and clinics are generally not our employees and, in many of the markets that we serve, most physicians have admitting privileges at other hospitals and are free to refer their patients to other providers. If we are unable to successfully cultivate and maintain strong relationships with these physicians, our hospitals admissions and clinics businesses may decrease, and our net operating revenues may decline.
17
Shortages in qualified nurses could increase our operating costs significantly.
Our specialty acute care hospitals are highly dependent on nurses for patient care. The availability of qualified nurses has declined in recent years, and the salaries for nurses have risen accordingly. We cannot assure you we will be able to attract and retain qualified nurses in the future. Additionally, the cost of attracting and retaining nurses may be higher than we anticipate, and as a result, our profitability could decline.
Future acquisitions may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.
As part of our growth strategy, we intend to pursue acquisitions of specialty acute care hospitals and outpatient rehabilitation clinics. Acquisitions may involve significant cash expenditures, debt incurrence, additional operating losses, dilutive issuances of equity securities and expenses that could have a material adverse effect on our financial condition and results of operations. Acquisitions involve numerous risks, including:
| difficulties integrating acquired personnel and harmonizing distinct cultures into our business; | ||
| diversion of managements time from existing operations; | ||
| potential loss of key employees or customers of acquired companies; and | ||
| assumption of the liabilities and exposure to unforeseen liabilities of acquired companies, including liabilities for failure to comply with healthcare regulations. |
We cannot assure you that we will succeed in obtaining financing for acquisitions at a reasonable cost, or that such financing will not contain restrictive covenants that limit our operating flexibility. We also may be unable to operate acquired hospitals and outpatient rehabilitation clinics profitably or succeed in achieving improvements in their financial performance.
Restrictions imposed by our senior credit facilities and the indenture governing our 9 1/2% senior subordinated notes limit our ability to engage in or enter into business, operating and financing arrangements, which could prevent us from taking advantage of potentially profitable business opportunities.
The operating and financial restrictions and covenants in our debt instruments, including the senior credit facilities and our 9 1/2% senior subordinated notes, may adversely affect our ability to finance our future operations or capital needs or engage in other business activities that may be in our interest. For example, our senior credit facilities limit our ability to, among other things:
incur additional debt;
pay dividends;
make certain investments;
incur or permit to exist certain liens;
enter into transactions with affiliates;
merge, consolidate or amalgamate with another company;
18
transfer or otherwise dispose of assets;
redeem subordinated debt;
incur capital expenditures; and
incur contingent obligations.
The indenture governing our 9 1/2% senior subordinated notes includes similar restrictions. See Item 7. Managements Discussion and Analysis of Financial Condition and Results of OperationsCapital Resources and Liquidity.
Competition may limit our ability to acquire hospitals and clinics and adversely affect our growth.
We have historically faced limited competition in acquiring specialty acute care hospitals and outpatient rehabilitation clinics, but we may face heightened competition in the future. Our competitors may acquire or seek to acquire many of the hospitals and clinics that would be suitable candidates for us. This could limit our ability to grow by acquisitions or make our cost of acquisitions higher and less profitable.
If we fail to compete effectively with other hospitals, clinics and healthcare providers, our net operating revenues and profitability may decline.
The healthcare business is highly competitive, and we compete with other hospitals, rehabilitation clinics and other healthcare providers for patients. If we are unable to compete effectively in the specialty acute care hospital and outpatient rehabilitation businesses, our net operating revenues and profitability may decline. More than half of our specialty hospitals operate in geographic areas where we compete with at least one other hospital that provides similar services. Our outpatient rehabilitation clinics face competition from a variety of local and national outpatient rehabilitation providers. Other outpatient rehabilitation clinics in markets we serve may have greater name recognition and longer operating histories than our clinics. The managers of these clinics may also have stronger relationships with physicians in their communities, which could give them a competitive advantage for patient referrals.
Significant legal actions could subject us to substantial uninsured liabilities.
In recent years, physicians, hospitals and other healthcare providers have become subject to an increasing number of legal actions alleging malpractice, product liability or related legal theories. Many of these actions involve large claims and significant defense costs. To protect ourselves from the cost of these claims, we maintain professional malpractice liability insurance and general liability insurance coverage in amounts and with deductibles that we believe to be appropriate for our operations. PHICO Insurance Company, which provided us medical malpractice coverage from June 1998 to December 2000, has recently been placed in liquidation. See Item 7 Managements Discussion and Analysis of Financial Condition and Results of OperationsCapital Resources and LiquidityCommitments and Contingencies. During the last year, the medical malpractice insurance markets have seen dramatic cost increases. Many insurance underwriters have become more selective in the insurance limits and types of coverage they will provide as a result of the September 11 terrorist activities, rising settlement costs and the significant failures of some nationally known insurance underwriters, such as PHICO Insurance Company. Our insurance coverage does not cover punitive damages and may not cover all claims against us or continue to be available at a reasonable cost. If we are unable to maintain adequate insurance coverage or are required to pay punitive damages, we may be exposed to substantial liabilities. We are also subject to lawsuits under a federal whistleblower statute designed to combat fraud and abuse in the healthcare industry. These lawsuits can involve significant monetary damages and award bounties to private plaintiffs who successfully bring the suits. See Item 3. Legal Proceedings and BusinessGovernment RegulationsOther Healthcare Regulations.
19
We may experience difficulties integrating the information systems relating to our outpatient rehabilitation business, which could cause business interruption.
We currently manage our outpatient rehabilitation business using six billing systems. Throughout 2002, we will continue our transition to a common system to manage all of our scheduling, billing, collecting and patient information for our outpatient rehabilitation clinics. If our systems integration fails or works improperly, we could face interruption in the segments of our business undergoing the transition while we correct the problem. The interruption in the affected segment of our business could include our inability to bill patients and payors for the services we provide. A sustained inability to bill and collect payments would have a material adverse effect on our cash flows and results of operations.
ITEM 2. PROPERTIES
We currently lease most of our facilities, including clinics, offices, long term acute care hospitals and the corporate headquarters. We lease all of our clinics and related offices, which, as of December 31, 2001, included 717 outpatient rehabilitation clinics throughout the United States and Canada. The outpatient rehabilitation clinics generally have a five-year lease term with two three-year renewals.
We also lease all of our hospital facilities except for one 176,000 square foot facility located in Houston, Texas. As of December 31, 2001, we had 62 hospital within a hospital leases and one freestanding building lease.
We generally seek a five-year lease for our hospitals, with an additional five-year renewal at our option. We lease our corporate headquarters, which is approximately 63,000 square feet, located in Mechanicsburg, Pennsylvania. We lease several other administrative spaces related to administrative and operational support functions. As of December 31, 2001, this comprised 23 locations throughout the U.S. with approximately 141,000 square feet in total.
ITEM 3. LEGAL PROCEEDINGS
On August 10, 1998 a complaint in the U.S. District Court for the Eastern District of Pennsylvania was filed that named as defendants NovaCare, Inc. (now known as NAHC, Inc.), other named defendants and 100 defendants who were to be named at a later time. This qui tam action sought triple damages and penalties under the False Claims Act against NAHC. The Department of Justice did not intervene in this action. The allegations involve, among other things, the distinction between individual and group billing in physical rehabilitation clinics that we acquired from NovaCare. On October 16, 2000 the relator plaintiff made a motion to amend the complaint to, among other things, add Select Medical Corporation and some of its subsidiaries acquired in the NovaCare acquisition as defendants in this case. This motion was granted in September of 2001. The amended complaint alleges that from about January 1, 1995 through the present, the defendants submitted false or fraudulent bills for physical therapy to various federal health programs. The United States Attorneys Office has asserted that because the complaint is being amended to add allegations against new defendants, it is entitled to a new period to determine whether to intervene in the new allegations. On January 3, 2002, NAHC and its related subsidiaries (including the subsidiaries acquired in the NovaCare acquisition) entered into a settlement agreement with the relator plaintiff and the government, pursuant to which, in exchange for a payment by NAHC of $375,000, the parties settled all claims arising out of conduct that took place before Select Medicals acquisition of the NovaCare subsidiaries that are defendants in the case. Claims against the Company and the NovaCare subsidiaries regarding conduct occurring after the NovaCare acquisition were not settled. As of February 28, 2002, the government had not advised the Company whether it intends to intervene in any remaining claims, and Select and the subsidiaries have not been served with the amended complaint. Based on a review of the amended complaint, we do not believe that this lawsuit is meritorious, and we intend to vigorously
20
defend against this action. However, because of the uncertain nature of the litigation, we cannot predict the outcome of this matter.
In addition, as part of our business, we are subject to legal actions alleging liability on our part. To cover claims arising out of the operations of our hospitals and outpatient rehabilitation facilities, we generally maintain professional malpractice liability insurance and general liability insurance in amounts and with deductibles that we believe to be sufficient for our operations. We also maintain umbrella liability coverage covering claims which, due to their nature or amount, are not covered by our insurance policies. We cannot assure you that professional liability insurance will cover all claims against us or continue to be available at reasonable costs for us to maintain adequate levels of insurance. These insurance policies also do not cover punitive damages. See Item 1. BusinessRisk FactorsRisks Relating to our BusinessSignificant legal actions could subject us to substantial uninsured liabilities.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
There were no matters submitted to a vote of security holders during the fourth quarter ended December 31, 2001, or through the date of this filing.
PART II
ITEM 5. MARKET FOR REGISTRANTS COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Our common stock is quoted on The Nasdaq National Market under the symbol SLMC. Prior to our initial public offering on April 5, 2001, there was no public market for our common stock. As of February 28, 2002, there were approximately 140 record holders of our common stock.
The following table sets forth, on a quarterly basis, the highest and
lowest sale price for our common stock for the year ended December 31, 2001 as
reported by the Nasdaq National Market:
2001
HIGH
LOW
$
20.50
$
9.50
$
22.00
$
11.93
$
18.50
$
13.65
We have never declared or paid dividends on our common stock, and we do not intend to pay dividends in the foreseeable future. Our current credit facilities and our 9 1/2% senior subordinated notes restrict us from declaring or paying dividends on our common stock. We plan to retain any earnings for use in the operation of our business and to fund future growth. See applicable discussion under Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations Liquidity and Capital Resources and Note 6 to Select Medical Corporations consolidated financial statements.
21
ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA
You should read the following selected consolidated historical financial data in conjunction with our consolidated financial statements and the accompanying notes. You should also read Managements Discussion and Analysis of Financial Condition and Results of Operations. All of these materials are contained in this report. Our operations commenced February 7, 1997 when we acquired all of the outstanding common stock of our predecessor company, Sports and Orthopedic Rehabilitation Services, P.A. The predecessor company data for the period from January 1, 1997 through February 6, 1997 has been derived from unaudited financial statements, which are not included in this report. The data as of December 31, 1997, 1998, 1999, 2000 and 2001 and for the years ended December 31, 1997, 1998, 1999, 2000 and 2001 have been derived from consolidated financial statements audited by PricewaterhouseCoopers LLP, independent accountants.
22
Predecessor
Company
January 1,
1997
Year Ended December 31,
Through
February 6,
2001
2000
1999
1998
1997
1997
(in
thousands, except per share data)
(unaudited)
$
958,956
$
805,897
$
455,975
$
149,043
$
11,194
$
456
846,938
714,227
413,731
145,450
13,740
300
32,290
30,401
16,741
4,942
285
8
5,223
10,157
79,728
61,269
20,280
(11,506
)
(2,831
)
148
6,022
29,209
35,187
21,099
4,976
(64
)
9
50,519
26,082
(819
)
(16,482
)
3,255
139
3,491
4,144
3,662
1,744
47,028
21,938
(4,481
)
(18,226
)
3,255
139
8,671
9,979
2,811
(182
)
1,308
38
38,357
11,959
(7,292
)
(18,044
)
1,947
101
8,676
6,247
5,814
29,681
5,712
(13,106
)
(18,044
)
1,947
$
101
(2,513
)
(8,780
)
(5,175
)
(2,540
)
(266
)
$
27,168
$
(3,068
)
$
(18,281
)
$
(20,584
)
$
1,681
$
0.90
$
0.13
$
(0.50
)
$
(1.64
)
$
0.26
(0.22
)
(0.25
)
(0.24
)
$
0.68
$
(0.12
)
$
(0.74
)
$
(1.64
)
$
0.26
$
0.81
$
0.12
$
(0.50
)
$
(1.64
)
$
0.26
(0.19
)
(0.24
)
(0.24
)
$
0.62
$
(0.12
)
$
(0.74
)
$
(1.64
)
$
0.26
39,957
25,457
24,557
12,517
6,557
45,464
25,907
24,557
12,517
6,564
$
112,018
$
91,670
$
42,244
$
3,593
$
(2,546
)
$
156
11.7
%
11.4
%
9.3
%
2.4
%
(22.7
)%
34.2
%
Cash flow (used in) provided by operating
activities
$
95,770
$
22,513
$
(25,157
)
$
(24,702
)
$
(2,367
)
(61,947
)
14,197
(181,262
)
(209,481
)
(671
)
(26,164
)
(37,616
)
197,480
242,298
7,897
23
______________________
As of December 31,
2001
2000
1999
1998
1997
(in thousands)
$
10,703
$
3,151
$
4,067
$
13,001
$
4,859
126,749
105,567
132,598
39,807
4,248
650,845
586,800
620,718
336,949
18,191
288,423
302,788
340,821
156,080
3,059
129,573
120,804
55,843
5,717
234,284
48,498
49,437
60,494
5,052
(a) | Operating expenses include cost of services, general and administrative expenses, and bad debt expenses. | ||
(b) | Reflects asset impairments of $6.3 million and litigation settlement costs of $3.8 million in 1998 and asset impairments of $5.2 million in 1999. | ||
(c) | Reflects interests held by other parties in subsidiaries, limited liability companies and limited partnerships owned and controlled by us. | ||
(d) | Reflects the write-off of deferred financing costs that resulted from the refinancing of our senior credit facilities in November 1999 and September 2000. Also reflects the write-off of deferred financing costs and discounts, net of tax, resulting from the repayment of debt with the proceeds from our initial public offering in April 2001 and the 9 1/2% senior subordinated notes offering in June 2001. | ||
(e) | For information concerning calculation of weighted average shares outstanding, see note 15 to Select Medical Corporations consolidated financial statements. | ||
(f) | We define EBITDA as net income (loss) before interest, income taxes, depreciation and amortization and special charges, other income, minority interest, and extraordinary items. EBITDA is not a measure of financial performance under generally accepted accounting principles. Items excluded from EBITDA are significant components in understanding and assessing financial performance. EBITDA is a measure commonly used by financial analysts and investors to evaluate the financial results of companies in our industry, and we believe it therefore provides useful information to investors. EBITDA should not be considered in isolation or as an alternative to net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is susceptible to varying calculations, EBITDA as presented may not be comparable to similarly titled measures of other companies. |
The following table reconciles EBITDA to net income (loss):
Year Ended December 31,
2001
2000
1999
1998
1997
(in thousands)
$
112,018
$
91,670
$
42,244
$
3,593
$
(2,546
)
(32,290
)
(30,401
)
(16,741
)
(4,942
)
(285
)
(5,223
)
(10,157
)
6,022
507
939
362
406
206
(29,716
)
(36,126
)
(21,461
)
(5,382
)
(142
)
(3,491
)
(4,144
)
(3,662
)
(1,744
)
(8,671
)
(9,979
)
(2,811
)
182
(1,308
)
(8,676
)
(6,247
)
(5,814
)
$
29,681
$
5,712
$
(13,106
)
$
(18,044)
$
1,947
24
ITEM 7.
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
As of December 31, 2001, we were the largest operator of specialty acute care hospitals for long term stay patients in the United States based on the number of facilities. We are also the second largest operator of outpatient rehabilitation clinics in the United States based on the number of clinics. As of December 31, 2001, we operated 64 specialty acute care hospitals in 22 states and 717 outpatient rehabilitation clinics in 31 states, the District of Columbia and seven Canadian provinces. We began operations in 1997 under the leadership of our current management team.
We operate through two business segments, our specialty acute care hospital segment and our outpatient rehabilitation segment. For the year ended December 31, 2001, we had net operating revenues of $959.0 million. Of this total, we earned 54% of our net operating revenues from our specialty hospitals and 46% from our outpatient rehabilitation businesses.
Our specialty acute care hospital segment consists of hospitals designed to serve the needs of long term stay acute patients. These patients typically suffer from serious and often complex medical conditions that require a high degree of care. Our outpatient rehabilitation business consists of clinics and contract services that provide physical, occupational and speech rehabilitation services. Our patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living.
Significant Acquisition
On November 19, 1999, we acquired the Physical Rehabilitation and Occupational Health Division of NovaCare, Inc. for approximately $200 million consisting of cash and the assumption of seller notes. The purchase was funded through the sale of Class B Preferred Stock, common stock, issuance of senior subordinated debt, and borrowings under our credit facility. At the time of the acquisition, NovaCare operated approximately 500 physical rehabilitation clinics and 35 occupational health centers. Following the completion of the acquisition, we sold 26 and closed 2 of these occupational health centers. As a result of this acquisition, the results of operations for the year ended December 31, 1999 and December 31, 2000 are not comparable.
25
Development of New Specialty Acute Care Hospitals and Clinics
Our goal is to open eight to ten new specialty acute care hospitals each year, utilizing our hospital within a hospital model. We internally developed and opened six hospitals in 1999 and ten hospitals in both 2000 and 2001. Each internally developed hospital has typically required approximately $500,000 for leasehold improvements and approximately $250,000 for equipment. During the initial year of operations, each newly developed hospital has typically incurred losses of approximately $500,000 and required an additional investment of $2.0 million to fund working capital. We also intend to open new clinics in our current markets where we can benefit from existing referral relationships and brand awareness to produce incremental growth. From time to time, we also intend to evaluate acquisition opportunities that may enhance the scale of our business and expand our geographic reach.
Critical Accounting Matters
Sources of Revenue
Our net operating revenues are derived from a number of sources, including commercial, managed care, private and governmental payors. Our net operating revenues include amounts estimated by management to be reimbursable from each of the applicable payors and the federal Medicare program. Amounts we receive for treatment of patients are generally less than the standard billing rates. We account for the differences between the estimated reimbursement rates and the standard billing rates as contractual adjustments, which we deduct from gross revenues to arrive at net operating revenues.
Our specialty hospitals are paid by Medicare under a cost-based reimbursement methodology. These payments are subject to final cost report settlements based on administrative review and audit by third parties. An annual cost report is filed for each provider to report the cost of providing services and to settle the difference between the interim payments we receive and final costs. We record adjustments to the original estimates in the periods that such adjustments become known. Historically these adjustments have not been significant. Because our routine payments from Medicare are different than the final reimbursement due to us under the cost based reimbursement system, we record a receivable or payable for the difference. As of December 31, 2000 we had a receivable from Medicare of $2.8 million. At December 31, 2001 we had a net amount due to Medicare of $3.4 million. We recorded this amount as due to third party payors on our balance sheet. Substantially all Medicare cost reports are settled through 1998.
Net operating revenues generated directly from the Medicare program represented approximately 37.3%, 35.1% and 48.1% of net operating revenues for the years ended December 31, 2001, 2000 and 1999, respectively. The decline in the percentage of our net operating revenue coming from Medicare during the year ended December 31, 2000 was principally related to the acquisition of the NovaCare Physical Rehabilitation and Occupational Health Division in the last quarter of 1999, which receives a comparatively lower percentage of its revenues from Medicare.
Legislative and regulatory action has resulted in continuing uncertainty about the Medicare reimbursement programs. The federal government might, in the future, reduce the funds available under that program or require more stringent utilization and quality reviews of hospital facilities. For example, because Congress has directed the Secretary of the Department of Health and Human Services to develop a prospective payment system for long term acute care hospitals, the way in which our specialty hospitals are reimbursed will change. The Secretary has not developed such a system to date, but is likely to do so in the near future. This change, when implemented, could reduce the reimbursements we receive from the Medicare program. Additionally, there may be a continued rise in managed care programs or future restructuring of the financing and delivery of healthcare in the United States. These events could have an adverse effect on our future financial results.
26
Other revenue primarily represents amounts the Medicare program reimburses us for a portion of our corporate expenses that are related to our specialty hospital operations.
Bad Debts
We estimate our bad debts based upon the age of our accounts receivable
and our historical collection percentages. These estimates are sensitive to
changes in the economy that affect our customers.
Results of Operations
The following table outlines, for the periods indicated, selected
operating data as a percentage of net operating revenues.
27
The following table summarizes selected financial data by business
segment, for the periods indicated.
28
The following table reconciles EBITDA to net income (loss):
Special Charge
We recorded a special charge of $5.2 million related to the impairment of
goodwill, leasehold improvements and equipment that resulted from closures and
relocations of certain hospitals and clinics in December 1999. See
Note 11 to
our consolidated financial statements.
Year Ended December 31, 2001 Compared to Year Ended December 31, 2000
Net Operating Revenues
Our net operating revenues increased by 19.0% to $959.0 million for the
year ended December 31, 2001 compared to $805.9 million for the year ended
December 31, 2000.
Specialty Acute Care Hospitals
. Our specialty hospital net operating
revenues increased 32.8% to $503.0 million for the year ended December 31, 2001
compared to $378.9 million for the year ended December 31, 2000. Net operating
revenues for the specialty hospitals opened before January 1, 2000 and operated
throughout both periods increased 20.2% to $430.4 million for the year ended
December 31, 2001 from $358.0 million for the year ended December 31, 2000.
This resulted from an improved occupancy rate and a higher non-Medicare payor
mix. The remaining increase of $51.7 million resulted from the internal
development of new specialty hospitals that commenced operations in 2000 and
2001.
Outpatient Rehabilitation
. Our outpatient rehabilitation net operating
revenues increased 5.8% to $440.8 million for the year ended December 31, 2001
compared to $416.8 million the year ended December 31, 2000. The increase was
related to an increase in the number of visits and the net revenue per visit
experienced at our outpatient rehabilitation location.
Other
. Our other revenues increased to $15.1 million for the year ended
December 31, 2001 compared to $10.2 million for the year ended December 31,
2000. The increase in other revenue reflects higher corporate general and
administrative costs in 2001, which resulted in higher Medicare reimbursements
for those costs.
Operating Expenses
Our operating expenses increased by 18.6% to $846.9 million for the year
ended December 31, 2001 compared to $714.2 million for the year ended December
31, 2000. The increase in operating expenses was principally related to the
internal development of new specialty hospitals that commenced operations in
2000 and 2001. As a percent of our net operating revenues, our operating
expenses
29
declined to 88.3% for the year ended December 31, 2001 from 88.6% for the
year ended December 31, 2000. Our operating expenses include our cost of
services, general and administrative expense and bad debt expense. Cost of
services as a percent of operating revenues declined to 81.0% for the year
ended December 31, 2001 from 81.5% for the year ended December 31, 2000. These
costs primarily reflect our labor expenses. The relative reduction in cost of
services as a percentage of net operating revenue resulted from a reduction in
non-labor costs experienced in both of our operating segments. General and
administrative expense as a percentage of net operating revenues increased to
3.7% for the year ended December 31, 2001 compared to 3.5% for the year ended
December 31, 2000. This increase is principally due to litigation costs
associated with disputes that we assumed through our NovaCare acquisition and
the costs associated with a secondary stock offering that was terminated in
November 2001. Our bad debt expense as a percentage of net operating revenues
remained stable at 3.6% for both periods.
EBITDA
Our total EBITDA increased 22.2% to $112.0 million for the year ended
December 31, 2001 compared to $91.7 million for the year ended December 31,
2000. Our EBITDA margins increased to 11.7% for the year ended December 31,
2001 compared to 11.4% for the year ended December 31, 2000. For cash flow
information, see Capital Resources and Liquidity.
Specialty Acute Care Hospitals
. EBITDA increased by 29.2% to $57.6
million for the year ended December 31, 2001 compared to $44.6 million for the
year ended December 31, 2000. The hospitals opened before January 1, 2000 and
operated throughout both periods accounted for $11.9 million of the increase.
This increase in the same hospital EBITDA resulted from an increase in
non-Medicare patient days and its associated revenue per patient day. The
balance of the increase of $1.1 million resulted from our newly developed
hospitals. Our EBITDA margins declined slightly to 11.4% for the year ended
December 31, 2001 from 11.8% for the year ended December 31, 2000. The decline
resulted from the effects of aggregate EBITDA losses generated by our newly opened
hospitals. Our same hospital EBITDA margin increased to 13.5% for 2001 from
12.9% in 2000.
Outpatient Rehabilitation
. EBITDA increased by 16.4% to $76.1 million
for the year ended December 31, 2001 compared to $65.4 million for the year
ended December 31, 2000. Our EBITDA margins increased to 17.3% for the year
ended December 31, 2001 from 15.7% for the year ended December 31, 2000. This
increase in EBITDA margins was the result of lower costs of services, as
discussed above under Operating Expenses, and a reduction in our relative bad
debt percentage.
Other
. The EBITDA loss increased to $21.7 million for the year ended
December 31, 2001 compared to a loss of $18.3 million for the year ended
December 31, 2000. This increase resulted from the increase in general and
administrative costs needed to support the growth of the organization and the
litigation and secondary stock offering costs discussed above under Operating
Expenses.
Income from Operations
Income from operations increased 30.1% to $79.7 million for the year ended
December 31, 2001 compared to $61.3 million for the year ended December 31,
2000. The increase in income from operations resulted from the EBITDA
increases described above, offset by an increase in depreciation and
amortization. Depreciation and amortization increased by 6.2% to $32.3 million
for the year ended December 31, 2001 from $30.4 million for the year ended
December 31, 2000. The increase resulted primarily from increases in
depreciation on fixed asset additions that are principally related to new
hospital development.
30
Interest Expense
Interest
expense decreased by $6.4 million to $29.7 million for the year
ended December 31, 2001 from $36.1 million for the year ended December 31,
2000. The decline in interest expense is due to the lower debt levels
outstanding in 2001 compared to 2000 and a lower effective interest rate in
2001. The lower average debt levels in 2001 resulted from the significant
repayment of debt that occurred in the third and fourth quarters of 2000 as a
result of the NovaCare settlement which is discussed below under Capital
Resources and Liquidity, and the divestiture of the NovaCare Occupational
Health businesses. Additionally, during 2001 we used a portion of our
operating cash flow to repay debt.
Minority Interests
Minority interests in consolidated earnings decreased 15.8% to $3.5
million for the year ended December 31, 2001 compared to $4.1 million for the
year ended December 31, 2000. This decrease resulted from a smaller percentage
of ownership held by minority interests. See Capital Resources and Liquidity
for a discussion of our repurchase of minority interests.
Income Taxes
We recorded income tax expense of $8.7 million for the year ended December
31, 2001. The expense represented an effective tax rate of 18.4%. Our lower
effective tax rate resulted from the reversal of our tax valuation allowance.
The reversal represented a reduction in the effective tax rate of 20.6
percentage points. Had the reversal not occurred, our effective tax rate would
have approximated the combined statutory federal and state tax rate of 39.0%.
We recorded income tax expense of $10.0 million for the year ended December 31,
2000. This expense represented an effective tax rate of 45.5%. This exceeded
the statutory rates primarily due to non-deductible goodwill. In 2001, we were
able to utilize net operating loss carryovers to offset the effect of our
non-deductible goodwill.
As a result of our limited operating history and the cumulative losses
incurred in prior years, we historically provided a valuation allowance for
substantially all of our deferred tax assets. Because of the cumulative
profitable operations over the last three years, we have concluded that it is
more likely than not that these deferred tax items will be realized. The
reversal of these valuation allowances in the fourth quarter of 2001 resulted
in a reduction in the tax provision of $9.7 million and a reduction in goodwill
of $18.5 million. The reduction in goodwill relates to those deferred tax
assets originating through acquisitions. The reduction in the tax provision
generated a positive earnings per share effect of $0.19 in the fourth quarter
and $0.21 for the year.
Extraordinary Item
As a result of our initial public offering of stock in April 2001 and the
issuance of $175 million of 9 1/2 % Senior Subordinated Notes in June 2001, we
repaid $75 million of our U.S. term loan and all $90 million of our 10% Senior
Subordinated Notes. The extraordinary item consists of $1.3 million of
unamortized deferred financing costs related to the repayment of our U.S. term
loan and $12.9 million of deferred financing costs and unamortized discount
related to the repayment of our 10% Senior Subordinated Notes. These costs
were offset by a tax benefit of $5.5 million.
Year Ended December 31, 2000 Compared to Year Ended December 31, 1999
Net Operating Revenues
Our net operating revenues increased 76.7% to $805.9 million for the year
ended December 31, 2000 compared to $456.0 million for the year ended December
31, 1999. The percentage of our net operating revenues coming from Medicare
declined to 35.1% during the year ended December 31, 2000
31
from 48.1% for 1999. This decline was principally related to the
acquisition of NovaCare, which receives a comparatively lower percentage of its
revenue from Medicare.
Specialty Acute Care Hospitals.
Our specialty hospital revenues increased
23.2% to $378.9 million for the year ended December 31, 2000 compared to $307.5
million for the year ended December 31, 1999. Net operating revenues for the
specialty hospitals operated throughout both periods increased 11.0% to $325.3
million for 2000 from $293.1 million for 1999. This increase resulted from an
improved occupancy rate and a higher non-Medicare payor mix. The remaining
increase of $39.2 million resulted from the internal development of new
specialty hospitals that commenced operations in 1999 and 2000.
Outpatient Rehabilitation.
Our outpatient rehabilitation revenues
increased 194.0% to $416.8 million for the year ended December 31, 2000
compared to $141.7 million for the year ended December 31, 1999. This increase
was principally related to the acquisition of the NovaCare Physical
Rehabilitation and Occupational Health Division in November 1999, which
accounted for $261.8 million of the increase. The remaining increase resulted
primarily from increased volume in existing businesses.
Other.
Our other revenues increased 50.8% to $10.2 million for the year
ended December 31, 2000 compared to $6.8 million for the year ended December
31, 1999. The increase in other revenue reflects higher corporate general and
administrative costs in 2000, which resulted in higher Medicare reimbursements
for those costs.
Operating Expenses
Our operating expenses increased by $300.5 million to $714.2 million for
the year ended December 31, 2000 compared to $413.7 million for the year ended
December 31, 1999. The increase in operating expenses was principally related
to the acquisition of the NovaCare Physical Rehabilitation and Occupational
Health Division, which accounted for $220.0 million of the increase. Our
specialty hospital segment experienced an increase in operating expenses of
$62.8 million. This increase principally related to growth in operating
expenses associated with the hospitals opened in 1999 and 2000. As a percent
of our net operating revenues, our operating expenses declined to 88.6% in 2000
from 90.7% in 1999. Our operating expenses include our cost of services,
general and administrative expense and bad debt expense. Cost of services as a
percent of net operating revenues declined to 81.5% during 2000 from 84.1%
during 1999. These costs primarily reflect our labor expenses. During the
same time period, general and administrative expense as a percent of net
operating revenues declined to 3.5% from 4.7%. The relative reductions in cost
of services and general and administrative expense were primarily the result of
our acquisition of NovaCare and the lower cost associated with providing
outpatient rehabilitation services relative to our specialty hospital services.
Bad debt expense as a percent of net operating revenues increased to 3.6%
during 2000 compared to 1.9% during 1999. This increase resulted primarily
from our acquisition of the NovaCare Physical Rehabilitation and Occupational
Health Division, which incurs higher bad debt as a percentage of net operating
revenues because of the large volume of relatively difficult to collect,
smaller dollar accounts receivables generated in an outpatient environment.
EBITDA
Our total EBITDA increased 117.0% to $91.7 million for the year ended
December 31, 2000 compared to $42.2 million for the year ended December 31,
1999. Our EBITDA margins increased to 11.4% for 2000 compared to 9.3% for
1999. For cash flow information, see Capital Resources and Liquidity.
Specialty Acute Care Hospitals.
EBITDA increased 24.0% to $44.6 million
for the year ended December 31, 2000 compared to $35.9 million for the year
ended December 31, 1999. Our EBITDA margins remained consistent at 11.8% and
11.7% in 2000 and 1999, respectively. The hospitals we
32
operated throughout both periods accounted for $5.3 million of the
increase. This increase in same hospital EBITDA resulted from an increase in
non-Medicare payor mix. Our same hospital EBITDA margin increased from 12.6%
to 13.0%. The balance of the increase of $3.4 million resulted from our newly
developed hospitals.
Outpatient Rehabilitation.
EBITDA increased by 188.2% to $65.4 million
for the year ended December 31, 2000 compared to $22.7 million for the year
ended December 31, 1999. The major contributor to this increase was the
NovaCare Physical Rehabilitation and Occupational Health Division acquisition
that accounted for $41.9 million of the increase. The remaining increase of
$0.8 million resulted from growth in our existing business. Our EBITDA margins
declined to 15.7% during 2000 from 16.0% during 1999. This decline resulted
from the acquisition of the NovaCare Physical Rehabilitation and Occupational
Health Division, which historically had lower margins than our existing
outpatient rehabilitation business. These lower margins were the result of
higher bad debt expense and costs of services as a percentage of net operating
revenues.
Other
. EBITDA loss increased by 11.7% to a loss of $18.3 million for the
year ended December 31, 2000 compared to a loss of $16.4 million for the year
ended December 31, 1999. This increase resulted from the increase in general
and administrative expenses associated with the growth of the organization,
principally the addition of the NovaCare division and our new hospital
development.
Income from Operations
Income from operations increased 202.1% to $61.3 million for the year
ended December 31, 2000 compared to $20.3 million for the year ended December
31, 1999. The increase in income from operations resulted from EBITDA
increases described above and from a reduction in the amount recorded as a
special charge, offset by an increase in depreciation and amortization.
Depreciation and amortization increased by 81.6% to $30.4 million for 2000
compared to $16.7 million for 1999. Approximately $10.3 million of the
increase in the depreciation and amortization was related to the amortization
of goodwill and identifiable intangibles resulting from the NovaCare
acquisition and the depreciation of the acquired NovaCare fixed assets. The
remaining increase resulted from depreciation of new fixed assets.
Interest Expense
Interest expense increased to $36.1 million for the year ended December
31, 2000 from $21.5 million for the year ended December 31, 1999. The increase
in interest expense resulted from higher average debt levels outstanding in
2000 compared to 1999, including the debt assumed as a result of the NovaCare
acquisition, and an increase in the average interest rate associated with
borrowings.
Minority Interests
Minority interests increased by $0.4 million to $4.1 million for the year
ended December 31, 2000 compared to $3.7 million for the year ended December
31, 1999. This increase resulted from improved operating performance in our
operating subsidiaries that are structured with a minority interest component.
Income Taxes
We recorded income tax expense of $10.0 million for the year ended
December 31, 2000. The expense represented an effective tax rate of 45.5% and
exceeded statutory federal and state tax rates as a result of non-deductible
goodwill. We recorded income tax expense of $2.8 million for the year ended
December 31, 1999. This expense represented an effective tax rate of 62.7%.
We had a higher effective tax rate in this period as a result of non-deductible
goodwill and state income taxes in the jurisdictions where we reported taxable
income.
33
Extraordinary Item
On September 22, 2000, we entered into a new $230 million senior credit
facility with a syndicate of banks that replaced our $225 million credit
facility dated November 19, 1999. The extraordinary item consists of the
unamortized deferred financing costs of $6.2 million related to the November
19, 1999 credit facility.
Capital Resources and Liquidity
Years Ended December 31, 2001, 2000, and 1999
Operating activities generated $95.8 million and $22.5 million in cash
during the years ended December 31, 2001 and December 31, 2000, respectively,
compared to cash usage of $25.2 million in the year ended December 31, 1999.
The increase in cash flow is attributable to improved operating income,
continued management of payables and lower accounts receivable days
outstanding. Our accounts receivable days outstanding were 77 days at December
31, 2001 compared to 85 days at December 31, 2000. The use of cash in 1999 was
primarily attributable to net losses and an increase in accounts receivable
that resulted from our growth.
Investing activities used $61.9 million of cash flow for the year ended
December 31, 2001. This usage resulted from purchases of property and equipment
of $24.0 million related principally to new hospital development.
Additionally, we incurred earnout and acquisition related payments of $5.7
million and $33.1 million, respectively. The earnout payments relate to
obligations we assumed as part of the NovaCare acquisition. Acquisition
related payments consist of approximately $22.2 paid for new business
acquisitions and the remainder relate to our purchases of minority interests.
The terms of our agreements with these minority owners allowed some of them to
sell their minority interests to us upon the completion of our initial public
offering. In total, we paid these minority owners $15.9 million for their
ownership interests. Of this amount, $10.9 million was paid in cash and $5.0
million was paid in our stock.
Investing activities provided $14.2 million of cash flow during 2000
compared to cash usages of $181.3 million in the year ended December 31, 1999.
For the year ended December 31, 2000, we received proceeds of $29.9 million
from two escrow funds established as part of the NovaCare acquisition and
proceeds of $13.0 million from the sale of the occupational health centers.
These occupational health centers were an operating division of NovaCare. The
claim against the escrow fund resulted from an increase in uncollectible
accounts receivable, which were paid with the proceeds from the escrow fund.
Cash inflows were offset principally by the purchases of $22.4 million of
equipment and acquisition and earnout payments of $9.3 million. The increase
in property and equipment purchases reflects the growth in new hospital
development during 2000. The principal usage of cash in 1999 was to fund
acquisitions. Our investment in property and equipment during 1999 was not
material because our operations required minimal capital expenditures on an
ongoing basis, and most of our locations were leased. Our investment in
equipment is mostly related to development of new hospitals.
Financing activities used $26.2 million of cash for the year ended
December 31, 2001. This was due principally to the repayment of seller and
other debt. In 2001, we had two significant financing transactions that
refinanced existing capital. On April 10, 2001 we completed an initial public
offering of 9 million shares of our common stock. Our net proceeds after
deducting expenses and underwriting discounts and commissions were
approximately $77.3 million. On April 20, 2001 the underwriters exercised
their option to purchase an additional 1.35 million shares of common stock to
cover overallotments. The net proceeds from the exercise of this option were
$11.9 million after deduction of the underwriters discount. The proceeds of the
stock offering were used to repay $24.0 million of our senior debt under the
term loan portion of our bank credit facility, to redeem $52.8 million of our
Class A Preferred Stock and the remainder was used for general corporate
purposes including the purchases of
34
minority interests. On June 11, 2001, we issued and sold $175.0 million
of 9 1/2% Senior Subordinated Notes due 2009. The net proceeds from the sale
were approximately $169.5 million, after deducting discounts, commissions and
expenses of the offering. We used $90.0 million of the net proceeds to retire
our 10% Senior Subordinated Notes which were issued in December 1998, February
1999 and November 1999. We used an additional $79.0 million of the net
proceeds to repay part of our senior indebtedness under both the term loan and
revolving portions of our senior credit facility. The remainder of the net
proceeds was used to pay accrued interest.
Financing activities used $37.6 million of cash for the year ended
December 31, 2000. This was due principally to the repayment of debt. In 1999
we had cash inflows of $197.5 million. We raised capital through the issuance
of common and preferred stock, senior subordinated debt and borrowings under
our senior credit facility. We incurred debt in connection with the
acquisition of the NovaCare Physical Rehabilitation and Occupational Health
Division.
Capital Resources
Net working capital was $126.7 million at December 31, 2001 compared to
$105.6 million at December 31, 2000. This increase is principally related to
the increase in the deferred tax asset of $28.9 million resulting from the
reversal of our valuation allowance.
On September 22, 2000 we entered into a new credit agreement that
refinanced our existing bank debt. In January 2001, in anticipation of our
initial public offering, we entered into an amendment to our credit agreement
that became effective in April 2001. The amendment allowed for the use of the
net proceeds of the offering to repay $24.0 million of our senior debt under
the U.S. term loan portion of our bank credit facility and to redeem $52.8
million of our Class A Preferred Stock. In May 2001, in anticipation of the
senior subordinated note offering, we entered into another amendment to our
credit agreement that became effective in June 2001. The amendment allowed for
the use of net proceeds to repay $51.0 million of our senior debt under the
U.S. term loan portion and $28.0 million of our senior debt under the U.S.
revolving portion of our bank credit facility and to repay $90.0 million of
existing subordinated debt. The amendment to the credit facility also
increased our revolving credit facility by $77.4 million. Our credit facility
now consists of a term facility of approximately $91.8 million, and a revolving
credit facility of approximately $152.4 million. The term debt began quarterly
amortization in September, 2001, with a final maturity date of September 2005.
As of December 31, 2001 we had availability to borrow an additional $143.1
million under our revolving facility. The revolving facility terminates in
September 2005.
Borrowings under the credit agreement bear interest at a fluctuating rate
of interest based upon financial covenant ratio tests. As of December 31,
2001, our weighted average interest rate under our credit agreement was
approximately 7.6%. A portion of the amount borrowed under our U.S. term loan
portion of our credit agreement is hedged through an interest rate swap
transaction, which fixes the rate paid through the term of the
agreement. See Item 7A Quantitative and Qualitative Disclosures on Market Risk for a discussion of
our floating interest rates on borrowings under our credit facility.
We are required to pay a quarterly commitment fee at a rate that ranges
from .375% to .500%, based upon financial covenant ratio tests. This fee
applies to unused commitments under the revolving credit facility.
The terms of the credit agreement include various restrictive covenants.
These covenants include:
35
The covenants also require us to maintain various financial ratios
regarding total indebtedness, interest, fixed charges and net worth. The
borrowings are collateralized by substantially all of the tangible and
intangible assets of us and our subsidiaries, including all of the capital
stock of our domestic subsidiaries and 65% of the capital stock of our direct
foreign subsidiaries. In addition, the loans have been guaranteed by our
domestic subsidiaries.
On June 11, 2001, we issued and sold $175.0 million aggregate principal
amount of 9 1/2% senior subordinated notes due June 15, 2009. The notes were
issued under an indenture dated as of June 11, 2001 between us and State Street
Bank and Trust Company, N.A., as Trustee. Interest on the notes is payable
semiannually in arrears on June 15 and December 15 of each year, commencing
December 15, 2001. The notes are unsecured senior subordinated obligations of
Select Medical, are subordinated in right of payment to all existing and future
senior indebtedness of Select Medical, and are senior in right of payment to
all future subordinated indebtedness of Select Medical. The notes are
guaranteed on a senior subordinated basis by all of our wholly-owned domestic
subsidiaries, subject to certain exceptions. On or after June 15, 2005, the
notes may be redeemed at our option, in whole or in part, at redemption prices
that decline annually to 100% on and after June 15, 2008, plus accrued and
unpaid interest.
Upon a change of control of Select Medical, each holder of notes may
require us to repurchase all or any portion of the holders notes at a purchase
price equal to 101% of the principal amount plus accrued and unpaid interest to
the date of purchase. The indenture contains certain covenants that, among
other things, limit the incurrence of additional debt by Select Medical and
certain of its subsidiaries; the payment of dividends on capital stock of
Select Medical and the purchase, redemption or retirement of capital stock or
subordinated indebtedness; investments; certain transactions with affiliates;
sales of assets, including capital stock of subsidiaries; and certain
consolidations, mergers and transfers of assets. The indenture also prohibits
certain restrictions on distributions from certain subsidiaries. All of these
limitations and prohibitions, however, are subject to a number of
qualifications.
We believe that existing cash balances, internally generated cash flows
and borrowings under our revolving credit facility will be sufficient to
finance operations for at least the next twelve months. In the year ended
December 31, 2001, we opened ten specialty hospitals. A new specialty hospital
has historically required approximately $3.3 million per hospital over the
initial year of operations to fund leasehold improvements, equipment, start-up
losses and working capital. From time to time, we may complete acquisitions of
specialty hospitals and outpatient rehabilitation businesses. As of December
31, 2001 we had approximately $143.1 million of unused capacity under our
revolving credit facility, some of which can be used for acquisitions. Based on the
size of the acquisition, approval of the acquisition by our lenders may be
required. If funds required for future acquisitions exceed existing sources of
capital, we will need to increase our credit facilities or obtain additional
capital by other means.
36
Commitments and Contingencies
In February 2002, PHICO Insurance Company (PHICO), at the request of the
Pennsylvania Insurance Department, was placed in liquidation by an Order of the
Commonwealth Court of Pennsylvania (Liquidation Order). From June 1998
through December 2000, we had placed our primary malpractice insurance coverage
through PHICO. In January 2001, these policies were replaced with policies
issued by other insurers. Currently we have approximately 20 unsettled claims
in eleven states from the policy years covered by PHICO issued policies. The
Liquidation Order refers these claims to various state guaranty
associations. These state guaranty association statutes generally provide for
coverage between $100,000-$300,000 per insured claim, depending upon the state.
Some states also have catastrophic loss funds to cover settlements in excess
of the available state guaranty funds. Most state insurance guaranty statutes
provide for net worth and residency limitations that, if applicable, may limit
or prevent us from recovering from these state guaranty association funds. At
this time, we believe that we will meet the requirements for coverage under the
applicable state guaranty association statutes, and that the
resolution of these claims will not have a material adverse effect on our financial position, cash
flow and results of operations. However, because the rules related to state
guaranty association funds are subject to interpretation, and because these
claims are still in the process of resolution, our conclusions may change as
this process progresses.
The following table summarizes our contractual obligations at December 31,
2001, and the effect such obligations are expected to have on our liquidity and
cash flow in future periods.
Related Party
We are party to various rental and other agreements with companies
affiliated through common ownership. These transactions and commitments are
described more fully in Note 17 to our consolidated
financial statements.
37
Inflation
The healthcare industry is labor intensive. Wages and other expenses
increase during periods of inflation and when labor shortages occur in the
marketplace. In addition, suppliers pass along rising costs to us in the form
of higher prices. We have implemented cost control measures, including our
case and resource management program, to curtail increases in operating costs
and expenses. We have, to date, offset increases in operating costs by
increasing reimbursement for services and expanding services. However, we
cannot predict our ability to cover or offset future cost increases.
Recent Accounting Pronouncements
In October 2001, the Financial Accounting Standards Board approved SFAS
No. 144 Accounting for the Impairment of Disposal of Long-Lived Assets which
is effective for financial statements issued for fiscal years beginning after
December 15, 2001. SFAS 144 supersedes the accounting provisions of APB 30
that address the disposal of a segment of a business and requires that such
long-lived assets be reported at fair value less cost to sell. It requires
that long lived assets to be abandoned, exchanged for similar productive assets
or distributed to owners in a spin-off be considered held for use until they
are abandoned, exchanged or distributed. It also eliminates the exception to
consolidation for a subsidiary while control is expected to be temporary. We
adopted SFAS 144 on January 1, 2002 with no material effect on net income.
In June 2001, the Financial Accounting Standards Board issued SFAS No. 141
Business Combinations and No. 142 Goodwill and Other Intangible Assets
which are effective for us on July 1, 2001 and January 1, 2002, respectively.
SFAS 141 requires that the purchase method of accounting be used for all
business combinations initiated after June 30, 2001. Under SFAS 142,
amortization of goodwill, including goodwill recorded in past business
combinations, will discontinue upon adoption of this standard. In addition,
goodwill recorded as a result of business combinations completed during the
six-month period ending December 31, 2001 was not amortized. All goodwill and
intangible assets will be tested for impairment in accordance with the
provisions of the Statement. An initial impairment test must be performed in
2002. At this time, we believe that any impairment charge in 2002 resulting from the adoption of
SFAS 142 will not be significant. If the new standard had been in
effect in 2001, pre-tax amortization expense in 2001 would have been
reduced by
approximately $8.7 million or approximately $0.12 per diluted share.
Year Ended December 31,
2001
2000
1999
100.0
%
100.0
%
100.0
%
81.0
81.5
84.1
3.7
3.5
4.7
3.6
3.6
1.9
11.7
11.4
9.3
3.4
3.8
3.7
1.2
8.3
7.6
4.4
3.0
4.4
4.6
5.3
3.2
(0.2
)
0.4
0.5
0.8
4.9
2.7
(1.0
)
0.9
1.2
0.6
4.0
1.5
(1.6
)
0.9
0.8
1.3
3.1
%
0.7
%
(2.9
)%
Table of Contents
Year Ended December 31,
Increase
Increase
(Decrease)
(Decrease)
2001
2000
1999
2000-2001
1999-2000
(dollars in thousands)
$
503,021
$
378,910
$
307,464
32.8
%
23.2
%
440,791
416,775
141,740
5.8
194.0
15,144
10,212
6,771
48.3
50.8
$
958,956
$
805,897
$
455,975
19.0
%
76.7
%
Specialty hospitals
$
57,556
$
44,550
$
35,929
29.2
%
24. 0
%
76,127
65,420
22,697
16.4
188.2
(21,665
)
(18,300
)
(16,382
)
(18.4
)
(11.7
)
$
112,018
$
91,670
$
42,244
22.2
%
117.0
%
$
46,472
$
35,421
$
28,016
31.2
%
26.4
%
60,790
50,422
16,222
20.6
210.8
(27,534
)
(24,574
)
(23,958
)
(12.0
)
(2.6
)
$
79,728
$
61,269
$
20,280
30.1
%
202.1
%
Specialty hospitals
11.4
%
11.8
%
11.7
%
(3.4
)%
0.9
%
17.3
15.7
16.0
10.2
(1.9
)
NM
NM
NM
NM
NM
11.7
%
11.4
%
9.3
%
2.6
%
22.6
%
$
303,910
$
246,495
$
250,034
318,224
329,874
350,419
28,711
10,431
20,265
$
650,845
$
586,800
$
620,718
$
13,452
$
13,677
$
7,243
8,800
6,399
3,085
1,759
2,354
568
$
24,011
$
22,430
$
10,896
NMNot Meaningful.
(a)
Cost of services include salaries, wages and benefits, operating
supplies, lease and rent expense and other operating costs.
(b)
We define EBITDA as net income (loss) before interest, income taxes,
depreciation and amortization and special charges, other income, minority
interest and extraordinary items. EBITDA is not a measure of financial
performance under generally accepted accounting principles. Items
excluded from EBITDA are significant components in understanding and
assessing financial performance. EBITDA is a measure commonly used by
financial analysts and investors to evaluate the financial results of
companies in our industry, and we believe it therefore provides useful
information to investors. EBITDA should not be considered in isolation or
as an alternative to net income, cash flows generated by operations,
investing or financing activities, or other financial statement data
presented in the consolidated financial statements as indicators of
financial performance or liquidity. Because EBITDA is not a measurement
determined in accordance with generally accepted accounting principles and
is susceptible to varying calculations, EBITDA as presented may not be
comparable to similarly titled measures of other companies.
Table of Contents
Year Ended December 31,
2001
2000
1999
(in thousands)
$
112,018
$
91,670
$
42,244
(32,290
)
(30,401
)
(16,741
)
(5,223
)
507
939
362
(29,716
)
(36,126
)
(21,461
)
(3,491
)
(4,144
)
(3,662
)
(8,671
)
(9,979
)
(2,811
)
(8,676
)
(6,247
)
(5,814
)
$
29,681
$
5,712
$
(13,106
)
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Table of Contents
restrictions against incurring additional indebtedness,
disposing of assets,
Table of Contents
incurring capital expenditures,
making investments,
restrictions against paying
certain dividends,
engaging in transactions with affiliates,
incurring contingent obligations, and
allowing or causing fundamental changes.
Table of Contents
Payments Due by Year
Contractual
Obligations
Total
2002
2003-2005
2006-2007
After 2007
(in
thousands)
$
175,000
$
175,000
96,782
$
17,714
$
79,068
14,849
8,659
6,102
$
88
1,473
303
1,170
319
98
221
288,423
26,774
86,561
88
175,000
4,361
250
4,111
11,250
1,250
3,750
2,500
3,750
39,419
1,400
4,298
2,996
30,725
155,492
53,247
81,207
15,116
5,922
16,619
1,197
3,467
2,304
9,651
$
515,564
$
84,118
$
183,394
$
23,004
$
225,048
Table of Contents
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to interest rate changes, primarily as a result of floating interest rates on borrowings under our credit facility. A change in interest rates by one percentage point on variable rate debt would have resulted in interest expense fluctuating approximately $0.8 million for the year ended December 31, 2001. As required by our credit agreement, on March 30, 2001 we entered into an interest rate swap agreement that fixes the interest rate cost to us on a portion of the U.S. term loans outstanding under our credit facility for a period of four years. The swap became effective on April 27, 2001. In January 2002 we amended the swap to mature in March 2003. As of December 31, 2001, approximately $69 million of variable credit facility debt has been converted to fixed rate debt. The fixed rate portion of all of our outstanding U.S. term loans was 91% as of December 31, 2001.
Approximately 17% of our term-loan borrowings under our credit agreement are denominated in Canadian dollars. Although we are not required by our credit agreement to maintain a hedge on our foreign currency risk, we have entered into a five year agreement that allows us to limit the cost of Canadian dollars to a range of U.S.$0.6631 to U.S.$0.6711 per Canadian dollar to limit our risk on the potential fluctuation in the exchange rate of the Canadian dollar to the U.S. dollar.
38
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
See Consolidated Financial Statements and Notes thereto commencing at Page F-1.
ITEM 9. CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
Not applicable
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information required under this item with respect to the Directors of the Registrant will appear under the caption Election of Directors (Item 1 on Proxy Card) in the definitive Proxy Statement relating to the Registrants 2002 Annual Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Securities Exchange Act of 1934 (the Exchange Act) and is hereby specifically incorporated herein by reference thereto.
The information required under this item with respect to the Executive Officers of the Registrant will appear under the caption Executive Officers in the definitive Proxy Statement relating to the Registrants 2002 Annual Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Exchange Act, and is hereby specifically incorporated herein by reference thereto.
ITEM 11. EXECUTIVE COMPENSATION
The information required under this item will appear under the caption Executive Compensation in the definitive Proxy Statement relating to the Registrants 2002 Annual Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Exchange Act, and is hereby specifically incorporated herein by reference thereto, except for the Report of the Compensation Committee of the Board of Directors on Executive Compensation contained therein, which is not so incorporated by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required under this item will appear under the caption Security Ownership of Certain Beneficial Owners and Management in the definitive Proxy Statement relating to the Registrants 2002 Annual Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Exchange Act, and is hereby specifically incorporated herein by reference thereto.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required under this item will appear under the caption Certain Relationships and Related Transactions in the definitive Proxy Statement relating to the Registrants 2002 Annual
39
Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Exchange Act, and is hereby specifically incorporated herein by reference hereto.
PART IV
EXHIBITS, FINANCIAL STATEMENTS SCHEDULE, AND
REPORTS ON FORM 8-K
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) The consolidated financial statements filed as part of this Annual Report on Form 10-K are described in the Index to Financial Statements.
(b) Form 8-K, dated October 1, 2001, pursuant to Item 5, in connection with the adoption by our Board of Directors of a Shareholder Rights Plan.
(c) The following exhibits are hereby filed as part of this Annual Report
on Form 10-K:
Exhibit
Number
Document
2.1
Stock Purchase Agreement dated as of October 1, 1999 by and among Select
Medical Corporation, NC Resources, Inc. and NovaCare, Inc., incorporated by
reference to Exhibit 2.3 of the Companys Registration Statement on Form
S-1 (Reg. No. 333-48856).
2.2
First Amendment dated as of November 19, 1999 to Stock Purchase Agreement
dated as of October 1, 1999 by and among Select Medical Corporation, NC
Resources, Inc. and NovaCare, Inc., incorporated by reference to Exhibit
2.4 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
3.1
Form of Restated Certificate of Incorporation, incorporated by reference to
Exhibit 3.1 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
3.2
Amended and Restated Bylaws.
3.3
Amendment No. 1 to Amended and Restated Bylaws.
3.4
Amendment No. 2 to Amended and Restated Bylaws.
4.1
Indenture governing 9 1/2% Senior Subordinated Notes due 2009 among Select
Medical Corporation, the Subsidiary Guarantors named therein and State
Street Bank and Trust Company, N.A., dated June 11, 2001, incorporated by
reference to Exhibit 4.1 of the Companys Registration Statement on Form
S-4 (Reg. No. 333-63828).
4.2
Form of 9 1/2% Senior Subordinated Notes due 2009 (included in
Exhibit 4.1).
40
Exhibit
Number
Document
4.3
Exchange and Registration Rights Agreement, dated June 11, 2001 by and
among Select Medical Corporation, the Subsidiary Guarantors named therein,
J.P. Morgan Securities Inc., Merrill Lynch, Pierce, Fenner & Smith
Incorporated, Credit Suisse First Boston Corporation, CIBC World Markets
Corp. and First Union Securities, Inc, incorporated by reference to Exhibit
4.3 of the Companys Registration Statement on Form S-4 (Reg. No.
333-63828).
10.1
Registration Agreement dated as of February 5, 1997 by and among Select
Medical Corporation; Golder, Thoma, Cressey, Rauner Fund V, L.P.; Welsh,
Carson, Anderson & Stowe VII, L.P., Rocco A. Ortenzio and Robert A.
Ortenzio, incorporated by reference to Exhibit 10.1 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.2
Amendment No. 1 dated as of December 15, 1998 to Registration Agreement
dated as of February 5, 1997 by and among Select Medical Corporation;
Golder, Thoma, Cressey, Rauner Fund V, L.P.; Welsh, Carson, Anderson &
Stowe VII, L.P., Rocco A. Ortenzio and Robert A. Ortenzio, incorporated by
reference to Exhibit 10.2 of the Companys Registration Statement on Form
S-1 (Reg. No. 333-48856).
10.3
Amendment No. 2 dated as of November 19, 1999 to Registration Agreement
dated as of February 5, 1997 by and among Select Medical; Golder, Thoma,
Cressey, Rauner Fund V, L.P.; Welsh, Carson, Anderson & Stowe VII, L.P.,
Rocco A. Ortenzio and Robert A. Ortenzio, incorporated by reference to
Exhibit 10.3 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.4
Credit Agreement dated as of September 22, 2000 among Select Medical
Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The
Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC,
Inc., incorporated by reference to Exhibit 10.4 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.5
Employment Agreement dated as of December 16, 1998 between Select Medical
Corporation and David W. Cross, incorporated by reference to Exhibit 10.8
of the Companys Registration Statement on Form S-1 (Reg.
No. 333-48856).
10.6
Other Senior Management Agreement dated as of June 2, 1997 between Select
Medical Corporation and S. Frank Fritsch, incorporated by reference to
Exhibit 10.9 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.7
Change of Control Agreement dated as of March 1, 2000 between Select
Medical Corporation and S. Frank Fritsch, incorporated by reference to
Exhibit 10.10 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.8
Change of Control Agreement dated as of March 1, 2000 between Select
Medical Corporation and Martin F. Jackson, incorporated by reference to
Exhibit 10.11 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
41
Exhibit
Number
Document
10.9
Employment Agreement dated as of December 21, 1999 between RehabClinics,
Inc. and Edward R. Miersch, incorporated by reference to Exhibit 10.12 of
the Companys Registration Statement on Form S-1 (Reg.
No. 333-48856).
10.10
Change of Control Agreement dated as of March 1, 2000 between Select
Medical Corporation and Edward R. Miersch, incorporated by reference to
Exhibit 10.13 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.11
Employment Agreement dated as of March 1, 2000 between Select Medical
Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit
10.14 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.12
Amendment dated as of August 8, 2000 to Employment Agreement dated as of
March 1, 2000 between Select Medical Corporation and Robert A. Ortenzio,
incorporated by reference to Exhibit 10.15 of the Companys Registration
Statement on Form S-1 (Reg. No. 333-48856).
10.13
Employment Agreement dated as of March 1, 2000 between Select Medical
Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit
10.16 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.14
Amendment dated as of August 8, 2000 to Employment Agreement dated as of
March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio,
incorporated by reference to Exhibit 10.17 of the Companys Registration
Statement on Form S-1 (Reg. No. 333-48856).
10.15
Split Dollar Agreement dated as of October 6, 2000 between Select Medical
Corporation, Michael E. Salerno and Rocco A. Ortenzio, incorporated by
reference to Exhibit 10.18 of the Companys Registration Statement on Form
S-1 (Reg. No. 333-48856).
10.16
Employment Agreement dated as of March 1, 2000 between Select Medical
Corporation and Patricia A. Rice, incorporated by reference to Exhibit
10.19 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.17
Amendment dated as of August 8, 2000 to Employment Agreement dated as of
March 1, 2000 between Select Medical Corporation and Patricia A. Rice,
incorporated by reference to Exhibit 10.20 of the Companys Registration
Statement on Form S-1 (Reg. No. 333-48856).
10.18
Other Senior Management Agreement dated as of March 28, 1997 between Select
Medical Corporation and Michael E. Tarvin, incorporated by reference to
Exhibit 10.21 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
42
Exhibit
Number
Document
10.19
Change of Control Agreement dated as of March 1, 2000 between Select
Medical Corporation and Michael E. Tarvin, incorporated by reference to
Exhibit 10.22 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.20
Employment Agreement dated as of May 22, 2000 between Select Medical
Corporation and LeRoy S. Zimmerman, incorporated by reference to Exhibit
10.23 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.21
Office Lease Agreement dated as of May 18, 1999 between Select Medical
Corporation and Old Gettysburg Associates I, incorporated by reference to
Exhibit 10.24 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.22
First Addendum dated June 1999 to Office Lease Agreement dated as of May
18, 1999 between Select Medical Corporation and Old Gettysburg Associates
I, incorporated by reference to Exhibit 10.25 of the Companys Registration
Statement on Form S-1 (Reg. No. 333-48856).
10.23
Second Addendum dated as of February 1, 2000 to Office Lease Agreement
dated as of May 18, 1999 between Select Medical Corporation and Old
Gettysburg Associates I, incorporated by reference to Exhibit 10.26 of the
Companys Registration Statement on Form S-1 (Reg.
No. 333-48856).
10.24
Office Lease Agreement dated as of June 17, 1999 between Select Medical
Corporation and Old Gettysburg Associates III, incorporated by reference to
Exhibit 10.27 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.25
Equipment Lease Agreement dated as of April 1, 1997 between Select Medical
Corporation and Select Capital Corporation, incorporated by reference to
Exhibit 10.28 of the Companys Registration Statement on Form S-1 (Reg. No.
333-48856).
10.26
First Amendment dated as of December 8, 1997 to Equipment Lease Agreement
dated as of April 1, 1997 between Select Medical Corporation and Select
Capital Corporation, incorporated by reference to Exhibit 10.29 of the
Companys Registration Statement on Form S-1 (Reg.
No. 333-48856).
10.27
Second Amendment dated as of January 28, 2000 to Equipment Lease Agreement
dated as of April 1, 1997 between Select Medical Corporation and Select
Capital Corporation, incorporated by reference to Exhibit 10.30 of the
Companys Registration Statement on Form S-1 (Reg.
No. 333-48856).
10.28
Amended and Restated 1997 Stock Option Plan, amended and restated February
22, 2001, incorporated by reference to Exhibit 10.31 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
43
Exhibit
Number
Document
10.29
First Amendment dated as of October 15, 2000 to Employment Agreement dated
as of December 16, 1998 between Select Medical Corporation and David W.
Cross, incorporated by reference to Exhibit 10.33 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.30
Amended and Restated Senior Management Agreement dated as of May 7, 1997
between Select Medical Corporation, John Ortenzio, Martin Ortenzio, Select
Investments II, Select Partners, L.P. and Rocco Ortenzio, incorporated by
reference to Exhibit 10.34 of the Companys Registration Statement on Form
S-1 (Reg. No. 333-48856).
10.31
Amendment No. 1 dated as of January 1, 2000 to Amended and Restated Senior
Management Agreement dated May 7, 1997 between Select Medical Corporation
and Rocco Ortenzio, incorporated by reference to Exhibit 10.35 of the
Companys Registration Statement on Form S-1 (Reg.
No. 333- 48856).
10.32
Naming, Promotional and Sponsorship Agreement dated as of October 1, 1997
between NovaCare, Inc. and the Philadelphia Eagles Limited Partnership,
assumed by Select Medical Corporation in a Consent and Assumption Agreement
dated November 19, 1999 by and among NovaCare, Inc., Select Medical
Corporation and the Philadelphia Eagles Limited Partnership, incorporated
by reference to Exhibit 10.36 of the Companys Registration Statement on
Form S-1 (Reg. No. 333-48856).
10.33
Cost Sharing Agreement, dated December 11, 2000, among Select Transport,
Inc., Select Medical Corporation and Select Air II Corporation,
incorporated by reference to Exhibit 10.39 of the Companys Registration
Statement on Form S-1 (Reg. No. 333-48856).
10.34
Amended and Restated Deferred Compensation Agreement dated January 1, 2000
between Select Medical Corporation and Rocco A. Ortenzio, incorporated by
reference to Exhibit 10.40 of the Companys Registration Statement on Form
S-1 (Reg. No. 333-48856).
10.35
Settlement Agreement dated as of July 6, 2000 by and among Select Medical
Corporation, NC Resources, Inc, NAHC Inc., and NovaCare Holdings, Inc,
incorporated by reference to Exhibit 10.44 of the Companys Registration
Statement on Form S-1 (Reg. No. 333-48856).
10.36
First Amendment dated December 28, 2000 to the Credit Agreement dated as of
September 22, 2000 among Select Medical Corporation, Canadian Back
Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of
Canada, Banc of America Securities, LLC and CIBC, Inc., incorporated by
reference to Exhibit 10.45 of the Companys Registration Statement on Form
S-1 (Reg. No. 333-48856).
10.37
Second Amendment dated January 18, 2001 to the Amended Credit Agreement
dated as of September 22, 2000 among Select Medical Corporation, Canadian
Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank
of Canada, Banc of America Securities, LLC and CIBC, Inc., incorporated by
reference to Exhibit 10.46 of the Companys Registration Statement on Form
S-1 (Reg. No. 333-48856).
44
Exhibit
Number
Document
10.38
Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated
as of March 1, 2000 between Select Medical Corporation and Rocco A.
Ortenzio, incorporated by reference to Exhibit 10.47 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.39
Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated
as of March 1, 2000 between Select Medical Corporation and Robert A.
Ortenzio, incorporated by reference to Exhibit 10.48 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.40
Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated
as of March 1, 2000 between Select Medical Corporation and Patricia A.
Rice, incorporated by reference to Exhibit 10.49 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.41
Amendment No. 1 dated as of February 23, 2001 to Employment Agreement dated
as of May 22, 2000 between Select Medical Corporation and LeRoy S.
Zimmerman, incorporated by reference to Exhibit 10.50 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.42
Amendment dated as of February 23, 2001 to Change of Control Agreement
dated as of March 1, 2000 between Select Medical Corporation and Edward R.
Miersch, incorporated by reference to Exhibit 10.51 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.43
Amendment dated as of February 23, 2001 to Change of Control Agreement
dated as of March 1, 2000 between Select Medical Corporation and Martin F.
Jackson, incorporated by reference to Exhibit 10.52 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.44
Amendment dated as of February 23, 2001 to Change of Control Agreement
dated as of March 1, 2000 between Select Medical Corporation and S. Frank
Fritsch, incorporated by reference to Exhibit 10.53 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.45
Amendment dated as of February 23, 2001 to Change of Control Agreement
dated as of March 1, 2000 between Select Medical Corporation and Michael E.
Tarvin, incorporated by reference to Exhibit 10.54 of the Companys
Registration Statement on Form S-1 (Reg. No. 333-48856).
10.46
Third Amendment dated May 31, 2001 to the Credit Agreement dated as of
September 22, 2000 among Select Medical Corporation, Canadian Back
Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of
Canada, Banc of America Securities, LLC and CIBC Inc., incorporated by
reference to Exhibit 10.49 of the Companys Registration Statement on Form
S-4 (Reg. No. 333-63828).
10.47
Amendment No. 3 dated as of April 24, 2001 to Employment Agreement dated as
of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio,
incorporated by reference to Exhibit 10.50 of the Companys Registration
Statement on Form S-4 (Reg. No. 333-63828).
45
Exhibit
Number
Document
10.48
First Amendment to Cost Sharing Agreement dated as of April 1, 2001 by and
among Select Medical Corporation, Select Transport, Inc. and Select Air II
Corporation, incorporated by reference to Exhibit 10.51 of the Companys
Registration Statement on Form S-4 (Reg. No. 333-63828).
10.49
Third Addendum dated as of May 17, 2001 to Office Lease Agreement dated as
of May 18, 1999 between Select Medical Corporation and Old Gettysburg
Associates I, incorporated by reference to Exhibit 10.52 of the Companys
Registration Statement on Form S-4 (Reg. No. 333-63828).
10.50
Office Lease Agreement dated as of May 15, 2001 by and between Select
Medical Corporation and Old Gettysburg Associates II, incorporated by
reference to Exhibit 10.53 of the Companys Registration Statement on Form
S-4 (Reg. No. 333-63828).
10.51
Purchase Agreement, dated June 11, 2001 by and among Select Medical
Corporation, the Subsidiary Guarantors named therein, J.P. Morgan
Securities Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit
Suisse First Boston Corporation, CIBC World Markets Corp. and First Union
Securities, Inc, incorporated by reference to Exhibit 10.54 of the
Companys Registration Statement on Form S-4 (Reg.
No. 333-63828).
10.52
Amendment No. 4 to Employment Agreement dated as of September 17, 2001
between Select Medical Corporation and Rocco A. Ortenzio.
10.53
Amendment No. 3 to Employment Agreement dated as of September 17, 2001
between Select Medical Corporation and Robert A. Ortenzio.
10.54
Fourth Addendum to Lease Agreement dated as of September 1, 2001 by and
between Old Gettysburg Associates and Select Medical Corporation.
10.55
Rights Agreement dated as of September 17, 2001, between Select Medical
Corporation and Mellon Investor Services LLC, as Rights Agent, incorporated
by reference to Exhibit 1.1 of the Companys Registration Statement on Form
8-A filed October 1, 2001 (SEC File No. 000-32499).
10.56
Change of Control Agreement dated as of March 1, 2000 between Select
Medical Corporation and Scott A. Romberger.
10.57
Amendment dated as of February 23, 2001 to Change of Control Agreement
dated as of March 1, 2000 between Select Medical Corporation and Scott A.
Romberger.
10.58
Change of Control Agreement dated as of March 1, 2000 between Select
Medical Corporation and James J. Talalai.
10.59
Amendment dated as of February 23, 2001 to Change of Control Agreement
dated as of March 1, 2000 between Select Medical Corporation and James J.
Talalai.
46
Exhibit
Number
Document
10.60
Fourth Amendment dated October 5, 2001 to the Credit Agreement dated as of
September 22, 2000 among Select Medical Corporation, Canadian Back
Institute Limited, The Chase Manhattan Bank, the Chase Manhattan Bank of
Canada, Banc of America Securities, LLC and CIBC Inc.
10.61
Change of Control Agreement dated as of November 21, 2001 between Select
Medical Corporation and David W. Cross.
12.1
Computation of
Ratio of Earnings to Fixed Charges.
21.1
Subsidiaries of Select Medical Corporation.
23.1
Consent of PricewaterhouseCoopers LLP.
47
Select Medical Corporation
Consolidated Financial Statements
With Report of Independent Accountants
Contents
F-1
F-2
F-3
F-4
F-5
F-6
Report of Independent Accountants
To the Board of Directors and Stockholders
of Select Medical Corporation
In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, changes in stockholders equity and comprehensive income (loss) and cash flows present fairly, in all material respects, the consolidated financial position of Select Medical Corporation and its subsidiaries (the Company) as of December 31, 2001 and 2000 and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2001, in conformity with accounting principles generally accepted in the United States of America. These consolidated financial statements are the responsibility of the Companys management; our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
/s/ PricewaterhouseCoopers LLP
Harrisburg, Pennsylvania
February 15, 2002
F-1
Select Medical Corporation
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
December 31, | ||||||||||||
|
||||||||||||
2001 | 2000 | |||||||||||
|
|
|||||||||||
Assets
|
||||||||||||
Current Assets:
|
||||||||||||
Cash and cash equivalents
|
$ | 10,703 | $ | 3,151 | ||||||||
Accounts receivable, net of allowance for doubtful accounts of $79,889
and $75,517 in 2001 and 2000, respectively
|
218,393 | 196,505 | ||||||||||
Prepaid income taxes
|
| 1,093 | ||||||||||
Current deferred tax asset
|
28,945 | | ||||||||||
Other current assets
|
18,444 | 17,407 | ||||||||||
|
|
|
||||||||||
Total Current Assets
|
276,485 | 218,156 | ||||||||||
Property and equipment, net
|
92,005 | 84,976 | ||||||||||
Intangible assets
|
247,257 | 251,399 | ||||||||||
Non-current deferred tax asset
|
6,674 | | ||||||||||
Other assets
|
28,424 | 32,269 | ||||||||||
|
|
|
||||||||||
Total Assets
|
$ | 650,845 | $ | 586,800 | ||||||||
|
|
|
||||||||||
Liabilities and Stockholders Equity
|
||||||||||||
Current Liabilities:
|
||||||||||||
Bank overdrafts
|
$ | 6,083 | $ | 14,218 | ||||||||
Current portion of long-term debt and notes payable
|
26,774 | 18,746 | ||||||||||
Accounts payable
|
33,520 | 28,795 | ||||||||||
Accrued payroll
|
27,160 | 21,466 | ||||||||||
Accrued vacation
|
12,820 | 7,701 | ||||||||||
Accrued restructuring
|
1,819 | 4,701 | ||||||||||
Accrued other
|
23,568 | 15,451 | ||||||||||
Income taxes payable
|
1,735 | | ||||||||||
Due to third party payors
|
16,257 | 1,511 | ||||||||||
|
|
|
||||||||||
Total Current Liabilities
|
149,736 | 112,589 | ||||||||||
Long-term debt, net of current portion
|
261,649 | 284,042 | ||||||||||
|
|
|
||||||||||
Total Liabilities
|
411,385 | 396,631 | ||||||||||
Commitments and Contingencies (Note 18)
|
||||||||||||
Minority interest in consolidated subsidiary companies
|
5,176 | 12,098 | ||||||||||
Preferred stock Class A, non-voting, $1,000 per share redemption value
Authorized shares 55,000, Issued and outstanding shares 52,838 in 2000
|
| 65,481 | ||||||||||
Convertible Preferred stock Class B, non-voting, $3.75 per share redemption value
Authorized shares 16,000,000, Issued and outstanding shares 16,000,000 shares in 2000
|
| 64,092 | ||||||||||
Stockholders Equity:
|
||||||||||||
Common stock $.01 per value: Authorized shares 200,000,000 and 78,000,000
in 2001 and 2000, respectively, Issued shares 46,488,000 and 25,697,000
in 2001 and 2000, respectively
|
465 | 257 | ||||||||||
Capital in excess of par
|
231,349 | 73,069 | ||||||||||
Retained earnings (accumulated deficit)
|
5,924 | (23,757 | ) | |||||||||
Treasury stock, at cost 461,000 and 221,000 shares in 2001 and 2000, respectively
|
(1,560 | ) | (1,039 | ) | ||||||||
Accumulated other comprehensive loss
|
(1,894 | ) | (32 | ) | ||||||||
|
|
|
||||||||||
Total Stockholders Equity
|
234,284 | 48,498 | ||||||||||
|
|
|
||||||||||
Total Liabilities and Stockholders Equity
|
$ | 650,845 | $ | 586,800 | ||||||||
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
F-2
Select Medical Corporation
Consolidated Statements of Operations
(in thousands, except per share amounts)
For the Year Ended December 31, | |||||||||||||||
|
|||||||||||||||
2001 | 2000 | 1999 | |||||||||||||
|
|
|
|||||||||||||
Net operating revenues
|
$ | 958,956 | $ | 805,897 | $ | 455,975 | |||||||||
|
|
|
|
||||||||||||
Costs and expenses:
|
|||||||||||||||
Cost of services
|
776,295 | 656,461 | 383,453 | ||||||||||||
General and administrative
|
35,630 | 28,431 | 21,420 | ||||||||||||
Bad debt expense
|
35,013 | 29,335 | 8,858 | ||||||||||||
Depreciation and amortization
|
32,290 | 30,401 | 16,741 | ||||||||||||
Special charge
|
| | 5,223 | ||||||||||||
|
|
|
|
||||||||||||
Total costs and expenses
|
879,228 | 744,628 | 435,695 | ||||||||||||
|
|
|
|
||||||||||||
Income from operations
|
79,728 | 61,269 | 20,280 | ||||||||||||
Other income and expense:
|
|||||||||||||||
Interest income
|
(507 | ) | (939 | ) | (362 | ) | |||||||||
Interest expense
|
29,716 | 36,126 | 21,461 | ||||||||||||
|
|
|
|
||||||||||||
Income (loss) before minority interests
and income taxes
|
50,519 | 26,082 | (819 | ) | |||||||||||
Minority interest in consolidated
subsidiary companies
|
3,491 | 4,144 | 3,662 | ||||||||||||
|
|
|
|
||||||||||||
Income (loss) before income taxes
|
47,028 | 21,938 | (4,481 | ) | |||||||||||
Income tax expense
|
8,671 | 9,979 | 2,811 | ||||||||||||
|
|
|
|
||||||||||||
Net income (loss) before extraordinary item
|
38,357 | 11,959 | (7,292 | ) | |||||||||||
Extraordinary item, net of tax
|
8,676 | 6,247 | 5,814 | ||||||||||||
|
|
|
|
||||||||||||
Net income (loss)
|
$ | 29,681 | $ | 5,712 | $ | (13,106 | ) | ||||||||
Less: Preferred dividends
|
2,513 | 8,780 | 5,175 | ||||||||||||
|
|
|
|
||||||||||||
Net income (loss) available to common stockholders
|
$ | 27,168 | $ | (3,068 | ) | $ | (18,281 | ) | |||||||
|
|
|
|
||||||||||||
Net income (loss) per common share:
|
|||||||||||||||
Basic:
|
|||||||||||||||
Income (loss) before extraordinary item
|
$ | 0.90 | $ | 0.13 | $ | (0.50 | ) | ||||||||
Extraordinary item
|
(0.22 | ) | (0.25 | ) | (0.24 | ) | |||||||||
|
|
|
|
||||||||||||
Income (loss) per common share
|
$ | 0.68 | $ | (0.12 | ) | $ | (0.74 | ) | |||||||
|
|
|
|
||||||||||||
Diluted:
|
|||||||||||||||
Income (loss) before extraordinary item
|
$ | 0.81 | $ | 0.12 | $ | (0.50 | ) | ||||||||
Extraordinary item
|
(0.19 | ) | (0.24 | ) | (0.24 | ) | |||||||||
|
|
|
|
||||||||||||
Income (loss) per common share
|
$ | 0.62 | $ | (0.12 | ) | $ | (0.74 | ) | |||||||
|
|
|
|
||||||||||||
Weighted average shares outstanding:
|
|||||||||||||||
Basic
|
39,957 | 25,457 | 24,557 | ||||||||||||
Diluted
|
45,464 | 25,907 | 24,557 |
The accompanying notes are an integral part of these consolidated financial statements.
F-3
Select Medical Corporation
Consolidated Statements of Changes in Stockholders Equity and Comprehensive Income (Loss)
(in thousands)
Common | Retained | Accumulated | |||||||||||||||||||||||||||
Stock | Capital in | Earnings/ | Other | ||||||||||||||||||||||||||
Common | Par | Excess of | (Accumulated | Treasury | Comprehensive | Comprehensive | |||||||||||||||||||||||
Stock | Value | Par | Deficit) | Stock | Loss | Income (Loss) | |||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at December 31, 1998
|
24,393 | $ | 244 | $ | 76,688 | $ | (16,363 | ) | $ | (48 | ) | $ | (27 | ) | |||||||||||||||
Net loss
|
(13,106 | ) | $ | (13,106 | ) | ||||||||||||||||||||||||
Other comprehensive income
|
5 | 5 | |||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
Total comprehensive loss
|
$ | (13,101 | ) | ||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
Issuance of common stock
|
1,132 | 11 | 6,239 | ||||||||||||||||||||||||||
Accretion of preferred stock issuance costs
|
(639 | ) | |||||||||||||||||||||||||||
Issuance of warrants
|
2,389 | ||||||||||||||||||||||||||||
Purchase of treasury stock
|
(781 | ) | |||||||||||||||||||||||||||
Preferred stock dividends
|
(5,175 | ) | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at December 31, 1999
|
25,525 | 255 | 79,502 | (29,469 | ) | (829 | ) | (22 | ) | ||||||||||||||||||||
Net income
|
5,712 | $ | 5,712 | ||||||||||||||||||||||||||
Other comprehensive loss
|
(10 | ) | (10 | ) | |||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
Total comprehensive income
|
$ | 5,702 | |||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
Issuance of common stock
|
172 | 2 | 1,116 | ||||||||||||||||||||||||||
Purchase of treasury stock
|
(210 | ) | |||||||||||||||||||||||||||
Issuance of warrants
|
1,104 | ||||||||||||||||||||||||||||
Valuation of non-employee options
|
127 | ||||||||||||||||||||||||||||
Preferred stock dividends
|
(8,780 | ) | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at December 31, 2000
|
25,697 | 257 | 73,069 | (23,757 | ) | (1,039 | ) | (32 | ) | ||||||||||||||||||||
Net income
|
29,681 | $ | 29,681 | ||||||||||||||||||||||||||
Other comprehensive loss
|
(1,862 | ) | (1,862 | ) | |||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
Total comprehensive income
|
$ | 27,819 | |||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
Issuance of common stock in
connection with initial public offering,
net of issuance costs of $2,262
|
10,350 | 104 | 89,077 | ||||||||||||||||||||||||||
Conversion of Class B Preferred Stock
|
9,216 | 92 | 59,908 | ||||||||||||||||||||||||||
Stock issued to acquire minority interest
|
523 | 5 | 4,968 | ||||||||||||||||||||||||||
Purchase of treasury stock
|
(521 | ) | |||||||||||||||||||||||||||
Issuance of common stock
|
702 | 7 | 4,327 | ||||||||||||||||||||||||||
Tax benefit of stock option exercises
|
2,513 | ||||||||||||||||||||||||||||
Preferred stock dividends
|
(2,513 | ) | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance at December 31, 2001
|
46,488 | $ | 465 | $ | 231,349 | $ | 5,924 | $ | (1,560 | ) | $ | (1,894 | ) | ||||||||||||||||
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
F-4
Select Medical Corporation
Consolidated Statements of Cash Flows
(in thousands)
For the Year Ended December 31, | ||||||||||||||
|
||||||||||||||
2001 | 2000 | 1999 | ||||||||||||
|
|
|
||||||||||||
Operating activities
|
||||||||||||||
Net income (loss)
|
$ | 29,681 | $ | 5,712 | $ | (13,106 | ) | |||||||
Adjustments to reconcile net income (loss) to net cash
provided by (used in) operating activities:
|
||||||||||||||
Depreciation and amortization
|
32,290 | 30,401 | 16,741 | |||||||||||
Provision for bad debts
|
35,013 | 29,335 | 8,858 | |||||||||||
Special charge
|
| | 5,223 | |||||||||||
Extraordinary item, net of tax
|
8,676 | 6,247 | 5,814 | |||||||||||
Deferred income taxes
|
(9,670 | ) | | | ||||||||||
Loss (gain) on sale of assets
|
| 111 | (215 | ) | ||||||||||
Minority interests
|
3,491 | 4,144 | 3,662 | |||||||||||
Changes in operating assets and liabilities, net of
effects from acquisition of businesses:
|
||||||||||||||
Accounts receivable
|
(49,432 | ) | (36,964 | ) | (47,290 | ) | ||||||||
Other current assets
|
(456 | ) | (2,692 | ) | (1,728 | ) | ||||||||
Other assets
|
1,053 | (5,019 | ) | (10,868 | ) | |||||||||
Accounts payable
|
4,715 | 1,380 | 29 | |||||||||||
Due to third-party payors
|
14,746 | (17,673 | ) | 8,715 | ||||||||||
Accrued expenses
|
14,023 | (17 | ) | (2,688 | ) | |||||||||
Income taxes
|
11,640 | 7,548 | 1,696 | |||||||||||
|
|
|
|
|||||||||||
Net cash provided by (used in) operating activities
|
95,770 | 22,513 | (25,157 | ) | ||||||||||
|
|
|
|
|||||||||||
Investing
activities
|
||||||||||||||
Purchases of property and equipment, net
|
(24,011 | ) | (22,430 | ) | (10,896 | ) | ||||||||
Escrow receivable
|
| 29,948 | | |||||||||||
Proceeds from disposal of assets held for sale
|
| 13,000 | | |||||||||||
Proceeds from disposal of assets
|
808 | 2,947 | 988 | |||||||||||
Earnout payments
|
(5,660 | ) | (3,430 | ) | | |||||||||
Acquisition of businesses, net of cash acquired
|
(33,084 | ) | (5,838 | ) | (171,354 | ) | ||||||||
|
|
|
|
|||||||||||
Net cash provided by (used in) investing activities
|
(61,947 | ) | 14,197 | (181,262 | ) | |||||||||
|
|
|
|
|||||||||||
Financing activities
|
||||||||||||||
Issuance of 9.5% Senior Subordinated Notes
|
175,000 | | | |||||||||||
Proceeds from issuance of debt
|
| | 68,194 | |||||||||||
Net proceeds (repayments) on credit facility debt
|
(98,320 | ) | (12,000 | ) | 86,655 | |||||||||
Repayment of 10% Senior Subordinated Notes
|
(90,000 | ) | | | ||||||||||
Principal payments on seller and other debt
|
(19,030 | ) | (27,577 | ) | (10,064 | ) | ||||||||
Net proceeds from issuance of Class B
convertable preferred stock
|
| | 59,361 | |||||||||||
Proceeds from initial public offering, net of fees
|
89,181 | | | |||||||||||
Proceeds from issuance of common stock
|
4,334 | 1,118 | 1,041 | |||||||||||
Acquisition of treasury stock
|
| (210 | ) | (781 | ) | |||||||||
Redemption of Class A Preferred Stock
|
(52,838 | ) | (11 | ) | (214 | ) | ||||||||
Payment of Class A and Class B Preferred Stock dividends
|
(19,248 | ) | | | ||||||||||
Proceeds from (payments of) bank overdrafts
|
(8,135 | ) | 7,253 | 4,893 | ||||||||||
Payment of deferred financing costs
|
(4,681 | ) | (4,563 | ) | (10,883 | ) | ||||||||
Distributions to minority interests
|
(2,427 | ) | (1,626 | ) | (722 | ) | ||||||||
|
|
|
|
|||||||||||
Net cash provided by (used in) financing activities
|
(26,164 | ) | (37,616 | ) | 197,480 | |||||||||
|
|
|
|
|||||||||||
Effect of exchange rate changes on cash
and cash equivalents
|
(107 | ) | (10 | ) | 5 | |||||||||
|
|
|
|
|||||||||||
Net increase (decrease) in cash and cash equivalents
|
7,552 | (916 | ) | (8,934 | ) | |||||||||
Cash and cash equivalents at beginning of period
|
3,151 | 4,067 | 13,001 | |||||||||||
|
|
|
|
|||||||||||
Cash and cash equivalents at end of period
|
$ | 10,703 | $ | 3,151 | $ | 4,067 | ||||||||
|
|
|
|
|||||||||||
Supplemental Cash Flow Information
|
||||||||||||||
Cash paid for interest
|
$ | 30,547 | $ | 36,125 | $ | 15,500 | ||||||||
Cash paid for income taxes
|
$ | 6,017 | $ | 3,476 | $ | 2,112 |
The accompanying notes are an integral part of these consolidated financial statements.
F-5
Select Medical Corporation
1. Organization and Significant Accounting Policies
Business Description
Select Medical Corporation and its subsidiaries (the Company) was formed in December 1996 and commenced operations during February 1997 upon the completion of its first acquisition. The Company provides long-term acute care hospital services through its Select Specialty Hospital division and provides physical, occupational, and speech rehabilitation services through its outpatient divisions. Select Specialty Hospital division owns and operates long-term acute care hospitals. These hospitals, which average approximately 30 to 40 beds in size, operate generally in space leased within general acute care hospitals. These hospitals offer intensive nursing care, vent weaning, and therapy services to high acuity patients who require long lengths of hospital care before being discharged to a nursing home or home care environment. At December 31, 2001, 2000 and 1999, the Company operated 64, 54 and 44 long-term acute care hospitals, respectively. The Companys outpatient divisions provide rehabilitation services in outpatient clinics owned or managed by the Company and under therapy contracts with nursing homes, schools, hospitals, and home care agencies. At December 31, 2001, 2000 and 1999, the Company had operations in Canada and 37, 35 and 33 states, respectively.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company, its majority owned subsidiaries, limited liability companies and limited partnerships the Company and its subsidiaries control through ownership of general and limited partnership interests. All significant intercompany balances and transactions are eliminated in consolidation. The Company does not consolidate professional corporations where it has a long-term management contract because the Company does not have a long-term controlling interest in the affiliated practices as defined in Emerging Issues Task Force No 97-2. Instead the Company reports management services revenue earned under the terms of the agreements.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
F-6
Select Medical Corporation
Notes to Consolidated Financial Statements
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three
months or less when purchased to be cash equivalents. Cash equivalents are
stated at cost which approximates market.
Property and Equipment
Property and equipment are stated at cost net of accumulated depreciation.
Depreciation and amortization are computed using the straight-line method over
the estimated useful lives of the assets or the term of the lease, as
appropriate. The general range of useful lives is as follows:
Leasehold improvements
5 years
Furniture and equipment
2 10 years
Buildings
40 years
Qualified internally developed software costs for internal use are capitalized subsequent to both the preliminary project stage and when management has committed to funding, in accordance with Statement of Position 98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal Use. Computer hardware and software are included in furniture and equipment.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash balances and trade receivables. The Company invests its excess cash with large banks. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Companys facilities and are insured under third-party payor agreements. Because of the geographic diversity of the Companys facilities and non-governmental third-party payors, Medicare represents the Companys only concentration of credit risk.
Assets Held for Sale
Assets held for sale, which were acquired as part of a business combination, were stated at their net realizable value less approximated costs to sell. The results of operations related to the assets held for sale were excluded from the Companys operating results and were reflected as an adjustment to the purchase price when the assets were sold. No depreciation or amortization was recognized on the assets held for sale.
F-7
Select Medical Corporation
Notes to Consolidated Financial Statements
Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Management provides a valuation allowance for net deferred tax assets when it is more likely than not that a portion of such net deferred tax assets will not be recovered.
Intangible Assets
Identifiable assets and liabilities acquired in connection with business combinations accounted for under the purchase method are recorded at their respective fair values. Deferred taxes have been recorded to the extent of differences between the fair value and the tax basis of the assets acquired and liabilities assumed. The excess of the purchase price over the fair value of tangible net assets acquired is amortized on a straight-line basis over the estimated useful life of the intangible assets. Company management has allocated the intangible assets between identifiable intangibles and goodwill. Intangible assets other than goodwill primarily consist of the values assigned to trademarks and assembled work force. Management Service Agreements (MSAs) represent consideration paid to therapists groups for entering into MSAs with the Company. The Companys MSAs are for a term of 20 years with renewal options. Management believes that the estimated useful lives established at the dates of each transaction were reasonable based on the economic factors applicable to each of the businesses.
The useful life of each class of intangible asset is as follows:
Goodwill
40 years
Trademarks
40 years
Management services agreements
20 years
Assembled workforce
7 years
In accordance with Statement of Financial Accounting Standards No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of (SFAS No. 121), the Company reviews the realizability of long-lived assets, certain intangible assets and goodwill whenever events or circumstances occur which indicate recorded costs may not be recoverable. In addition, the Company also analyzes the recovery of long-lived assets on an enterprise basis.
If the expected future cash flows (undiscounted) are less than the carrying amount of such assets, the Company recognizes an impairment loss for the difference between the carrying amount of the assets and their estimated fair value (Note 11).
F-8
Select Medical Corporation
Notes to Consolidated Financial Statements
Due to Third-Party Payors
Due to third-party payors represents the difference between amounts received under interim payment plans from third-party payors for services rendered and amounts estimated to be reimbursed by those third-party payors upon settlement of cost reports.
Insurance Risk Programs
The Company is insured for malpractice claims based on a claims made or claims incurred policy purchased in the commercial market. A liability is estimated for the premium cost for tail coverage. The Company has the unilateral right to purchase tail coverage for its claims made policy at a fixed price.
Certain insurable risks such as workers compensation are insured through a captive insurance company where the Company assumes direct responsibility for lower dollar claims and shares the risk of high dollar claims with the members of the captive. Accruals for claims under the captive insurance program are recorded on a claims-incurred basis.
Minority Interests
The interests held by other parties in subsidiaries, limited liability companies and limited partnerships owned and controlled by the Company are reported on the consolidated balance sheets as minority interests. Minority interests reported in the consolidated statements of operations reflect the respective interests in the income or loss of the subsidiaries, limited liability companies and limited partnerships attributable to the other parties, the effect of which is removed from the Companys consolidated results of operations.
Treasury Stock
Treasury stock is carried at cost, determined by the first-in, first-out method.
Revenue Recognition
Net operating revenues consists of patient, contract therapy, and management services revenues and are recognized as services are rendered.
Patient service revenue is reported net of provisions for contractual allowances from third-party payors and patients. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The differences between the estimated program reimbursement rates and the standard
F-9
Select Medical Corporation
Notes to Consolidated Financial Statements
billing rates are accounted for as contractual adjustments, which are deducted from gross revenues to arrive at net operating revenues. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. Accounts receivables resulting from such payment arrangements are recorded net of contractual allowances. Net operating revenues generated directly from the Medicare program represented approximately 37%, 35% and 48% of the Companys consolidated net operating revenues for the years ended December 31, 2001, 2000 and 1999, respectively. Approximately 30% and 31% of the Companys gross accounts receivable at December 31, 2001 and 2000, respectively, are from this payor source. Medicare payments received by the Company's specialty hospitals are paid under a cost-based reimbursement methodology and are subject to final settlement based on administrative review and audit by third parties.
Contract therapy revenues are comprised primarily of billings for services rendered to nursing homes, hospitals, schools and other third parties under the terms of contractual arrangements with these entities.
Management services revenues represent revenues earned under management service agreements with professional corporations and associations in the business of providing physical, occupational, and speech therapy. Management fee receivables resulting from such management services are included in other assets.
Significant reductions in the patient service revenues generated in a hospital may occur if the Company is unable to maintain the certification of the hospital as a long-term acute care hospital (LTACH) in accordance with Medicare regulations. Additionally, the majority of the Companys hospitals operate in space leased from general acute care hospitals (host hospitals); consequently, these hospitals are also subject to Medicare Hospital within Hospital (HIH) regulations in addition to the general LTACH regulations. The HIH regulations are designed to ensure that the hospitals are organizationally and functionally independent of their host hospital. If an LTACH located in a host hospital fails to meet the HIH regulations it also loses its status as an LTACH. These determinations are made on an annual basis. Management believes its LTACHs are in compliance with the Medicare regulations regarding HIHs and LTACHs and that it will be able to meet the tests to maintain the future status of its hospitals as LTACHs under the current Medicare regulations.
Foreign Currency Translations
The Company uses the local currency as the functional currency for its Canadian operations. All assets and liabilities of foreign operations are translated into U.S. dollars at year-end exchange rates. Income statement items are translated at average exchange rates prevailing during the year. The resulting translation adjustments impacting
F-10
Select Medical Corporation
Notes to Consolidated Financial Statements
comprehensive income (loss) are recorded as a separate component of stockholders equity.
Basic and Diluted Net Income (Loss) Per Share
Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding during each year. Diluted net income (loss) per common share is based on the weighted average number of shares of common stock outstanding during each year, adjusted for the effect of common stock equivalents arising from the assumed exercise of stock options, warrants and convertible preferred stock, if dilutive.
Financial Instruments and Hedging
Effective January 1, 2001, the Company adopted SFAS No. 133. Since the Company had no derivative financial instruments at January 1, 2001, there was no cumulative effect upon adoption. The Company enters into various instruments, including derivatives, to manage interest rate and foreign exchange risks. Derivatives are limited in use and not entered into for speculative purposes. The Company enters into interest rate swaps to manage interest rate risk on a portion of its long-term borrowings. Interest rate swaps are reflected at fair value in the consolidated balance sheet and the related gains or losses are deferred in stockholders equity as a component of other comprehensive income. These deferred gains or losses are then amortized as an adjustment to interest expense over the same period in which the related interest payments being hedged are recognized in income. To the extent that any derivative instrument is not designated as a hedge under SFAS No. 133, the gains and losses are recognized in income based on fair market value.
Recent Accounting Pronouncements
Statement of Financial Accounting Standards (SFAS) No. 141 Business Combinations
In July 2001, the Financial Accounting Standards Board (FASB) issued SFAS No. 141 which addresses financial accounting and reporting for business combinations. SFAS No. 141 supersedes Accounting Principles Board Opinion No. 16, Business Combinations (ABP 16) and SFAS No. 38, Accounting for Preacquisition Contingencies of Purchased Enterprises (SFAS 38). SFAS No. 141 requires the use of the purchase method of accounting for business combinations initiated after June 1, 2001 and prohibits the use of the pooling-of-interests method. The Company has historically not used the pooling-of-interests method and therefore this aspect of the new rules will not have an impact on the Companys financial position or results of operations. SFAS No. 141 also changes the definition of intangible assets acquired in a business combination.
F-11
Select Medical Corporation
Notes to Consolidated Financial Statements
SFAS No. 142 Goodwill and Other Intangible Assets
In July 2001, the Financial Accounting Standards Board issued SFAS No. 142 which eliminates the amortization for goodwill, requires annual impairment testing of goodwill and introduces the concept of indefinite life intangible assets. The Company adopted SFAS No. 142 on January 1, 2002. SFAS No. 142 supersedes APB No. 17, Intangible Assets. An initial impairment test must be performed in 2002. Management believes that any impairment charge resulting from the adoption of SFAS No. 142 will not be material.
If the new standard had been in effect in 2001, pre-tax amortization expense in 2001 would have been reduced by approximately $8.7 million or approximately $.12 per diluted share.
SFAS No. 144 Accounting for the Impairment or Disposal of Long-Lived Assets
In October 2001, the FASB approved SFAS No. 144, which addresses financial accounting and reporting for the impairment and disposal of long-lived assets. SFAS No. 144 supercedes SFAS No. 121, Accounting for the Impairment of Long Lived Assets to Be Disposed Of. However, it retains the fundamental provisions of SFAS No. 121 for recognition and measurement of the impairment of long lived assets to be held, used or disposed of by sale.
Additionally, SFAS No. 144 supersedes the accounting and reporting provisions of APB Opinion No. 30 (APB 30), Reporting the Results of Operations Reporting the Effect of Disposal of a Segment of a Business and Extraordinary, Unusual and Infrequently Occurring Events and Transactions for the disposal of a segment of a business. SFAS No. 144 retains the requirement of APB 30 to report discontinued operations separately from continuing operations and extends that reporting to a component of an entity (rather than a segment of a business) that either has been disposed of or is classified as held for sale. SFAS No. 144 also amends Accounting Research Bulletin No. 51, Consolidated Financial Statements (ARB 51), to eliminate the exception to consolidation for a temporarily controlled subsidiary.
The Company adopted SFAS No. 144 on January 1, 2002 with no material effect on net income. Prospectively, future transactions under the scope of SFAS No. 144 may result in changes in the income statement classification, from that under prior standards, for components of the Company that are disposed of or are classified as held for sale.
F-12
Select Medical Corporation
Notes to Consolidated Financial Statements
2. Acquisitions, Disposal and Management Services Agreements
For the Year Ended December 31, 2001
Certain outpatient rehabilitation subsidiaries had minority equity owners whose purchase agreements allowed them to sell all or part of their interest to the Company in the event of an initial public offering. During 2001, the Company completed the repurchase of all or part of the minority interests of NW Rehabilitation Associates, LP, P.T. Services, Inc., Avalon Rehabilitation and Healthcare, LLC, Kentucky Orthopedic Rehabilitation, LLC and Canadian Back Institute Limited. Total consideration for these acquisitions totaled $15.9 million, including $10.9 million cash and $5.0 million of common stock.
During 2001, the Company acquired controlling interests in two outpatient therapy businesses. Outpatient therapy acquisitions consisted of Metro Therapy, Inc. on September 5, 2001 and Healthcare Innovations, Inc. on November 15, 2001.
For the Year Ended December 31, 2000
During 2000, the Company acquired controlling interests in four outpatient therapy businesses. Outpatient therapy acquisitions consisted of Delta Rehab Group, Inc. on January 20, 2000, S.T.A.R Rehab, Inc. on March 31, 2000, Crisan Physiotherapy and Sports Medicine Center, P.A. on May 31, 2000 and Rehab Health, Inc. on July 31, 2000.
For the Year Ended December 31, 1999
On January 8, 1999, the Company acquired 80% of the undivided interest in the business and certain assets of Kentucky Orthopedic Rehab Team, PSC (KORT). KORT operates rehabilitation clinics.
On November 19, 1999, the Company acquired 100% of the outstanding stock of NovaCare Physical Rehabilitation and Occupational Health Group (NovaCare) for $160,416,000 cash and $64,734,000 of liabilities assumed. The purchase was funded through the sale of 16,000,000 shares of Select Class B Convertible Preferred stock and subordinate and bank debt. The Company was indemnified against certain risks including receivables collection and certain joint venture agreements through a $36,800,000 escrow account. In November 1999, the Company recorded a $29,948,000 receivable related to the receivable collection and severance indemnification. Of this amount, $29,400,000 represents the change in estimate for allowance for doubtful accounts recorded in the NovaCare July 1, 1999 to November 19, 1999 financial statements. On July 6, 2000, the Company received proceeds of $29,948,000 from the escrow account established in connection with its acquisition of NovaCare from NovaCares former owner, NAHC, Inc. The Company also received $1.95 million in notes in satisfaction of certain severance and
F-13
Select Medical Corporation
Notes to Consolidated Financial Statements
other obligations NAHC, Inc. had to the Company under the purchase agreement. As a part of the acquisition, the Company accrued $5.7 million of costs related to the planned closure of approximately 60 outpatient rehab clinics, the downsizing and relocation of the NovaCare corporate headquarters and transaction-related expenses. NovaCare provides outpatient physical therapy and rehabilitation services.
The Company divested the Occupational Health segment of NovaCare with total sale proceeds of $13,000,000. The net proceeds of this sale and the cash flows of this segment until it was sold were allocated to assets held for sale in the allocation of the NovaCare purchase price. Differences between the actual and expected amount were recorded as an adjustment to goodwill during 2000.
During 1999, the Company acquired controlling interests in four outpatient therapy businesses. Outpatient therapy acquisitions consisted of Sports Rehabilitation and Physical Therapy Center, P.A. on March 1, 1999, Senior Rehab, Inc. on March 31, 1999, Central Jersey Rehabilitation Services, Inc. on May 15, 1999 and Hunsel Physical Therapy Services, Inc. on July 15, 1999.
Certain purchase agreements require additional payments to the former owners if specific financial targets are met. At December 31, 2001, aggregate contingent payments in connection with all acquisitions of approximately $1,200,000 have not been included in the initial cost of the business since the additional amount of such contingent consideration which may be paid in the future, if any, is not presently determinable.
The acquisitions were accounted for using the purchase method of accounting, and results of operations from acquired companies are included in these consolidated financial statements from the dates of acquisition.
The following unaudited results of operations have been prepared assuming all acquisitions consummated on or before December 31, 1999 had occurred as of the beginning of the periods presented. The acquisitions completed during 2000 and 2001 are not significant for pro forma disclosure. These results are not necessarily indicative of results of future operations nor of the results that would have occurred had the acquisitions been consummated as of the beginning of the periods presented.
1999 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
|
Revenues
|
$
|
720,116,000
|
|
|
|
|
|
|
Loss before extraordinary items
|
|
(78,569,000
|
)
|
|
|
|
|
|
Net loss
|
|
(84,383,000
|
)
|
|
F-14
Select Medical Corporation
Information with respect to businesses acquired in purchase transactions is as
follows:
Notes to Consolidated Financial Statements
For the year ended December 31,
2001
2000
1999
$
33,084,000
$
5,838,000
$
171,354,000
4,100,000
3,207,000
7,783,000
4,973,000
--
42,157,000
9,045,000
179,137,000
2,357,000
255,000
65,744,000
44,514,000
9,300,000
244,881,000
9,048,000
1,606,000
144,623,000
8,268,000
--
40,000,000
1,520,000
9,200,000
$
27,198,000
$
7,694,000
$
49,538,000
3. Property and Equipment
Property and equipment consists of the following:
December 31,
2001
2000
$
501,000
$
501,000
46,325,000
29,836,000
17,000,000
17,000,000
87,154,000
74,170,000
1,578,000
366,000
152,558,000
121,873,000
60,553,000
36,897,000
$
92,005,000
$
84,976,000
F-15
Select Medical Corporation
4. Intangible Assets
Intangible assets consist of the following:
Notes to Consolidated Financial Statements
December 31,
2001
2000
$
205,667,000
$
201,171,000
40,000,000
40,000,000
11,250,000
10,343,000
17,544,000
17,544,000
274,461,000
269,058,000
27,204,000
17,659,000
$
247,257,000
$
251,399,000
The following summarizes the Companys intangible asset activity:
December 31,
2001
2000
$
251,399,000
$
258,079,000
27,198,000
7,694,000
(26,564,000
)
(8,402,000
)
(1,113,000
)
(441,000
)
(33,000
)
635,000
5,660,000
3,430,000
(9,290,000
)
(9,596,000
)
(4,142,000
)
(6,680,000
)
$
247,257,000
$
251,399,000
5. Restructuring Reserves
During December 1998, the Company recorded a $7,648,000 restructuring reserve in connection with the acquisition of Intensiva Healthcare Corporation. The Company also recorded a restructuring reserve in 1999 related to the NovaCare acquisition of $5,743,000. The reserves primarily included costs associated with workforce reductions of 25 and 162 employees in 1998 and 1999, respectively, and lease buyouts in accordance with the Companys restructuring plan. During 2000, the Company revised its estimates for the NovaCare termination costs, severance liabilities and the anticipated closure of two central billing offices related to the NovaCare acquisition. The reserves for the billing office closures primarily included costs associated with lease buyouts and workforce reductions of 67 employees. These changes in estimates have been reflected as an adjustment to the purchase price of NovaCare.
F-16
Select Medical Corporation
The following summarizes the Companys restructuring activity:
Notes to Consolidated Financial Statements
Lease
Termination
Costs
Severance
Other
Total
$
536,000
$
5,914,000
$
1,198,000
$
7,648,000
(109,000
)
(5,914,000
)
(1,198,000
)
(7,221,000
)
3,187,000
3,187,000
3,600,000
700,000
1,443,000
5,743,000
7,214,000
700,000
1,443,000
9,357,000
214,000
841,000
184,000
1,239,000
(3,743,000
)
(601,000
)
(1,551,000
)
(5,895,000
)
3,685,000
940,000
76,000
4,701,000
55,000
106,000
161,000
(2,053,000
)
(914,000
)
(76,000
)
(3,043,000
)
$
1,687,000
$
132,000
$
1,819,000
All employees to be terminated have been severed and the Company expects to pay out the remaining restructuring reserves through 2003.
6. Long-Term Debt and Notes Payable
The components of long-term debt and notes payable are shown in the following
table:
December 31,
December 31,
2001
2000
$
175,000,000
96,782,000
$
195,877,000
76,772,000
14,849,000
27,888,000
1,792,000
2,251,000
288,423,000
302,788,000
26,774,000
18,746,000
$
261,649,000
$
284,042,000
On June 11, 2001, the Company issued and sold $175.0 million aggregate principle amount of 9 1/2 % Senior Subordinated Notes due June 15, 2009. The net proceeds from the sale of the 9 1/2 % Senior Subordinated Notes were used to repay debt under the Companys senior credit facility and to repay 10% Senior Subordinated Notes. Deferred financing costs and discounts of $8,676,000 related to the repayments, net of tax, were
F-17
Select Medical Corporation
Notes to Consolidated Financial Statements
reflected as an extraordinary loss in 2001. The 9 1/2 % Senior Subordinated Notes are fully and unconditionally guaranteed, jointly and severally, by certain wholly owned subsidiaries (the Subsidiary Guarantors). Certain of the Companys subsidiaries have not guaranteed the notes (the Non-Guarantor Subsidiaries). The creditors of the Non-Guarantor Subsidiaries have priority over the rights of the Company to receive dividends or distributions from such subsidiaries.
The credit facility consists of a term portion of approximately $91.8 million and a revolving credit portion of approximately $152.4 million. The term debt began quarterly amortization in September 2001, with a final maturity date of September 2005. The revolving commitment also matures in September 2005. Borrowings under the facility bear interest at either LIBOR or Prime rate, plus applicable margins based on financial covenant ratio tests. Borrowings bore interest at approximately 7.6% and 10.2% at December 31, 2001 and 2000, respectively. Deferred financing costs of approximately $6,247,000 related to the Companys November 19, 1999 credit facility were charged to expense as an extraordinary item during 2000. A commitment fee of .375% to .5% per annum is charged on the unused portion of the credit facility. Availability under the revolving credit facility at December 31, 2001 was approximately $143.1 million. The credit facility is collateralized by a pledge of the Companys equity interest in its subsidiaries and includes restrictions on certain payments by the Company, including dividend payments, minimum net worth requirements and other covenants. The Company is authorized to issue up to $10,000,000 in letters of credit. Letters of credit reduce the capacity under the revolving credit facility and bear interest at applicable margins based on financial covenant ratio tests. Approximately $4.4 million and $3.6 million in letters of credit were issued at December 31, 2001 and 2000, respectively.
In 1999 and 1998, the Company issued 10% Senior Subordinated Notes to a principal stockholder of the Company and had common shares attached which were recorded at the estimated fair market value on the date of issuance. The common shares issued were recorded as a discount to the Senior Subordinated Notes and were amortized using the interest method. In connection with the repayment of the 10% Senior Subordinated Notes in full during 2001, 240,048 shares of common stock were returned to the Company.
The Companys obligations under its previous credit agreements, which were refinanced in 1999, were collateralized by guarantees of two of the Companys principal stockholders. In connection with the debt guarantees, the Company and certain shareholders entered into a warrant agreement. The Company issued 549,000, 460,000 and 864,000 warrants to these shareholders in 2000, 1999 and 1998, respectively, that entitle the holder of each warrant to purchase one share of common stock at an exercise price of $6.08 per share or at a price equal to the lowest selling price of common shares sold by the Company after June 30, 1998. The warrants expire on June 30, 2003. The
F-18
Select Medical Corporation
Notes to Consolidated Financial Statements
value of the warrants was accounted for as a financing cost and amortized over the term of the guarantees.
The Seller Notes relate to the acquisition of related businesses and require periodic payments of principal and interest that mature on various dates through 2007. Also, certain of the notes contain minimum net worth requirements. Interest rates are at 6% per annum.
Maturities of long-term debt for the years after 2002 are approximately as
follows:
$
28,655,000
30,509,000
27,397,000
44,000
175,044,000
7. Redeemable Preferred Stock and Stockholders Equity
Shareholder Rights Plan
On September 17, 2001, the Companys Board of Directors adopted a Shareholder Rights Plan (the Plan). Under the Plan, rights were distributed as a dividend at the rate of one right for each share of common stock of the Company held by the shareholders of record as of the close of business on October 2, 2001. Until the occurrence of certain events, the rights are represented by and traded in tandem with the common stock. Each right will separate and entitle the shareholders to buy stock upon an occurrence of certain takeover or stock accumulation events. Should any person or group (Acquiring Person) acquire beneficial ownership of 15% or more of the Companys common stock, each right not held by the Acquiring Person becomes the right to purchase, at an exercise price of $104, that number of shares of the Company's common stock that at the time of the transaction, have a market value of twice the exercise price. In addition, if after a person or group becomes an Acquiring Person the Company merges, consolidates or engages in a similar transaction in which it does not survive, each holder has a flip-over right to buy discounted stock in the acquiring company. Certain of our principal stockholders will not be and cannot become an Acquiring Person and will not be counted as affiliates or associates of any other person in determining whether such person is an Acquiring Person under the Plan.
Under certain circumstances, the rights are redeemable by the Company at a price of $0.001 per right. Further, if any person or group becomes an Acquiring Person, the Board of Directors has the option to exchange one share of common stock for each right held by any Person other than the Acquiring Person. The rights expire on September 17, 2011.
F-19
Select Medical Corporation
Notes to Consolidated Financial Statements
Class A Preferred Stock
The Company was authorized to issue 55,000 shares of cumulative, non-voting Class A Preferred Stock. The Company sold 48,000 shares of Class A Preferred Stock during 1998. The Class A Preferred Stock had an annual cash dividend rate of 8% per share, which accrued on a daily basis.
In connection with the Companys initial public offering in April 2001, all outstanding Class A Preferred Stock was redeemed. The accrued dividends on the Class A Preferred Stock totaling $14.1 million were subsequently paid on May 2, 2001.
Class B Preferred Stock
In connection with the NovaCare acquisition (Note 2), the Company sold 16,000,000 shares of Class B Preferred Stock at a price of $3.75 per share for net proceeds of $59,361,000. Each share of Class B preferred stock was convertible at any time, at the option of the stockholder, into .576 shares of common stock. The Class B Preferred Stock had an annual cash dividend rate of 6% per share, which accrued on a daily basis.
In connection with the Companys initial public offering in April 2001, all 16,000,000 outstanding Class B Preferred Stock were automatically converted into 9,216,000 shares of common stock. The accrued dividends on the Class B Preferred Stock totaling $5.2 million were paid on May 2, 2001.
Common Stock
On April 10, 2001, the Company amended its Restated Certificate of Incorporation to increase the total common shares authorized to 200,000,000 from 78,000,000.
On March 28, 2001, the Company effected a 1 for .576 reverse split of its common stock. Accordingly, all common issued and outstanding share and per share information has been retroactively restated to reflect the effects of this reverse stock split.
F-20
Select Medical Corporation
Notes to Consolidated Financial Statements
In connection with the debt offering as described in Note 6, the Company repaid its 10% Senior Subordinated Notes which resulted in the return to the Company of 240,048 shares of common stock that were issued to WCAS Capital Partners III, L.P. in conjunction with the 10% Senior Subordinated Notes.
Shares of common stock sold during 2000 totaled 172,000. The shares were issued to management at $6.51 per share for proceeds totaling $1,118,000. The Company purchased 32,000 shares as treasury stock during 2000 for $210,000.
Shares of common stock sold in 1999 totaled 172,000. The shares were sold to management at prices ranging from $6.08 to $6.51 for proceeds totaling $1,041,000. The Company purchased 173,000 shares as treasury stock during 1999 for $781,000. In addition, 960,000 shares of common stock were sold in conjunction with the issuance of the 10% Senior Subordinated Notes (Note 6).
8. Initial Public Offering
On April 10, 2001, the Company completed an initial public offering of 9,000,000 shares of its common stock at an offering price of $9.50 per share before an underwriters discount of $.665 per share. On April 20, 2001, the underwriters of the offering exercised an overallotment option and purchased an additional 1,350,000 shares at a gross price of $9.50 per share. The overallotment offering closed on April 25, 2001. The net proceeds of the initial offering and the overallotment offering of $89.2 million were used to repay senior debt under the term and revolving loan portions of the Companys credit facility and to redeem Class A Preferred Stock. All 52,838 shares of the Class A Preferred Stock were redeemed on April 10, 2001 for $52,838,000. In addition, the Companys Class B Preferred Stock automatically converted into 9,216,000 shares of common stock upon completion of the offering.
In January 2001, in anticipation of the initial public offering, the Company entered into an amendment to its credit agreement that became effective in April 2001. The amendment allowed for the use of the net proceeds of the offering to repay $24.0 million of our senior debt under the U.S. term loan portion of the bank credit facility and to redeem $52.8 million of Class A Preferred Stock.
In conjunction with the Companys initial public offering, the Company purchased outstanding minority interests of certain of its subsidiaries for $10.9 million in cash and
F-21
Select Medical Corporation
Notes to Consolidated Financial Statements
$5.0 million in common stock. The acquisitions were accounted for using the purchase method of accounting.
9. Stock Option Plan
The Companys 1997 Stock Option Plan (the Plan) provides for the granting of options to purchase shares of Company stock to certain executives, employees and directors.
Options under the Plan carry various restrictions. Under the Plan, certain options granted to employees will be qualified incentive stock options within the meaning of Section 422A of the Internal Revenue Code and other options will be considered nonqualified stock options. Both incentive stock options and nonqualified stock options may be granted for no less than market value at the day of the grant and expire no later than ten years after the date of the grant.
Originally under the Plan, options to acquire up to 5,760,000 shares of the stock could be granted. On February 22, 2001, the Plan was amended and restated to provide for the issuance of up to 5,760,000 shares of common stock plus any additional amount necessary to make the total shares available for issuance under the Plan equal to the sum of 5,760,000 plus 14% of the total issued and outstanding common stock in excess of 34,560,000 shares, subject to adjustment for stock splits, stock dividends and similar changes in capitalization. Total options available for grant at December 31, 2001 were 7,365,000.
Transactions and other information related to the Stock Option Plan are as
follows:
Price
Weighted Average
Per Share
Shares
Exercise Price
$1.74 to 6.08
1,579,000
$
6.02
6.08 to 6.51
1,270,000
6.46
1.74 to 6.08
(88,000
)
6.08
$1.74 to 6.51
2,761,000
$
6.21
6.51 to 10.42
1,876,000
7.60
6.08
(4,000
)
6.08
1.74 to 6.51
(132,000
)
6.65
$1.74 to 10.42
4,501,000
$
6.79
9.50 to 17.05
2,555,000
11.34
6.08 to 10.42
(702,000
)
6.18
6.08 to 11.28
(96,000
)
9.30
$1.74 to 17.05
6,258,000
$
8.79
F-22
Select Medical Corporation
Additional information with respect to the outstanding options as of December
31, 2001, 2000, 1999 and 1998 is as follows:
Notes to Consolidated Financial Statements
Range of Exercise Prices
$1.74
$6.08-$6.51
$9.50-$11.75
$14.15-$17.05
18,000
1,561,000
8.86
9.91
3,000
1,267,000
18,000
2,743,000
7.86
9.34
6,000
2,419,000
18,000
3,973,000
510,000
6.86
8.58
9.79
10,000
1,404,000
1,095,000
18,000
3,239,000
2,896,000
104,000
5.86
7.68
9.21
9.75
13,000
2,110,000
988,000
As permitted by Statement of Financial Accounting Standards No. 123, Accounting for Stock Based Compensation (SFAS No. 123), the Company has chosen to apply APB Opinion No. 25, Accounting for Stock Issued to Employees (APB 25) and related interpretations in accounting for its Plan. Accordingly, no compensation cost has been recognized for options granted under the Plan. Had compensation costs for the Plan been determined based on the fair value at the grant dates for awards under the Plan consistent with the method of SFAS No. 123, approximately $4,454,000, $241,000 and $1,020,000 of additional compensation expense, net of tax, would have been recognized during the years ended December 31, 2001, 2000 and 1999, respectively.
The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option pricing model assuming no dividend yield, volatility of 39% in 2001 and no volatility in 2000 and 1999 (before the initial public offering), an expected life of four years from the date of vesting and a risk free interest rate of 4.4%, 5.9% and 5.7% in 2001, 2000 and 1999, respectively.
F-23
Select Medical Corporation
For purposes of pro forma disclosures, the estimated fair value of the options
is amortized to expense over the options vesting period. The Companys pro
forma net earnings and earnings per share were as follows:
Notes to Consolidated Financial Statements
For the year ended December 31,
2001
2000
1999
$
29,681,000
$
5,712,000
$
(13,106,000
)
25,227,000
5,471,000
(14,126,000
)
4.54
0.93
1.60
0.68
(0.12
)
(0.74
)
0.57
(0.13
)
(0.79
)
0.62
(0.12
)
(0.74
)
0.52
(0.13
)
(0.79
)
10. Income Taxes
Significant components of the Companys tax provision (benefit) before
extraordinary items for the years ended December 31, 2001, 2000 and 1999 are as
follows:
For the year ended December 31,
2001
2000
1999
$
14,630,000
2,772,000
$
1,275,000
$
1,497,000
939,000
301,000
18,341,000
1,576,000
1,497,000
(9,670,000
)
8,403,000
1,314,000
$
8,671,000
$
9,979,000
$
2,811,000
F-24
Select Medical Corporation
The difference between the expected income tax provision at the federal
statutory rate of 34% and the income tax expense (benefit) recognized in the
financial statements is as follows:
Notes to Consolidated Financial Statements
For the year ended December 31,
2001
2000
1999
35.0
%
35.0
%
(34.0
%)
3.8
3.8
22.1
3.2
6.7
36.4
0.5
0.7
5.2
0.6
0.4
(1.1
)
(20.6
)
(0.2
)
32.6
(7.2
)
-
3.1
(0.9
)
1.5
18.4
%
45.5
%
62.7
%
Undistributed earnings of the Companys foreign subsidiary are permanently reinvested. Accordingly, no deferred taxes have been provided on these earnings.
A summary of deferred tax assets and liabilities is as follows:
For the year ended December 31,
2001
2000
$
25,232,000
$
14,713,000
3,034,000
1,853,000
679,000
339,000
28,945,000
16,905,000
84,000
2,983,000
8,759,000
14,887,000
693,000
1,238,000
120,000
9,536,000
19,228,000
38,481,000
36,133,000
(2,862,000
)
(35,196,000
)
$
35,619,000
$
937,000
F-25
Select Medical Corporation
Notes to Consolidated Financial Statements
As a result of the Company's limited operating history and the cumulative losses incurred in prior years, the Company's historically provided a valuation allowance for substantially all of its deferred tax assets. Because of the cumulative profitable operations over the last three years, management has concluded that it is more likely than not that these deferred tax items will be realized. The reversal of these valuation allowances in the fourth quarter of 2001 resulted in a reduction in the tax provision of $9.7 million and a reduction in goodwill of $18.5 million. The reduction in goodwill relates to those deferred tax assets originating through acquisitions.
The decrease in the valuation allowance in 2000 is related to the utilization of net operating loss carryforwards, the benefit from which was allocated to reduce goodwill. As of December 31, 2001, the Company has approximately $9,400,000 in federal net operating loss carry forwards.
Net operating loss carry forwards expire as follows:
$
461,000
-
-
-
8,939,000
As a result of the acquisition of Intensiva, American Transitional Hospitals, Inc. and NovaCare, the Company is subject to the provisions of Section 382 of the Internal Revenue Code which provide for annual limitations on the deductibility of acquired net operating losses and certain tax deductions. These limitations apply until the earlier of utilization or expiration of the net operating losses. Additionally, if certain substantial changes in the Companys ownership should occur, there would be an annual limitation on the amount of the carryforwards that can be utilized.
11. Special Charge
During 1999, the Company recorded a special charge for asset impairments of $5,223,000. The charge relates to the impairment of goodwill, leasehold improvements and equipment that resulted from closures and relocations of certain hospitals and clinics in December 1999. The Company also recorded an impairment writedown under FAS No. 121, on a held for use basis, related to certain outpatient rehabilitation facilities.
F-26
Select Medical Corporation
Notes to Consolidated Financial Statements
12. Extraordinary item
As a result of the initial public offering of stock in April 2001 and the issuance of $175 million of 9 1/2% Senior Subordinated Notes in June 2001, the Company repaid $75 million of the U.S. term loan and all $90 million of the 10% Senior Subordinated Notes. The extraordinary item consists of $1.3 million of unamortized deferred financing costs related to the repayment of the U.S. term loan and $12.9 million of deferred financing costs and unamortized discount related to the repayment of our 10% Senior Subordinated Notes. These costs were offset by a tax benefit of $5.5 million.
On September 22, 2000, the Company entered into a new $230 million credit facility. This credit facility replaced the Companys $225 million credit facility from November 19, 1999. The extraordinary item recorded during 2000 consists of the unamortized deferred financing costs of $6,247,000 related to the November 19, 1999 credit facility. There was no tax effect related to this transaction.
On November 19, 1999, the Company entered into a new $225 million credit facility in connection with the NovaCare acquisition. This credit facility replaced the Companys $155 million credit facility from February 9, 1999. The extraordinary item recorded during 1999 consists of the unamortized deferred financing costs of $5,814,000 related to the February 9, 1999 credit facility. There was no tax effect related to this transaction.
13. Retirement Savings Plan
Beginning March 1, 1998, the Company sponsored a defined contribution retirement savings plan for substantially all of its employees. Employees may elect to defer up to 15% of their salary. The Company matches 50% of the first 6% of compensation employees contribute to the plan. The employees vest in the employer contributions over a three-year period beginning on employee hire date. The expense incurred by the Company related to this plan was $4,617,000, $4,083,000 and $1,728,000 during the years ended December 31, 2001, 2000 and 1999, respectively.
A subsidiary sponsored a noncontributory defined contribution retirement plan for its employees during 1999. The plan was frozen during 2000 and the Company does not anticipate making future contributions to the plan. The subsidiary contributed 7.60% of employee salaries up to a maximum contribution of $13,000 per employee in 1999. Approximately $560,000 of contributions related to this plan were expensed during the year ended December 31, 1999.
F-27
Select Medical Corporation
Notes to Consolidated Financial Statements
14. Segment Information
SFAS No. 131, Disclosure about Segments of an Enterprise and Related Information, establishes standards for reporting information about operating segments and related disclosures about products and services, geographic areas and major customers. The adoption of SFAS No. 131 did not affect the Companys results of operations or financial position.
The Companys segments consist of (i) inpatient hospitals and (ii) outpatient rehabilitation. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on EBITDA of the respective business units. EBITDA is defined as earnings before interest, minority interest, income taxes, extraordinary items, special charges, depreciation and amortization. All segment revenues are from external customers.
The following table summarizes selected financial data for the Companys
reportable segments:
Year Ended December 31, 2001
Inpatient
Outpatient
Hospitals
Rehabilitation
All Other
Total
$
503,021,000
$
440,791,000
$
15,144,000
$
958,956,000
57,556,000
76,127,000
(21,665,000
)
112,018,000
303,910,000
318,224,000
28,711,000
650,845,000
13,452,000
8,800,000
1,759,000
24,011,000
Year Ended December 31, 2000
Inpatient
Outpatient
Hospitals
Rehabilitation
All Other
Total
$
378,910,000
$
416,775,000
$
10,212,000
$
805,897,000
44,550,000
65,420,000
(18,300,000
)
91,670,000
246,495,000
329,874,000
10,431,000
586,800,000
13,677,000
6,399,000
2,354,000
22,430,000
Year Ended December 31, 1999
Inpatient
Outpatient
Hospitals
Rehabilitation
All Other
Total
$
307,464,000
$
141,740,000
$
6,771,000
$
455,975,000
35,929,000
22,697,000
(16,382,000
)
42,244,000
250,034,000
350,419,000
20,265,000
620,718,000
7,243,000
3,085,000
568,000
10,896,000
F-28
Select Medical Corporation
A reconciliation of EBITDA to net income (loss) is as follows:
Notes to Consolidated Financial Statements
2001
2000
1999
$
112,018,000
$
91,670,000
$
42,244,000
(32,290,000
)
(30,401,000
)
(16,741,000
)
(5,223,000
)
507,000
939,000
362,000
(29,716,000
)
(36,126,000
)
(21,461,000
)
(3,491,000
)
(4,144,000
)
(3,662,000
)
(8,671,000
)
(9,979,000
)
(2,811,000
)
(8,676,000
)
(6,247,000
)
(5,814,000
)
$
29,681,000
$
5,712,000
$
(13,106,000
)
15. Net Income (Loss) per Share
Under SFAS No. 128, Earnings per Share (EPS), the Companys granting of certain stock options, warrants and convertible preferred stock resulted in potential dilution of basic EPS. The following table sets forth for the periods indicated the calculation of net income (loss) per share in the Companys consolidated Statement of Operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute diluted EPS:
F-29
Select Medical Corporation
Notes to Consolidated Financial Statements
2001
2000
1999
$
38,357,000
$
11,959,000
$
(7,292,000
)
(8,676,000
)
(6,247,000
)
(5,814,000
)
29,681,000
5,712,000
(13,106,000
)
2,513,000
8,780,000
5,175,000
$
27,168,000
$
(3,068,000
)
$
(18,281,000
)
1,067,000
$
28,235,000
$
(3,068,000
)
$
(18,281,000
)
39,957,000
25,457,000
24,557,000
1,909,000
316,000
1,073,000
134,000
2,525,000
45,464,000
25,907,000
24,557,000
$
0.90
$
0.13
$
(0.50
)
(0.22
)
(0.25
)
(0.24
)
$
0.68
$
(0.12
)
$
(0.74
)
$
0.81
$
0.12
$
(0.50
)
(0.19
)
(0.24
)
(0.24
)
$
0.62
$
(0.12
)
$
(0.74
)
The following share amounts are shown here for informational and comparative purposes
only since their inclusion would be anti-dilutive:
2001
2000
1999
100,000
510,000
123,000
10,000
9,216,000
1,136,000
16. Fair Value of Financial Instruments
Financial instruments include cash and cash equivalents, notes payable, long-term debt and preferred stock. The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.
The Company is exposed to the impact of interest rate changes. The Companys objective is to manage the impact of the interest rate changes on earnings and cash flows and on the market value of its borrowings. The Company entered into an interest rate swap in March 2001 which became effective in April 2001. The swap originally matured in March 2005. In January 2002, the swap maturity date was amended to March 2003. At December 31, 2001, approximately $69 million (notional amount) of the variable credit facility debt was converted to fixed
F-30
Select Medical Corporation
Notes to Consolidated Financial Statements
rate. At December 31, 2001, the variable interest rate of the debt was 5.3% and the fixed rate of the swap was 8.4%. The differential to be paid or received from the counterparty in the agreement is recorded as interest expense as rates reset. The net settlement resulted in a $0.8 million increase in interest expense in 2001. The swap agreement is made with a counterparty of high credit quality; therefore, management considers the risk of non-performance by the counterparty to be negligible.
The fair market value of this swap recorded as of December 31, 2001 was a liability of $1.6 million. The interest rate swap has been designated as a hedge and qualified under the provision of SFAS No. 133 as an effective hedge under the short-cut method. Accordingly, the change in the fair value for the year ended December 31, 2001 was recorded in other comprehensive income.
Borrowings under the credit facility which are not subject to the swap have variable rates that reflect currently available terms and conditions for similar debt. The carrying amount of this debt is a reasonable estimate of fair value.
The 9 1/2% Senior Subordinated Notes, which were issued and sold on June 11, 2001, are traded in public markets. The carrying value and estimated fair value of these notes was $175.0 million and $174.1 million at December 31, 2001.
The fair value of the Companys Class A Preferred Stock, which was redeemed in 2001, and the Class B Preferred Stock, which converted into common stock in 2001, was not practicable to estimate as it was untraded; accordingly it was recorded at its redemption value.
17. Related Party Transactions
The Company has been party to various rental and other agreements with companies affiliated through common ownership. The Company made rental and other payments aggregating $1,186,000, $1,295,000, and $1,228,000 during the years ended December 31, 2001, 2000 and 1999, respectively, to the affiliated companies.
F-31
Select Medical Corporation
As of December 31, 2001, future rental commitments under outstanding agreements
with the affiliated companies are approximately as follows:
Notes to Consolidated Financial Statements
$
1,197,000
1,242,000
1,139,000
1,086,000
1,130,000
10,825,000
$
16,619,000
As further discussed in Note 6, the Company has issued warrants to certain of its principal stockholders in connection with guarantees of previous credit agreements.
In April 2000, the Company sold all of the assets of Georgia Health Group, Inc., for $5,000,000 to a company in which a principal stockholder has a majority owned interest.
In March 2000, the Company entered into three-year employment agreements with two of its principal stockholders. Under these agreements, the two stockholders will receive a combined total annual salary of $1,600,000. Additionally, one such shareholder has a life insurance policy for which the Company will pay premiums of $1,250,000 each fiscal year until 2010.
In December 1999, the Company acquired Select Air Corporation from a related party in exchange for consideration of $2,700,000, net of cash acquired.
F-32
Select Medical Corporation
18. Commitments and Contingencies
Leases
The Company leases facilities and equipment from unrelated parties under
operating leases. Minimum future lease obligations on long-term non-cancelable
operating leases in effect at December 31, 2001 are approximately as follows:
Notes to Consolidated Financial Statements
$
53,247,000
38,067,000
25,853,000
17,287,000
12,663,000
8,375,000
$
155,492,000
Total rent expense for operating leases for the years ended December 31 2001, 2000 and 1999 was approximately $75,621,000, $68,731,000 and $35,929,000 respectively.
Other
In February 2002, PHICO Insurance Company (PHICO), at the request of the Pennsylvania Insurance Department, was placed in liquidation by an Order of the Commonwealth Court of Pennsylvania (Liquidation Order). The Company had placed its primary malpractice insurance coverage through PHICO from June 1998 through December 2000. In January 2001, these policies were replaced by policies issued with other issuers. Currently, the Company has approximately 20 unsettled cases in 11 states from the policy years covered by PHICO issued policies. The Liquidation Order refers these claims to various state guaranty associations. These state guaranty association statutes generally provide for coverage between $100,000-$300,000 per insured claim, depending on the state. Some states also have catastrophic loss funds to cover settlements in excess of the available state guaranty funds. Most state insurance guaranty statutes provide for net worth and residency limitations that, if applicable, may limit or prevent the Company from the recovering from these state guaranty association funds. At this time, the Company believes that it will meet the requirements for coverage under the applicable state guarantee association statutes, and that the resolution of these claims will not have a material adverse effect on the Companys financial position, cash flow or results of operations. However, because the rules related to state guarantee funds are subject to interpretation and because these claims are still in the process of resolution, the Companys conclusions may change as this process progresses.
F-33
Select Medical Corporation
Notes to Consolidated Financial Statements
A subsidiary of the Company has entered into a naming, promotional and sponsorship agreement for a sports complex. The naming, promotional and sponsorship agreement is in effect until 2026. The subsidiary is required to make payments in accordance with the contract terms over 25 years ranging from $1,400,000 to $1,963,000 per year and provide physical therapy and training services.
Litigation
On August 10, 1998 a complaint in the U.S. District Court for the Eastern District of Pennsylvania was filed that named as defendants NovaCare, Inc. (now known as NAHC, Inc.), other named defendants and 100 defendants who were to be named at a later time. This qui tam action sought triple damages and penalties under the False Claims Act against NAHC. The Department of Justice did not intervene in this action. The allegations involve, among other things, the distinction between individual and group billing in physical rehabilitation clinics that the Company acquired from NovaCare. On October 16, 2000 the relator plaintiff made a motion to amend the complaint to, among other things, add Select Medical Corporation and some of its subsidiaries acquired in the NovaCare acquisition as defendants in this case. This motion was granted in September of 2001. The amended complaint alleges that from about January 1, 1995 through the present, the defendants submitted false or fraudulent bills for physical therapy to various federal health programs. The United States Attorneys Office has asserted that because the complaint is being amended to add allegations against new defendants, it is entitled to a new period to determine whether to intervene in the new allegations. On January 3, 2002, NAHC entered into a settlement agreement with the relator plaintiff and the government, pursuant to which, in exchange for a payment by NAHC of $375,000, the parties settled all claims arising out of conduct that took place before Select Medicals acquisition of the NovaCare subsidiaries that are defendants in the case. Claims against the Company and the NovaCare subsidiaries regarding conduct occurring after the NovaCare acquisition were not settled. As of February 28, 2002, the government had not advised the Company whether it intends to intervene in any remaining claims, and Select and the subsidiaries have not been served with the amended complaint. Based on a review of the amended complaint, the Company does not believe that this lawsuit is meritorious and intends to vigorously defend against this action. However, because of the uncertain nature of the litigation, the Company cannot predict the outcome of this matter.
The Company is subject to legal proceedings and claims that have arisen in the ordinary course of its business and have not been finally adjudicated, which include malpractice claims covered (subject to the above discussion regarding PHICO Insurance Company) under the Companys insurance policy. In the opinion of management, the outcome of these actions will not have a material adverse effect on the financial position or results of operations of the Company.
F-34
Select Medical Corporation
19. Supplemental Disclosures of Cash Flow Information
Non-cash investing and financing activities are comprised of the following for
the years ended December 31 2001, 2000 and 1999:
Notes to Consolidated Financial Statements
Description of Transaction
2001
2000
1999
$
4,973,000
$
$
$
4,100,000
$
3,207,000
$
7,783,000
$
2,357,000
$
255,000
$
65,744,000
$
$
$
5,209,000
$
$
1,104,000
$
2,389,000
$
$
$
2,700,000
$
2,513,000
$
8,780,000
$
5,175,000
$
$
187,000,000
$
$
2,513,000
$
$
20. Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries
The Company conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for the Company, the Subsidiary Guarantors and the Non-Guarantor Subsidiaries at December 31, 2001 and 2000 and for the years ended December 31, 2001, 2000 and 1999. All Subsidiary Guarantors were wholly-owned as of the date of the issuance of the 9 1/2% Senior Subordinated Notes as described in Note 6.
On October 1, 2000, the Company transferred the operating assets of one of its guarantor subsidiaries into a newly organized partnership and simultaneously sold partnership units to unaffiliated investors. The operations of this business (through a 100% owned subsidiary) through October 1, 2000 have been included as a Subsidiary Guarantor. The operations commencing on October 1, 2000 through a minority owned partnership are presented as a Non-Guarantor Subsidiary.
F-35
Select Medical Corporation
Notes to Consolidated Financial Statements
The equity method has been used by the Company with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.
The following table sets forth the Non-Guarantor Subsidiaries:
Canadian Back Institute Limited |
Kentucky Orthopedic Rehabilitation, LLC |
Medical Information Management Systems, LLC |
Metro Therapy, Inc. |
Millennium Rehab Services, LLC |
Rehab Advantage Therapy Services, LLC |
Select Houston Partners, L.P. |
Select Management Services, LLC |
Select Specialty Hospital Biloxi, Inc. |
TJ Corporation I, LLC |
F-36
Select Medical Corporation
Condensed Consolidating Balance Sheets
December 31, 2001
Select Medical
Corporation
(Parent Company
Subsidiary
Non-Guarantor
Only)
Guarantors
Subsidiaries
Eliminations
Consolidated
(dollars in
thousands)
$
559
$
8,086
$
2,058
$
$
10,703
(491
)
185,787
33,097
218,393
1,881
27,064
28,945
1,964
13,766
2,714
18,444
3,913
234,703
37,869
276,485
7,406
65,464
19,135
92,005
320,458
72,145
(392,603
)(a)
5,854
193,070
48,333
247,257
(343
)
7,017
6,674
12,494
14,095
1,835
28,424
$
349,782
$
586,494
$
107,172
$
(392,603
)
$
650,845
$
6,083
$
$
$
$
6,083
480
26,278
16
26,774
3,090
25,860
4,570
33,520
54,253
(59,675
)
5,422
644
26,494
22
27,160
2,413
9,070
1,337
12,820
154
1,665
1,819
12,335
9,763
1,470
23,568
1,735
1,735
(29,451
)
48,736
(3,028
)
16,257
50,001
89,926
9,809
149,736
65,497
151,336
44,816
261,649
115,498
241,262
54,625
411,385
5,176
5,176
465
465
231,349
231,349
5,924
21,605
8,664
(30,269
)(b)
5,924
323,627
38,707
(362,334
)(a)
(1,560
)
(1,560
)
(1,894
)
(1,894
)
234,284
345,232
47,371
(392,603
)
234,284
$
349,782
$
586,494
$
107,172
$
(392,603
)
$
650,845
(a) | Elimination of investments in subsidiaries. | |
(b) | Elimination of investments in subsidiaries earnings. |
F-37
Select Medical Corporation
Condensed Consolidating Statement of Operations
For the Year Ended December 31, 2001
Select Medical
Corporation
(Parent Company
Subsidiary
Non-Guarantor
Only)
Guarantors
Subsidiaries
Eliminations
Consolidated
(dollars in
thousands)
$
14,300
$
774,206
$
170,450
$
$
958,956
637,681
138,614
776,295
35,630
35,630
30,356
4,657
35,013
1,764
25,383
5,143
32,290
37,394
693,420
148,414
879,228
(23,094
)
80,786
22,036
79,728
(51,183
)
41,621
9,562
(401
)
(102
)
(4
)
(507
)
7,223
17,478
5,015
29,716
21,267
21,789
7,463
50,519
578
2,913
3,491
21,267
21,211
4,550
47,028
11,638
(3,906
)
939
8,671
28,728
1,818
(30,546
)(a)
38,357
26,935
3,611
(30,546
)
38,357
8,676
8,676
$
29,681
$
26,935
$
3,611
$
(30,546
)
$
29,681
(a) | Elimination of equity in net income (loss) from consolidated subsidiaries. |
F-38
Select Medical Corporation
Condensed Consolidating Statement of Cash Flows
For the Year Ended December 31, 2001
Select Medical
Corporation
(Parent Company
Subsidiary
Non-Guarantor
Only)
Guarantors
Subsidiaries
Eliminations
Consolidated
(dollars in
thousands)
$
29,681
$
26,935
$
3,611
$
(30,546
)(a)
$
29,681
1,764
25,383
5,143
32,290
30,356
4,657
35,013
578
2,913
3,491
8,676
8,676
2,461
(12,131
)
(9,670
)
(28,728
)
(1,818
)
30,546
(a)
55,044
(55,973
)
929
191
(39,401
)
(10,222
)
(49,432
)
(7,035
)
7,530
(951
)
(456
)
(1,633
)
3,296
(610
)
1,053
743
3,307
665
4,715
(13,681
)
27,046
1,381
14,746
7,170
7,218
(365
)
14,023
(8,190
)
19,316
514
11,640
46,463
41,642
7,665
95,770
(1,682
)
(19,101
)
(3,228
)
(24,011
)
808
808
(5,660
)
(5,660
)
(33,084
)
(33,084
)
(34,766
)
(23,953
)
(3,228
)
(61,947
)
175,000
175,000
(98,320
)
(98,320
)
(90,000
)
(90,000
)
(4,681
)
(4,681
)
(19,030
)
(19,030
)
89,181
89,181
(52,838
)
(52,838
)
(19,248
)
(19,248
)
4,334
4,334
4,571
(9,938
)
(2,768
)
(8,135
)
(680
)
(1,747
)
(2,427
)
(11,031
)
(10,618
)
(4,515
)
(26,164
)
(107
)
(107
)
559
7,071
(78
)
7,552
1,015
2,136
3,151
$
559
$
8,086
$
2,058
$
$
10,703
(a) | Elimination of equity in earnings of subsidiary. |
F-39
Select Medical Corporation
Condensed Consolidating Balance Sheets
December 31, 2000
Select Medical
Corporation
(Parent Company
Subsidiary
Non-Guarantor
Only)
Guarantors
Subsidiaries
Eliminations
Consolidated
(dollars in
thousands)
$
$
1,015
$
2,136
$
$
3,151
(300
)
169,273
27,532
196,505
(6,599
)
7,417
275
1,093
1,528
14,116
1,763
17,407
(5,371
)
191,821
31,706
218,156
4,839
60,861
19,276
84,976
213,618
26,704
(240,322
)(a)
5,953
204,735
40,711
251,399
10,861
20,183
1,225
32,269
$
229,900
$
504,304
$
92,918
$
(240,322
)
$
586,800
$
1,511
$
9,939
$
2,768
$
$
14,218
4,923
13,641
182
18,746
2,347
22,543
3,905
28,795
(30,624
)
30,981
(357
)
582
20,839
45
21,466
1,466
5,287
948
7,701
4,701
4,701
6,328
6,922
2,201
15,451
1,591
(1,352
)
(239
)
(15,770
)
21,690
(4,409
)
1,511
(27,646
)
135,191
5,044
112,589
79,475
155,241
49,326
284,042
51,829
290,432
54,370
396,631
4,516
7,582
12,098
65,481
65,481
64,092
64,092
257
257
73,069
73,069
(23,757
)
(5,330
)
5,053
277
(b)
(23,757
)
214,686
25,913
(240,599
)(a)
(1,039
)
(1,039
)
(32
)
(32
)
48,498
209,356
30,966
(240,322
)
48,498
$
229,900
$
504,304
$
92,918
$
(240,322
)
$
586,800
(a) | Elimination of investments in subsidiaries. | |
(b) | Elimination of investments in subsidiaries earnings. |
F-40
Select Medical Corporation
Condensed Consolidating Statement of Operations
For the Year Ended December 31, 2000
Select Medical
Corporation
(Parent Company
Subsidiary
Non-Guarantor
Only)
Guarantors
Subsidiaries
Eliminations
Consolidated
(dollars in
thousands)
$
10,157
$
698,416
$
97,324
$
$
805,897
577,406
79,055
656,461
28,431
28,431
26,934
2,401
29,335
1,644
25,390
3,367
30,401
30,075
629,730
84,823
744,628
(19,918
)
68,686
12,501
61,269
(42,151
)
40,606
1,545
(644
)
(295
)
(939
)
9,856
21,803
4,467
36,126
13,021
6,572
6,489
26,082
1,408
2,736
4,144
13,021
5,164
3,753
21,938
4,415
5,263
301
9,979
3,353
3,198
(6,551
)(a)
11,959
3,099
3,452
(6,551
)
11,959
6,247
6,247
$
5,712
$
3,099
$
3,452
$
(6,551
)
$
5,712
(a) | Elimination of equity in net income (loss) from consolidated subsidiaries. |
F-41
Select Medical Corporation
Condensed Consolidating Statement of Cash Flows
For the Year Ended December 31, 2000
Select Medical
Corporation
(Parent Company
Subsidiary
Non-Guarantor
Only)
Guarantors
Subsidiaries
Eliminations
Consolidated
(dollars in
thousands)
$
5,712
$
3,099
$
3,452
$
(6,551
)(a)
$
5,712
1,644
25,390
3,367
30,401
26,934
2,401
29,335
1,408
2,736
4,144
6,247
6,247
111
111
(3,353
)
(3,198
)
6,551
(a)
12,938
(32,020
)
19,082
(1,050
)
(22,117
)
(13,797
)
(36,964
)
(739
)
(912
)
(1,041
)
(2,692
)
13,269
(5,045
)
(13,243
)
(5,019
)
1,478
(2,056
)
1,958
1,380
(6,081
)
(7,166
)
(4,426
)
(17,673
)
961
(3,442
)
2,464
(17
)
3,426
4,581
(459
)
7,548
34,563
(14,544
)
2,494
22,513
(2,354
)
(16,118
)
(3,958
)
(22,430
)
29,948
29,948
13,000
13,000
2,452
495
2,947
(3,430
)
(3,430
)
(5,838
)
(5,838
)
(5,740
)
23,895
(3,958
)
14,197
(12,000
)
(12,000
)
(13,344
)
(14,233
)
(27,577
)
1,118
1,118
(210
)
(210
)
(11
)
(11
)
197
4,751
2,305
7,253
(4,563
)
(4,563
)
(329
)
(1,297
)
(1,626
)
(28,813
)
(9,811
)
1,008
(37,616
)
(10
)
(10
)
(460
)
(456
)
(916
)
1,475
2,592
4,067
$
$
1,015
$
2,136
$
$
3,151
(a) | Elimination of equity in earnings of subsidiary. |
F-42
Select Medical Corporation
Condensed Consolidating Statement of Operations
For the Year Ended December 31, 1999
Select Medical
Corporation
(Parent Company
Subsidiary
Non-Guarantor
Only)
Guarantors
Subsidiaries
Eliminations
Consolidated
(dollars in
thousands)
$
6,771
$
386,222
$
62,982
$
$
455,975
333,023
50,430
383,453
21,420
21,420
7,800
1,058
8,858
1,111
13,257
2,373
16,741
5,223
5,223
22,531
359,303
53,861
435,695
(15,760
)
26,919
9,121
20,280
(16,079
)
15,058
1,021
(238
)
(124
)
(362
)
7,509
11,169
2,783
21,461
(6,952
)
816
5,317
(819
)
1,349
2,313
3,662
(6,952
)
(533
)
3,004
(4,481
)
5,278
(2,467
)
2,811
(340
)
2,853
(2,513
)(a)
(7,292
)
(2,958
)
3,004
(46
)
(7,292
)
5,814
5,814
$
(13,106
)
$
(2,958
)
$
3,004
$
(46
)
$
(13,106
)
(a) | Elimination of equity in net income (loss) from consolidated subsidiaries. |
F-43
Select Medical Corporation
Condensed Consolidating Statement of Cash Flows
For the Year Ended December 31, 1999
Select Medical
Corporation
(Parent Company
Subsidiary
Non-Guarantor
Only)
Guarantors
Subsidiaries
Eliminations
Consolidated
(dollars in
thousands)
$
(13,106
)
$
(2,958
)
$
3,004
$
(46
)(a)
$
(13,106
)
1,111
13,257
2,373
16,741
7,800
1,058
8,858
5,223
5,223
5,814
5,814
(215
)
(215
)
1,349
2,313
3,662
340
(2,853
)
2,513
(a)
(35,895
)
20,866
15,029
4,335
(43,257
)
(8,368
)
(47,290
)
(660
)
(1,095
)
27
(1,728
)
(1,506
)
909
(10,271
)
(10,868
)
717
(1,434
)
746
29
(9,689
)
18,423
(19
)
8,715
1,753
(4,183
)
(258
)
(2,688
)
8,641
(4,617
)
139
(2,467
)
1,696
(38,145
)
7,215
5,773
(25,157
)
(568
)
(6,761
)
(3,567
)
(10,896
)
988
988
(171,354
)
(171,354
)
(171,922
)
(5,773
)
(3,567
)
(181,262
)
68,194
68,194
86,655
86,655
(5,393
)
(4,671
)
(10,064
)
1,041
1,041
59,361
59,361
(781
)
(781
)
(214
)
(214
)
1,314
3,128
451
4,893
(10,883
)
(10,883
)
(295
)
(427
)
(722
)
199,294
(1,838
)
24
197,480
5
5
(10,768
)
(396
)
2,230
(8,934
)
10,768
1,871
362
13,001
$
$
1,475
$
2,592
$
$
4,067
(a) | Elimination of equity in earnings of subsidiary. |
F-44
21. | Selected Quarterly Financial Data (Unaudited) |
The table below sets forth selected unaudited financial data for each quarter of the last two years.
First
Second
Third
Fourth
Quarter
Quarter
Quarter
Quarter
(in thousands, except per share amounts)
$
225,088
$
234,199
$
239,155
$
260,514
19,216
20,789
17,794
21,929
6,121
7,598
6,343
18,295
8,676
6,121
(1,078
)
6,343
18,295
$
0.15
$
0.17
$
0.14
$
0.40
(0.20
)
$
0.15
$
(0.03
)
$
0.14
$
0.40
$
0.13
$
0.16
$
0.13
$
0.37
(0.19
)
$
0.13
$
(0.03
)
$
0.13
$
0.37
First
Second
Third
Fourth
Quarter
Quarter
Quarter
Quarter
(in thousands, except per share amounts)
$
196,722
$
200,700
$
196,917
$
211,558
15,230
18,278
13,177
14,584
2,834
4,190
1,050
3,885
6,247
2,834
4,190
(5,197
)
3,885
$
0.03
$
0.08
$
(0.04
)
$
0.06
(0.25
)
$
0.03
$
0.08
$
(0.29
)
$
0.06
$
0.03
$
0.08
$
(0.04
)
$
0.06
(0.25
)
$
0.03
$
0.08
$
(0.29
)
$
0.06
F-45
Report of Independent Accountants on
To the Board of Directors and Stockholders
Our audits of the consolidated financial statements referred to
in our report dated February 15, 2002 appearing in this
Annual Report on Form 10-K of Select Medical Corporation
also included an audit of the financial statement schedule
listed in Item 14(a)(2) of this Form 10-K. In our
opinion, this financial statement schedule presents fairly, in
all material respects, the information set forth therein when
read in conjunction with the related consolidated financial
statements.
PricewaterhouseCoopers LLP
Table of Contents
Schedule II-Valuation and
Qualifying Accounts
Balance
Balance
at
Charged to
at
Beginning
Cost
and
End of
Description
of Year
Expenses
Acquisitions(A)
Deductions(B)
Year
Year
ended December 31, 2001 allowance for doubtful accounts
$
75,517
$
35,013
$
1,214
$
(31,855
)
$
79,889
Year
ended December 31, 2000 allowance for doubtful accounts
$
69,492
$
29,335
$
$
(23,310
)
$
75,517
Year
ended December 31, 1999 allowance for doubtful accounts
$
15,701
$
8,858
$
53,989
$
(9,056
)
$
69,492
Year
ended December 31, 2001 income tax valuation allowance
$
35,196
$
(9,670
)
$
$
(22,664
)
$
2,862
Year
ended December 31, 2000 income tax valuation allowance
$
38,941
$
$
(3,745
)
$
$
35,196
Year
ended December 31, 1999 income tax valuation allowance
$
18,867
$
$
20,074
$
$
38,941
(A) | Represents opening balance sheet reserves resulting from purchase accounting entries. |
(B) | Allowance for doubtful accounts deductions represent writeoffs against the reserve. Income tax valuation allowance deductions primarily represent the reversal of valuation allowances because the Company believes certain deferred tax items will be realized. |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned, thereunto duly authorized.
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report is signed below by the following persons on behalf of the Registrant on
the dates and in the capacities indicated.
SELECT MEDICAL CORPORATION
By:
/s/ Robert A. Ortenzio
Robert A. Ortenzio
Chief Executive Officer and President
(principal executive officer)
Signature
Title
Date
/s/ Rocco A. Ortenzio
Rocco A. Ortenzio
Director and Executive Chairman
March 4, 2002
/s/ Robert A. Ortenzio
Robert A. Ortenzio
Director, Chief Executive
Officer and President
(principal executive officer)
March 4, 2002
/s/ Martin F. Jackson
Martin F. Jackson
Chief Financial Officer
(principal financial officer)
March 4, 2002
/s/ Scott A. Romberger
Scott A. Romberger
Chief Accounting Officer
(principal accounting officer)
March 4, 2002
/s/ Russell L. Carson
Russell L. Carson
Director
March 4, 2002
/s/ David S.
Chernow
David S. Chernow
Director
March 4, 2002
/s/ Bryan C.
Cressey
Bryan C. Cressey
Director
March 4, 2002
/s/ James E.
Dalton, Jr.
James E. Dalton, Jr.
Director
March 4, 2002
/s/ Donald J.
Edwards
Donald J. Edwards
Director
March 4, 2002
/s/ Meyer
Feldberg
Meyer Feldberg
Director
March 4, 2002
/s/ Leopold
Swergold
Leopold Swergold
Director
March 4, 2002
/s/ LeRoy S. Zimmerman
LeRoy S. Zimmerman
Director
March 4, 2002
Table of Contents
EXHIBIT INDEX
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Exhibit 3.2
SELECT MEDICAL CORPORATION
AMENDED AND RESTATED BYLAWS
As adopted on March 23, 2001
TABLE OF CONTENTS
ii
iii
SELECT MEDICAL CORPORATION
BYLAWS
AMENDED AND RESTATED AS OF
March 23, 2001
ARTICLE I
STOCKHOLDERS
Section 1.1 Annual Meetings. The annual meeting of the stockholders of the
Corporation for the election of Directors and for the transaction of such other
business as properly may come before such meeting, including, without
limitation, for the purpose of the delivery of an annual report of the Board of
Directors, shall be held at such place, within or without the State of
Delaware, such date, and such time as designated by the Board of Directors and
set forth in the notice or waiver of notice of the meeting.
Section 1.2 Special Meetings. Special meetings of the stockholders for any
proper purpose or purposes may be called at any time by the Chief Executive
Officer, or pursuant to a resolution approved by a majority of the entire Board
of Directors. Such special meetings of the stockholders shall be held at such
places, within or without the State of Delaware, as shall be specified in the
respective notices or waivers of notice thereof. Only business within the
purpose or purposes described in the notice or waiver thereof required by these
Bylaws may be conducted at a special meeting of the stockholders. No
stockholder shall have the power to require that a meeting of the stockholders
be held or that any matter be voted on by the stockholders at any special
meeting, except as required by law.
Section 1.3 Notice of Meetings; Waiver.
(a) Written or printed notice of the place, date and hour of the meeting of the
stockholders, and, in the case of a special meeting, the purpose or purposes
for which such meeting is called, shall be delivered not less than ten nor more
than sixty days prior to the meeting, either personally or by mail, by or at
the direction of the Board of Directors or person calling the meeting, to each
stockholder of record entitled to vote at such meeting. If such notice is
mailed, it shall be deemed to have been delivered to a stockholder on the third
day after it is deposited in the United States mail, postage prepaid, addressed
to the stockholder at his or her address as it appears on the record of
stockholders of the Corporation, or, if he or she shall have filed with the
Secretary of the Corporation a written request that notices to him or her be
mailed
to some other address, then directed to him or her at such other
address. Such further notice shall be given as may be required by law or
otherwise by these Bylaws.
(b) No notice of any meeting of stockholders need be given to any stockholder
who submits a signed waiver of notice, whether before or after the meeting.
Neither the business to be transacted at, nor the purpose of, any regular or
special meeting of the stockholders need be specified in a written waiver of
notice. The attendance of any stockholder at a meeting of stockholders shall
constitute a waiver of notice of such meeting, except when the stockholder
attends a meeting for the express purpose of objecting, at the beginning of the
meeting, to the transaction of any business on the ground that the meeting is
not lawfully called or convened.
Section 1.4 Quorum. Except as otherwise required by law or by the Certificate
of Incorporation, a quorum shall be present at a meeting of stockholders if the
holders of record of more than 50% of the then outstanding shares entitled to
vote at a meeting of the stockholders are represented at the meeting in person
or by proxy.
Section 1.5 Voting. If, pursuant to Section 5.5 of these Bylaws, a record date
has been fixed, every holder of record of shares entitled to vote at a meeting
of stockholders shall be entitled to one vote, or such other number of votes as
may be prescribed in a Preferred Stock Certificate of Designation (as such term
is defined in the Certificate of Incorporation), for each share
outstanding in
his or her name on the books of the Corporation at the close of business on
such record date. If no record date has been fixed, then every holder of record
of shares entitled to vote at a meeting of stockholders shall be entitled to
one vote, or such other number of votes as may be prescribed in a Preferred
Stock Certificate of Designation, for each share of stock standing in his or
her name on the books of the Corporation at the close of business on the
business day next preceding the day on which notice of the meeting is given,
or, if notice is waived, at the close of business on the business day next
preceding the day on which the meeting is held. Except as otherwise required by
law or by the Certificate of Incorporation or by these Bylaws, the vote of a
majority of the shares represented in person or by proxy at any meeting at
which a quorum is present shall be sufficient for the transaction of any
business at such meeting.
Section 1.6 Voting by Ballot. No vote of the stockholders need be taken by
written ballot unless otherwise required by law. Any vote which need not be
taken by ballot may be conducted in any manner approved by the chairman of the
meeting.
Section 1.7 Adjournment. The chairman of the meeting or the holders of record
of more than 50% of the then outstanding shares entitled to vote at a meeting
of the stockholders shall have the power to adjourn such meeting from time to
time, without any notice other than announcement at the meeting of the time and
place of the holding of the adjourned meeting, provided that if the adjournment
is for more than thirty days, or if after the adjournment a new record date for
the adjourned meeting is fixed pursuant to Section 5.5 of these Bylaws, a
notice of the adjourned meeting, conforming to the requirements of
Section 1.3 of these Bylaws, shall be given to each stockholder of record
entitled to vote at such meeting. If such meeting is adjourned by the
stockholders, the resumption of such meeting shall occur at such time and place
2
as shall be determined by a vote of the holders of record of more than 50% of
the then outstanding shares entitled to vote at such meeting of the
stockholders. Upon the resumption of such adjourned meeting, any business may
be transacted that might have been transacted at the meeting as originally
called.
Section 1.8 Proxies. Any stockholder entitled to vote at any meeting of the
stockholders or to express consent to or dissent from corporate action in
writing without a meeting may vote in person or may authorize another person or
persons to vote at any such meeting and express such consent or dissent for him
or her by proxy executed in writing by the stockholder. A stockholder may
authorize a valid proxy by executing a written instrument signed by such
stockholder, or by causing his or her signature to be affixed to such writing
by any reasonable means, including, but not limited to, by facsimile signature
or photographic, photostatic, or similar reproduction or by transmitting or
authorizing the transmission of a telegram or any other means of electronic
communication that results in a writing to the person designated as the holder
of the proxy, a proxy solicitation firm or a like authorized agent. No such
proxy shall be voted or acted upon after the expiration of three years from the
date of such proxy unless such proxy provides for a longer period. A
stockholder may revoke any proxy which is not irrevocable by attending the
meeting and voting in person or by filing an instrument in writing revoking the
proxy or by filing another duly executed proxy bearing a later date with the
Secretary. Proxies by telegram or other electronic communication must either
set forth or be submitted with information from which it can be determined that
the telegram or other electronic communication was authorized by the
stockholder. Any copy, facsimile telecommunication or other reliable
reproduction of a writing or transmission created pursuant to this section may
be substituted or used in lieu of the original writing or transmission for any
and all purposes for which the original writing or transmission could be used,
provided that such copy, facsimile telecommunication or other reproduction
shall be a complete reproduction of the entire original writing or
transmission.
Section 1.9 Notice of Stockholder Business and Nominations.
(a) Annual Meetings of Stockholders.
(1) Nominations of persons for election to the Board of Directors of the
Corporation and the proposal of business to be considered by the stockholders
may be made at an annual meeting of stockholders (i) by or at the direction of
the Board of Directors or the Chairman of the Board, or (ii) by any stockholder
of the Corporation who is entitled to vote at the meeting, who complies with
the notice procedures set forth in clauses (2) and (3) of this paragraph and
who was a stockholder of record at the time such notice is delivered to the
Secretary or any Assistant Secretary of the Corporation.
(2) For nominations or other business to be properly brought before an annual
meeting by a stockholder, pursuant to clause (ii) of paragraph (A)(1) of this
Bylaw, the stockholder must have given timely notice thereof in writing to the
Secretary or any Assistant Secretary of the Corporation. To be timely, a
stockholders notice shall be delivered to the Secretary or any Assistant
Secretary at the principal executive offices of the Corporation not
3
less than ninety days nor more than one hundred and twenty days prior to the
first anniversary of the preceding years annual meeting; provided, that if the
date of the annual meeting is advanced by more than twenty days or delayed by
more than seventy days from such anniversary date, notice by the stockholder to
be timely must be so delivered not earlier than one hundred and twenty days
prior to such annual meeting and not later than the close of business on the
later of the ninetieth day prior to such annual meeting or the tenth day
following the day on which public announcement of the date of such meeting is
first made. In no event shall the adjournment of an annual meeting commence a
new time period for the giving of a stockholders notice as described above.
Such stockholders notice shall set forth (a) as to each person whom the
stockholder proposes to nominate for election or reelection as a Director all
information relating to such person that is required to be disclosed in
solicitations of proxies for election of Directors, or is otherwise required,
in each case pursuant to Regulation 14A under the Securities Exchange Act of
1934, as amended (the Exchange Act), and Rule 14a-11 thereunder, in each case
including any successor Rule or Regulation thereto, including such persons
written consent to being named in the proxy statement as a nominee and to
serving as a Director if elected; (b) as to any other business that the
stockholder proposes to bring before the meeting, a brief description of the
business desired to be brought before the meeting, the reasons for conducting
such business at the meeting and any material interest in such business of such
stockholder and of any beneficial owner on whose behalf the proposal is made;
and (c) as to the stockholder giving the notice and any beneficial owner on
whose behalf the nomination or proposal is made (i) the name and address of
such stockholder, as they appear on the Corporations books, and of such
beneficial owner and (ii) the class and number of shares of the Corporation
which are owned beneficially and of record by such stockholder and such
beneficial owner.
(3) Notwithstanding anything in the second sentence of paragraph (A)(2) of this
Bylaw to the contrary, in the event that the number of Directors to be elected
to the Board of Directors of the Corporation is increased and there is no
public announcement naming all of the nominees for Director or specifying the
size of the increased Board of Directors made by the Corporation at least one
hundred days prior to the first anniversary of the preceding years annual
meeting, a stockholders notice under this paragraph shall also be considered
timely, but only with respect to nominees for any new positions created by such
increase, if it shall be delivered to the Secretary at the principal executive
offices of the Corporation not later than the close of business on the tenth
day following the day on which such public announcement is first made by the
Corporation.
(b) Special Meetings of Stockholders. Only such business as shall have been
brought before the special meeting of the stockholders pursuant to the
Corporations notice of meeting pursuant to Section 1.3 of these Bylaws shall
be conducted at such meeting. Nominations of persons for election to the Board
of Directors may be made at a special meeting of stockholders at which
Directors are to be elected pursuant to the Corporations notice of meeting (i)
by or at the direction of the Board of Directors or (ii) by any stockholder of
the Corporation who is entitled to vote at the meeting, who complies with the
notice procedures set forth in this Bylaw and who is a stockholder of record at
the time such notice is delivered to the Secretary of the Corporation.
Nominations by stockholders of persons for election to the Board
4
of Directors may be made at such special meeting of stockholders if the
stockholders notice as required by paragraph (A)(2) of this Bylaw shall be
delivered to the Secretary at the principal executive offices of the
Corporation not earlier than the one hundred and twentieth day prior to such
special meeting and not later than the close of business on the later of the
ninetieth day prior to such special meeting or the tenth day following the day
on which public announcement is first made of the date of the special meeting
and of the nominees proposed by the Board of Directors to be elected at such
meeting. In no event shall the adjournment of a special meeting commence a new
time period for the giving of a stockholders notice as described above.
(c) General.
(1) Only persons who are nominated in accordance with the procedures set forth
in this Bylaw shall be eligible to serve as Directors and only such business
shall be conducted at a meeting of stockholders as shall have been brought
before the meeting in accordance with the procedures set forth in this Bylaw.
Except as otherwise provided by law, the Certificate of Incorporation or these
Bylaws, the chairman of the meeting shall have the power and duty to determine
whether a nomination or any business proposed to be brought before the meeting
was made in accordance with the procedures set forth in this Bylaw and, if any
proposed nomination or business is not in compliance with this Bylaw, to
declare that such defective proposal or nomination shall be disregarded.
(2) For purposes of this Bylaw, public announcement shall mean disclosure in a
press release reported by the Dow Jones News Service, Associated Press or
comparable national news service or in a document publicly filed by the
Corporation with the Securities and Exchange Commission pursuant to
Section 13, 14, or 15(d) of the Exchange Act.
(3) Notwithstanding the foregoing provisions of this Bylaw, a stockholder shall
also comply with all applicable requirements of the Exchange Act and the rules
and regulations thereunder with respect to the matters set forth in this Bylaw.
Nothing in this Bylaw shall be deemed to affect any right of stockholders to
request inclusion of proposals in the Corporations proxy statement pursuant to
Rule 14a-8 under the Exchange Act.
Section 1.10 Organization; Procedure. At every meeting of stockholders the
presiding officer shall be the chairman of the meeting, who shall be a Director
(or representative thereof) designated by a majority of the Board of Directors.
The order of business and all other matters of procedure at every meeting of
stockholders, including the regulation of the manner of voting and the conduct
of discussion as seem to him or her in order, shall be determined by such
presiding officer. All meetings of the stockholders shall be held at the
principal place of business of the Corporation or at such other place within or
without the State of Delaware as shall be specified or fixed in the notices or
waivers of notice thereof.
Section 1.11 Inspectors of Elections. Preceding any meeting of the
stockholders, the Board of Directors shall appoint one or more persons to act
as inspectors of elections, and may designate one or more alternate inspectors.
In the event no inspector or alternate is able to act, the person presiding at
the meeting shall appoint one or more inspectors to act at the meeting.
5
Each inspector, before entering upon the discharge of the duties of an
inspector, shall take and sign an oath faithfully to execute the duties of
inspector with strict impartiality and according to the best of his or her
ability. The inspector shall:
(a) ascertain the number of shares outstanding and the voting power of each,
(b) determine the shares represented at a meeting and the validity of proxies
and ballots, count all votes and ballots,
(c) determine and retain for a reasonable period a record of the disposition of
any challenges made to any determination by the inspectors; and
(d) certify his or her determination of the number of shares represented at the
meeting, and his or her count of all votes and ballots.
The inspector may appoint or retain other persons or entities to assist in the
performance of the duties of inspector.
When determining the shares represented and the validity of proxies and
ballots, the inspector shall be limited to an examination of the proxies, any
envelopes submitted with those proxies, any information provided in accordance
with Section 1.8 of these Bylaws, ballots and the regular books and records of
the Corporation. The inspector may consider other reliable information for the
limited purpose of reconciling proxies and ballots submitted by or on behalf of
banks, brokers or their nominees or a similar person which represent more votes
than the holder of a proxy is authorized by the record owner to cast or more
votes than the stockholder holds of record. If the inspector considers other
reliable information as outlined in this section, the inspector, at the time of
his or her certification pursuant to (d) of this section, shall specify the
precise information considered, the person or persons from whom the information
was obtained, when this information was obtained, the means by which the
information was obtained, and the basis for the inspectors belief that such
information is accurate and reliable.
Section 1.12 Opening and Closing of Polls. The date and time for the opening
and the closing of the polls for each matter to be voted upon at a stockholder
meeting shall be announced at the meeting. The inspector of the election shall
be prohibited from accepting any ballots, proxies or votes or any revocations
thereof or changes thereto after the closing of the polls, unless the Court of
Chancery upon application by a stockholder shall determine otherwise.
Section 1.13 No Stockholder Action by Written Consent or Telephone Conference.
Any action required or permitted to be taken by the stockholders of the
Corporation must be effected at a duly called annual or special meeting of the
stockholders of the Corporation, and the ability of the stockholders to consent
in writing or by telephone to the taking of any action is specifically denied.
6
ARTICLE II
BOARD OF DIRECTORS
Section 2.1 General Powers. Except as may otherwise be provided by law, by the
Certificate of Incorporation or by these Bylaws, the property, affairs and
business of the Corporation shall be managed by or under the direction of the
Board of Directors and the Board of Directors may exercise all the powers of
the Corporation and may make all decisions and take all actions for the
Corporation. The powers of the Corporation which may be exercised by the
Directors without the approval of the stockholders shall include, without
limitation, the power to purchase, hold and sell investments; to borrow and
loan funds and provide guarantees of the obligations of others; and to acquire
other companies in the ordinary course of business.
Section 2.2 Number and Term of Office. The number of Directors shall be fixed
from time to time exclusively pursuant to a resolution adopted by a majority of
the entire Board of Directors, but shall consist of not less than five (5)
Directors nor more than nine (9) Directors. The Directors, other than those who
may be elected by the holders of any series of Preferred Stock, if any, shall
be divided into three classes, designated Classes I, II and III, which shall be
as nearly equal in number as possible. Directors of Class I shall be elected to
hold office for a term expiring at the annual meeting of stockholders to be
held in 2002, Directors of Class II shall be elected to hold office for a term
expiring at the annual meeting of stockholders to be held in 2003 and Directors
of Class III shall be elected to hold office for a term expiring at the annual
meeting of stockholders to be held in 2004. At each succeeding annual meeting
of stockholders following such initial classification and election, the
respective successors of each class shall be elected for three year terms. Each
Director (whenever elected) shall hold office until his or her successor has
been duly elected and qualified, or until his or her earlier death, insanity,
retirement, resignation or removal. Directors need not be residents of the
State of Delaware.
Section 2.3 Election of Directors. Except as otherwise provided in Sections
2.11 and 2.12 of these Bylaws, the Directors shall be elected at each annual
meeting of the stockholders. If the annual meeting for the election of
Directors is not held on the date designated therefor, the Directors shall
cause the meeting to be held as soon thereafter as convenient. At each meeting
of the stockholders for the election of Directors, provided a quorum is
present, the Directors shall be elected by a plurality of the votes validly
cast in such election.
Section 2.4 Annual and Regular Meetings. The annual meeting of the Board of
Directors for the purpose of electing officers and for the transaction of such
other business as may come before the meeting shall be held as soon as possible
following adjournment of the annual meeting of the stockholders at the place of
such annual meeting of the stockholders. Notice of such annual meeting of the
Board of Directors need not be given. The Board of Directors from time to time
may by resolution provide for the holding of regular meetings and fix the place
(which may be within or without the State of Delaware) and the date and hour of
such meetings, provided that such meetings shall be held no less frequently
than quarterly. Notice of regular meetings need not be given, provided,
however, that if the Board of Directors
7
shall fix or change the time or place of any regular meeting, notice of such
action shall be mailed promptly, or sent by telephone, including a voice
messaging system or other system or technology designed to record and
communicate messages, telegraph, facsimile, electronic mail or other electronic
means to each Director who shall not have been present at the meeting at which
such action was taken, addressed to him or her at his or her usual place of
business, or shall be delivered to him or her personally.
Section 2.5 Special Meetings; Notice. Special meetings of the Board of
Directors shall be held whenever called by the Chairman or the Chief Executive
Officer, or by a majority of the Directors, date and hour as may be specified
in the respective notices or waivers of notice of such meetings. Special
meetings of the Board of Directors may be called on at least seventy-two hours
notice to each other Director, if notice is given to each Director personally
or by telephone, including a voice messaging system or other system or
technology designed to record and communicate messages, telegraph, facsimile,
electronic mail or other electronic means, or on five days notice from the
official date of deposit in the mail if notice is mailed to each Director,
addressed to him or her at his or her usual place of business. Such notice need
not state the purpose or purposes of, nor the business to be transacted at,
such meeting, except as may otherwise be required by law or provided for by the
Certificate of Incorporation.
Section 2.6 Quorum; Voting. Unless otherwise required by law or provided in the
Certificate of Incorporation, at all meetings of the Board of Directors, the
presence of a majority of the total number of Directors then in office shall
constitute a quorum for the transaction of business of the Directors. Except as
otherwise required by law, or except as provided herein or in the Certificate
of Incorporation, the act or vote of a majority of directors present at a
meeting at which a quorum is present shall be the act of the Board of
Directors. A Director who is present at a meeting of the Directors at which
action on any matter of the Corporation is taken shall be presumed to have
assented to the action unless his dissent shall be entered in the minutes of
the meeting or unless he shall file his written dissent to such action with the
person acting as secretary of the meeting before the adjournment thereof or
shall deliver such dissent to the Corporation immediately after the adjournment
of the meeting. Such right to dissent shall not apply to a Director who voted
in favor of such action.
Section 2.7 Adjournment. A majority of the Directors present, whether or not a
quorum is present, may adjourn any meeting of the Board of Directors to another
time or place. No notice need be given of any adjourned meeting unless the time
and place of the adjourned meeting are not announced at the time of
adjournment, in which case notice conforming to the requirements of Section 2.5
of these Bylaws shall be given to each Director.
Section 2.8 Action Without a Meeting. Any action permitted or required by law,
the Certificate of Incorporation, or these Bylaws to be taken at a meeting of
the Directors or of any committee designated by the Directors may be taken
without a meeting if a consent in writing, setting forth the action to be
taken, is signed by all the Directors or members of such committee, as the case
may be, provided that the writing or writings are filed with the minutes of
proceedings of the Board of Directors or committee. Such consent shall have the
same force and
8
effect as a unanimous vote at a meeting and may be stated as such in any
document or instrument filed with the Secretary of State of Delaware, and the
execution of such consent shall constitute attendance or presence in person at
a meeting of the Board of Directors or any such committee, as the case may be.
Subject to the requirements of law, the Certificate of Incorporation, or these
Bylaws for notice of meetings, Directors, or members of any committee
designated by the Board of Directors, may participate in and hold a meeting of
the Board of Directors or any committee of Directors, as the case may be, by
means of a conference telephone or similar communications equipment by means of
which all persons participating in the meeting can hear each other, and
participation in such meeting shall constitute attendance and presence in
person at such meeting, except where a person participates in the meeting for
the express purpose of objecting to the transaction of any business on the
ground that the meeting is not lawfully called or convened.
Section 2.9 Regulations; Manner of Acting. Meetings of the Board of Directors
may be held at such place or places as shall be determined from time to time by
resolution of the Directors. At all meetings of the Board of Directors,
business shall be transacted in such order as shall from time to time be
determined by resolution of the Directors to the extent consistent with
applicable law, the Certificate of Incorporation and these Bylaws. The Board of
Directors may adopt such other rules and regulations for the conduct of
meetings of the Board of Directors and for the management of the property,
affairs and business of the Corporation as the Board of Directors may deem
appropriate. Attendance of a Director at a meeting shall constitute a waiver of
notice of such meeting, except where a Director attends a meeting for the
express purpose of objecting to the transaction of any business on the ground
that the meeting is not lawfully called or convened. The Directors shall act
only as a Board, and the individual Directors shall have no power as such.
Section 2.10 Resignations. Any Director may resign at any time. Such
resignation shall be made in writing, signed by such Director, to the
Corporation and shall take effect at the time specified therein, or if no time
be specified, at the time of its receipt by the Chairman or the Secretary. The
acceptance of a resignation shall not be necessary to make it effective, unless
expressly so provided in the resignation.
Section 2.11 Removal of Directors. Any Director may be removed at any time, but
only for cause upon the affirmative vote of the holders of a majority of the
combined voting power of the then outstanding stock of the Corporation entitled
to vote generally in the election of Directors at any meeting of such
stockholders, including meetings called expressly for that purpose, and at
which a quorum of stockholders is present. Subject to the rights of the holders
of any series of preferred stock of the Corporation, any vacancy in the Board
of Directors caused by any such removal shall be filled at such meeting by the
stockholders entitled to vote for the election of the Director so removed.
Section 2.12 Vacancies and Newly Created Directorships. Subject to the rights
of the holders of any series of preferred stock of the Company and except as
provided in Section 2.11, if any vacancies occur in the Board of Directors, by
reason of death, resignation, removal or otherwise, or if the authorized number
of Directors shall be increased, the Directors then in
9
office shall continue to act and such vacancies and newly created Directorships
may be filled by a majority of the Directors then in office, although less than
a quorum. A Director elected to fill a vacancy or a newly created Directorship
shall hold office until the next election of the class of Directors for which
such Director has been chosen and until his or her successor has been elected
and qualified or until his or her earlier death, resignation or removal.
Section 2.13 Reliance on Accounts and Reports, etc. A Director, or a member of
any committee designated by the Board of Directors shall, in the performance of
his or her duties, be fully protected in relying in good faith upon the records
of the Corporation and upon information, opinions, reports or statements
presented to the Corporation by any of the Corporations officers or employees,
or committees designated by the Board of Directors, or by any other person as
to the matters the Director or member reasonably believes are within such other
persons professional or expert competence and who has been selected with
reasonable care by or on behalf of the Corporation.
ARTICLE III
COMMITTEES OF DIRECTORS AND ADVISORY BOARD
Section 3.1 Committees of Directors. The Board of Directors may designate one
or more committees, each such committee to consist of one or more Directors, as
fixed from time to time by the Board of Directors. The Board of Directors may
designate one or more Directors as alternate members of any such committee, who
may replace any absent or disqualified member or members at any meeting of such
committee. Thereafter, members (and alternate members, if any) of each such
committee may be designated at the annual meeting of the Board of Directors.
Any such committee may be dissolved or re-designated from time to time by the
Board of Directors. Each member (and each alternate member) of any such
committee (whether designated at an annual meeting of the Board of Directors or
to fill a vacancy or otherwise) shall hold office until his or her successor
shall have been designated or until he or she shall cease to be a Director, or
until his or her earlier death, resignation or removal.
Section 3.2 Proceedings. Any such committee may fix its own rules of procedure
and may meet at such place (within or without the State of Delaware), at such
time and upon such notice, if any, as it shall determine from time to time. Any
such committee shall keep regular minutes of its meetings and report the same
to the Board of Directors at the next meeting of the Board following such
committee meeting, except that when the Board meeting is held within two days
after the committee meeting, such report shall, if not made at the first
meeting, be made to the Board of Directors at its second meeting following such
committee meeting.
Section 3.3 Quorum and Manner of Acting. Except as may be otherwise provided in
the resolution creating such committee, at all meetings of any committee the
presence of members (or alternate members) constituting a majority of the total
authorized membership of such committee shall constitute a quorum for the
transaction of business. The act of the majority of the members present at any
meeting at which a quorum is present shall be the act of such committee. Any
action required or permitted to be taken at any meeting of any such committee
10
may be taken without a meeting if all members of such committee shall consent
to such action in writing and such writing or writings are filed with the
minutes of the proceedings of the committee. The members of any such committee
shall act only as a committee, and the individual members of such committee
shall have no power as such.
Section 3.4 Action by Telephonic Communications. Members of any committee
designated by the Board of Directors may participate in a meeting of such
committee by means of conference telephone or similar communications equipment
by means of which all persons participating in the meeting can hear each other,
and participation in a meeting pursuant to this provision shall constitute
presence in person at such meeting.
Section 3.5 Absent or Disqualified Members. In the absence or disqualification
of a member of any committee, the member or members thereof present at any
meeting and not disqualified from voting, whether or not he, she or they
constitute a quorum, may unanimously appoint another member of the Board of
Directors to act at the meeting in the place of any such absent or disqualified
member.
Section 3.6 Resignations. Any member (and any alternate member) of any
committee may resign at any time by delivering a written notice of resignation,
signed by such member, to the Chairman, the Chief Executive Officer or the
President. Unless otherwise specified therein, such resignation shall take
effect upon delivery.
Section 3.7 Removal. Any member (and any alternate member) of any committee may
be removed from his or her position as a member (or alternate member, as the
case may be) of such committee at any time, either for or without cause, by
resolution adopted by a majority of the whole Board of Directors.
Section 3.8 Vacancies. If any vacancy shall occur in any committee, by reason
of disqualification, death, resignation, removal or otherwise, the remaining
members (and any alternate members) shall continue to act, and any such vacancy
may be filled by the Board of Directors.
ARTICLE IV
OFFICERS
Section 4.1 Number. The officers of the Corporation shall be designated by the
Board of Directors and shall include such officers as the Directors may from
time to time determine, which officers may (but need not) include a Chairman of
the Board, a Vice Chairman of the Board, a Chief Executive Officer, a
President, one or more Vice Presidents (and in the case of each such Vice
President, with such descriptive title, if any, as the Directors shall deem
appropriate), a Secretary, an Assistant Secretary, and a Treasurer. The Board
of Directors also may elect one or more other officers as the Board of
Directors may determine. Any number of offices may be held by the same person.
No officer need be a Director of the Corporation.
11
Section 4.2 Election. Officers shall be chosen in such manner and shall hold
their offices for such terms as determined by the Board of Directors. Each
officer shall hold office until his or her successor has been elected and
qualified in his stead, or until his or her earlier death, resignation,
retirement, disqualification, or removal from office.
Section 4.3 Compensation. The Corporation shall have the authority to pay and
provide compensation and other benefits to its officers and employees. The
compensation and benefits of all officers of the Corporation shall be fixed
from time to time by the Board of Directors, unless otherwise delegated by the
Board of Directors to a particular committee or officer.
Section 4.4 Removal and Resignation; Vacancies. Any officer may be removed for
or without cause at any time by the Board of Directors, the Chief Executive
Officer or the President, if such powers of removal have been expressly
conferred by the Board of Directors, but such removal shall be without
prejudice to the contract rights, if any, of the person so removed. Designation
of an officer shall not itself create contract rights. Any officer may resign
at any time by delivering a written notice of resignation, signed by such
officer, to the Board of Directors, the Chief Executive Officer or the
President. Unless otherwise specified therein, such resignation shall take
effect upon delivery. Any vacancy occurring in any office of the Corporation by
death, resignation, removal or otherwise, shall be filled by the Board of
Directors. The Board of Directors may abolish any office at any time unless
prohibited by law or statute.
Section 4.5 Authority and Duties of Officers. In addition to any specifically
enumerated duties, services, and powers, the officers of the Corporation shall
have such authority and shall exercise such powers and perform such duties as
may be specified by law or statute, by the Certificate of Incorporation, and by
these Bylaws, or as the Board of Directors may from time to time determine or
as may be assigned to such officers by any competent superior officer. The
Board of Directors may also at any time limit or circumvent the enumerated
duties, services and powers of any officer. In addition to the designation of
officers and the enumeration of their respective duties, services and powers,
the Board of Directors may grant powers of attorneys to individuals to act as
agent for or on behalf of the Corporation, to do any act which would be binding
on the Corporation, to incur any expenditures on behalf of or for the
Corporation, or to execute, deliver and perform any agreements, acts,
transactions or other matters on behalf of the Corporation. Such powers of
attorney may be revoked or modified as deemed necessary by the Board of
Directors.
Section 4.6 Chairman of the Board. The Chairman of the Board shall, if one is
designated by the Board of Directors and if present, preside at all meetings of
the stockholders and of the Board of Directors and exercise and perform such
other powers and duties as may be from time to time assigned by the Board of
Directors. He shall assist the Directors in the formulation of the policies of
the Corporation, and shall be available to other officers for consultation and
advice.
12
Section 4.7 Vice Chairman of the Board. The Vice Chairman of the Board, if one
is designated by the Board of Directors, shall, in the absence of the Chairman
of the Board, preside at all meetings of the stockholders and of the Board of
Directors and exercise and perform such other powers and duties as may be from
time to time assigned by the Board of Directors.
Section 4.8 Chief Executive Officer. The Chief Executive Officer shall have
day-to-day supervision of the affairs of the Corporation, such powers and
duties subject at all times to the authority of the Board of Directors. In the
absence or disability of the Chairman of the Board and the Vice Chairman of the
Board, the Chief Executive Officer shall exercise the powers and perform the
duties of the Chairman of the Board.
Section 4.9 President. The President, if one is designated by the Board of
Directors, shall generally assist the Chief Executive Officer and shall have
such powers and perform such duties and services as shall from time to time be
prescribed or delegated to him by the Chief Executive Officer or the Board of
Directors. In the absence or disability of the Chief Executive Officer, the
President shall exercise the powers and perform the duties of the Chief
Executive Officer.
Section 4.10 Vice Presidents. Each Vice President that is designated by the
Board of Directors shall generally assist the President and shall have such
powers and perform such duties and services as shall from time to time be
prescribed or delegated to him by the President or the Board of Directors.
Section 4.11 Secretary. The Secretary, if one is designated by the Board of
Directors, shall have the following powers and duties:
(a) He or she shall keep or cause to be kept a record of all the proceedings of
the meetings of the stockholders and of the Board of Directors in books
provided for that purpose.
(b) He or she shall cause all notices to be duly given in accordance with the
provisions of these Bylaws and as required by law.
(c) Whenever any committee shall be appointed pursuant to a resolution of the
Board of Directors, he or she shall furnish a copy of such resolution to the
members of such committee.
(d) He or she shall be the custodian of the records and of the seal of the
Corporation and cause such seal (or a facsimile thereof) to be affixed to all
certificates representing shares of the Corporation prior to the issuance
thereof and to all instruments the execution of which on behalf of the
Corporation under its seal shall have been duly authorized in accordance with
these Bylaws, and when so affixed he or she may attest the same.
13
(e) He or she shall properly maintain and file all books, reports, statements,
certificates and all other documents and records required by law, the
Certificate of Incorporation or these Bylaws.
(f) He or she shall have charge of the stock books and ledgers of the
Corporation and shall cause the stock and transfer books to be kept in such
manner as to show at any time the number of shares of stock of the Corporation
of each class issued and outstanding, the names (alphabetically arranged) and
the addresses of the holders of record of such shares, the number of shares
held by each holder and the date as of which each became such holder of record.
(g) He or she shall sign (unless the Treasurer, an Assistant Treasurer or an
Assistant Secretary shall have signed) certificates representing shares of the
Corporation the issuance of which shall have been authorized by the Board of
Directors.
(h) He or she shall perform, in general, all duties incident to the office of
Secretary and such other duties as may be specified in these Bylaws or as may
be assigned to him or her from time to time by the Board of Directors, the
Chief Executive Officer or the President.
Section 4.12 Assistant Secretary. The Assistant Secretary, if one is designated
by the Board of Directors, shall generally assist the Secretary.
Section 4.13 Treasurer. The Treasurer, if one is designated by the Board of
Directors, or such other officer as may be designated by the Board of
Directors, shall be the chief accounting and financial officer of the
Corporation and have custody of all the funds, securities and other valuables
of the Corporation which may have or shall come into his or her hands. The
Treasurer shall have active control of and shall be responsible for all matters
pertaining to the accounts and finances of the Corporation and shall have such
powers and perform such duties as may be prescribed by the Chief Executive
Officer, the President, the Board of Directors or elsewhere in these Bylaws.
Section 4.14 Additional Officers. The Board of Directors may appoint such other
officers and agents as it may deem appropriate, and such other officers and
agents shall hold their offices for such terms and shall exercise such powers
and perform such duties as may be determined from time to time by the Board of
Directors. The Board of Directors from time to time may delegate to the Chief
Executive Officer or President the power to appoint subordinate officers or
agents and to prescribe their respective rights, terms of office, authorities
and duties. Any such officer or agent may remove any such subordinate officer
or agent appointed by him or her, for or without cause.
Section 4.15 Security. The Board of Directors may require any officer, agent or
employee of the Corporation to provide security for the faithful performance of
his or her duties, in such amount and of such character as may be determined
from time to time by the Board of Directors.
14
ARTICLE V
CAPITAL STOCK
Section 5.1 Certificates of Stock, Uncertificated Shares. The shares of the
Corporation shall be represented by certificates, provided that the Board of
Directors may provide by resolution or resolutions that some or all of any or
all classes or series of the stock of the Corporation shall be uncertificated
shares. Any such resolution shall not apply to shares represented by a
certificate until each certificate is surrendered to the Corporation.
Notwithstanding the adoption of such a resolution by the Board of Directors,
every holder of stock in the Corporation represented by certificates and upon
request every holder of uncertificated shares shall be entitled to have a
certificate signed by, or in the name of the Corporation, by the Chief
Executive Officer, the President or a Vice President, and by the Treasurer or
an Assistant Treasurer, or the Secretary or an Assistant Secretary,
representing the number of shares registered in certificate form. Such
certificate shall be in such form as the Board of Directors may determine, to
the extent consistent with applicable law, the Certificate of Incorporation and
these Bylaws.
Section 5.2 Signatures; Facsimile. All of such signatures on the certificate
referred to in Section 5.1 of these Bylaws may be a facsimile, engraved or
printed, to the extent permitted by law. In case any officer, transfer agent or
registrar who has signed, or whose facsimile signature has been placed upon a
certificate shall have ceased to be such officer, transfer agent or registrar
before such certificate is issued, it may be issued by the Corporation with the
same effect as if he or she were such officer, transfer agent or registrar at
the date of issue.
Section 5.3 Lost, Stolen or Destroyed Certificates. The Corporation may direct
that a new certificate be issued in place of any certificate theretofore issued
by the Corporation alleged to have been lost, stolen or destroyed, upon
delivery to the Corporation of an affidavit of the owner or owners of such
certificate, setting forth such allegation. The Corporation may require the
owner of such lost, stolen or destroyed certificate, or his or her legal
representative, to give the Corporation a bond sufficient to indemnify it
against any claim that may be made against it on account of the alleged loss,
theft or destruction of any such certificate or the issuance of any such new
certificate.
Section 5.4 Transfer of Stock. Upon surrender to the Corporation or the
transfer agent of the Corporation of a certificate for shares, duly endorsed or
accompanied by appropriate evidence of succession, assignment or authority to
transfer, the Corporation shall issue a new certificate to the person entitled
thereto, cancel the old certificate and record the transaction upon its books.
Within a reasonable time after the transfer of uncertificated stock, the
Corporation shall send to the registered owner thereof a written notice
containing the information required to be set forth or stated on certificates
pursuant to Sections 151, 156, 202(a) or 218(a) of the Delaware General
Corporation Law. Subject to the provisions of the Certificate of Incorporation
and these Bylaws, the Board of Directors may prescribe such additional rules
and regulations as
15
it may deem appropriate relating to the issue, transfer and registration of
shares of the Corporation.
Section 5.5 Record Date. In order to determine the stockholders entitled to
notice of, or entitled to vote at, any meeting of stockholders or any
adjournment thereof, the Board of Directors may fix in advance a record date,
which record date shall not precede the date on which the resolution fixing the
record date is adopted by the Board of Directors, and which shall not be more
than sixty nor less than ten days before the date of such meeting. A
determination of stockholders of record entitled to notice of or entitled to
vote at a meeting of stockholders shall apply to any adjournment of the
meeting, provided, however, that the Board of Directors may fix a new record
date for the adjourned meeting.
In order that the Corporation may determine the stockholders entitled to
receive payment of any dividend or other distribution or allotment of any
rights of the stockholders entitled to exercise any rights in respect of any
change, conversion or exchange of stock, or for the purpose of any other lawful
action, the Board of Directors may fix a record date, which record date shall
not precede the date upon which the resolution fixing the record date is
adopted, and which record date shall be not more than sixty days prior to such
action. If no record date is fixed, the record date for determining
stockholders for any such purpose shall be at the close of business on the day
on which the Board of Directors adopts the resolution relating thereto.
Section 5.6 Registered Stockholders. Prior to due surrender of a certificate
for registration of transfer, the Corporation may treat the registered owner as
the person exclusively entitled to receive dividends and other distributions,
to vote, to receive notice and otherwise to exercise all the rights and powers
of the owner of the shares represented by such certificate, and the Corporation
shall not be bound to recognize any equitable or legal claim to or interest in
such shares on the part of any other person, whether or not the Corporation
shall have notice of such claim or interests. Whenever any transfer of shares
shall be made for collateral security, and not absolutely, it shall be so
expressed in the entry of the transfer if, when the certificates are presented
to the Corporation for transfer or uncertificated shares are requested to be
transferred, both the transferor and transferee request the Corporation to do
so.
Section 5.7 Transfer Agent and Registrar. The Board of Directors may appoint
one or more transfer agents and one or more registrars, and may require all
certificates representing shares to bear the signature of any such transfer
agents or registrars.
ARTICLE VI
INDEMNIFICATION
Section 6.1 Nature of Indemnity. The Corporation shall indemnify any person who
was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding (a Proceeding), whether civil,
criminal, administrative, arbitrative, or investigative, or any appeal in such
a Proceeding or any inquiry or investigation that could lead to such a
Proceeding, by reason of the fact that he or she, or a person of whom he or she
is the
16
legal representative, is or was or has agreed to become a Director or officer
of the Corporation, or is or was serving or has agreed to serve at the request
of the Corporation as a director, officer, partner, venturer, proprietor,
trustee, employee, agent, or similar functionary of another foreign or domestic
corporation, limited liability company, partnership, joint venture, sole
proprietorship, trust, employee benefit plan, or other enterprise, or by reason
of any action alleged to have been taken or omitted in such capacity, against
expenses (including attorneys fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred by him or her or on his or her
behalf in connection with such action, suit or proceeding and any appeal
therefrom, provided that he or she acted in good faith and in a manner he or
she reasonably believed to be in or not opposed to the best interests of the
Corporation, and, with respect to any criminal action or proceeding had no
reasonable cause to believe his or her conduct was unlawful. The
indemnification provided in this Article VI could involve indemnification for
negligence or under theories of strict liability. In the case of an action or
suit by or in the right of the Corporation to procure a judgment in its favor
(1) the indemnification of a Director or officer shall be limited to expenses
(including attorneys fees) actually and reasonably incurred by such person in
the defense or settlement of such action or suit, and (2) no indemnification
shall be made in respect of any claim, issue or matter as to which such person
shall have been adjudged to be liable to the Corporation unless and only to the
extent that the Delaware Court of Chancery or the court in which such action or
suit was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case,
such person is fairly and reasonably entitled to indemnity for such expenses
which the Delaware Court of Chancery or such other court shall deem proper.
Notwithstanding the foregoing, but subject to Section 6.5 of these Bylaws, the
Corporation shall not be obligated to indemnify a Director or officer of the
Corporation in respect of a Proceeding (or part thereof) instituted by such
Director or officer, unless such Proceeding (or part thereof) has been
authorized by the Board of Directors.
The termination of any action, suit or proceeding by judgment, order,
settlement, conviction, or upon a plea of nolo contendere or its equivalent,
shall not, of itself, create a presumption that the person did not act in good
faith and in a manner which he or she reasonably believed to be in or not
opposed to the best interests of the Corporation, and, with respect to any
criminal action or proceeding, had reasonable cause to believe that his or her
conduct was unlawful.
The rights granted pursuant to this Article VI shall be deemed contract rights.
No amendment, modification or repeal of this Article VI shall have the effect
of limiting or denying any such rights with respect to actions taken or
Proceedings arising prior to any such amendment, modification or repeal.
Section 6.2 Successful Defense. To the extent that a present or former Director
or officer of the Corporation has been successful on the merits or otherwise in
defense of any action, suit or proceeding referred to in Section
6.1 of these Bylaws or in defense of any claim, issue or matter therein, he or
she shall be indemnified against expenses (including attorneys fees) actually
and reasonably incurred by him or her in connection therewith.
17
Section 6.3 Determination that Indemnification is Proper. Any indemnification
of a present or former Director or officer of the Corporation under Section 6.1
of these Bylaws (unless ordered by a court) shall be made by the Corporation
unless a determination is made that indemnification of the Director or officer
is not proper in the circumstances because he or she has not met the applicable
standard of conduct set forth in Section 6.1 of these Bylaws. Any such
determination shall be made (1) by a majority vote of the Directors who are not
parties to such action, suit or proceeding, even though less than a quorum, or
(2) by a committee of such directors designated by majority vote of such
directors, even though less than a quorum, or (3) if there are no such
Directors, or if such Directors so direct, by independent legal counsel in a
written opinion, or (4) by the stockholders.
Section 6.4 Advance Payment of Expenses. The right to indemnification conferred
in this Article VI shall include the right to be paid or reimbursed by the
Corporation the reasonable expenses incurred by a person of the type entitled
to be indemnified under Sections 6.1, 6.2, and 6.3 who was, is, or is
threatened to be made a named defendant or respondent in a Proceeding in
advance of the final disposition of the Proceeding and without any
determination as to the persons ultimate entitlement to indemnification;
provided, however, that the payment of such expenses incurred by any such
person in advance of the final disposition of a Proceeding shall be made only
upon delivery to the Corporation of a written affirmation by such person of his
or her good faith belief that he or she has met the standard of conduct
necessary for indemnification under this Article VI and a written undertaking,
by or on behalf of such person, to repay all amounts so advanced if it shall
ultimately be determined that such person is not entitled to be indemnified
under this Article VI or otherwise. The Board of Directors may authorize the
Corporations counsel to represent such present or former Director or officer
in any action, suit or proceeding, whether or not the Corporation is a party to
such action, suit or proceeding.
Section 6.5 Procedure for Indemnification of Directors and Officers. Any
indemnification of a Director or officer of the Corporation under Sections
6.1, 6.2, and 6.3 of these Bylaws, or advance of costs, charges and expenses to
a Director or officer under Section 6.4 of these Bylaws, shall be made
promptly, and in any event within thirty days, upon the written request of such
person. If a determination by the Corporation that the Director or officer is
entitled to indemnification pursuant to this Article is required, and the
Corporation fails to respond within sixty days to a written request for
indemnity, the Corporation shall be deemed to have approved such request. If
the Corporation denies a written request for indemnity or advancement of
expenses, in whole or in part, or if payment in full pursuant to such request
is not made within thirty days, the right to indemnification or advances as
granted by this Article shall be enforceable by the Director or officer in any
court of competent jurisdiction. Such persons costs and expenses incurred in
connection with successfully establishing his or her right to indemnification,
in whole or in part, in any such action shall also be indemnified by the
Corporation. It shall be a defense to any such action (other than an action
brought to enforce a claim for the advance of costs, charges and expenses under
Section 6.4 of these Bylaws where the required undertaking, if any, has been
received by or tendered to the Corporation) that the claimant has not met the
standard of conduct set forth in
Section 6.1 of these Bylaws, but the burden of proving such defense shall be on
the Corporation. Neither the failure of the
18
Corporation (including its Board of Directors, its independent legal counsel,
and its stockholders) to have made a determination prior to the commencement of
such action that indemnification of the claimant is proper in the circumstances
because he or she has met the applicable standard of conduct set forth in
Section 6.1 of these Bylaws, nor the fact that there has been an actual
determination by the Corporation (including its Board of Directors, its
independent legal counsel, and its stockholders) that the claimant has not met
such applicable standard of conduct, shall be a defense to such action or
create a presumption that the claimant has not met the applicable standard of
conduct.
Section 6.6 Survival; Preservation of Other Rights. The foregoing
indemnification provisions shall be deemed to be a contract between the
Corporation and each Director or officer who serves in any such capacity at any
time while these provisions are in effect and any repeal or modification
thereof shall not affect any right or obligation then existing with respect to
any state of facts then or previously existing or any action, suit or
proceeding previously or thereafter brought or threatened based in whole or in
part upon any such state of facts. Such a contract right may not be modified
retroactively without the consent of such Director or officer.
The indemnification and the advancement and payment of expenses provided by
this Article VI shall not be deemed exclusive of any other rights to which
those indemnified may be entitled under any Bylaw, common or statutory law,
provision of the Certificate of Incorporation, agreement, vote of stockholders
or disinterested Directors or otherwise, both as to action in his or her
official capacity and as to action in another capacity while holding such
office, and shall continue as to a person who has ceased to be a Director or
officer and shall inure to the benefit of the heirs, executors and
administrators of such a person.
Section 6.7 Insurance. The Corporation shall purchase and maintain insurance,
at its expense, to protect the Corporation and any person who is or was or has
agreed to become a Director or officer, or is or was serving at the request of
the Corporation as a Director, officer, partner, venturer, proprietor, trustee,
employee, agent, or similar functionary of another foreign or domestic
corporation, limited liability company, partnership, joint venture, sole
proprietorship, trust, employee benefit plan, or other enterprise against any
expense, liability, or loss asserted against him or her or incurred by him or
her or on his or her behalf in any such capacity, or arising out of his or her
status as such, whether or not the Corporation would have the power to
indemnify him or her against such liability under the provisions of this
Article, provided that such insurance is available on acceptable terms, which
determination shall be made by a vote of a majority of the entire Board of
Directors.
Section 6.8 Severability. If this Article VI or any portion hereof shall be
invalidated on any ground by any court of competent jurisdiction, then the
Corporation shall nevertheless indemnify and hold harmless each Director or
officer or any other person indemnified pursuant to this Article VI as to
costs, charges and expenses (including reasonable attorneys fees), judgments,
fines and amounts paid in settlement with respect to any action, suit or
proceeding, whether civil, criminal, administrative or investigative to the
full extent permitted by any
19
applicable portion of this Article VI that shall not have been invalidated and
to the fullest extent permitted by applicable law.
Section 6.9 Limitation on Liability. No Director or officer shall be personally
liable, as such, for any action taken or omitted from being taken unless: (i)
such Director or officer breached or failed to perform the duties of his
office; and (ii) the breach or failure to perform constituted recklessness,
self-dealing or willful misconduct. The foregoing shall not apply to any
responsibility or liability under a criminal statute or liability for the
payment of taxes under Federal, state, or local law.
Section 6.10 Appearance as a Witness. Notwithstanding any other provision of
this Article VI, the Corporation shall pay or reimburse expenses incurred by a
Director or officer in connection with his appearance as a witness or other
participation in a Proceeding at a time when he is not a named defendant or
respondent in the Proceeding.
Section 6.11 Indemnification of Employees and Agents. The Corporation, by
adoption of a resolution of the Board of Directors, may indemnify and advance
expenses to an employee or agent of the Corporation to the same extent and
subject to the same conditions under which it may indemnify and advance
expenses to Directors and officers under this Article VI; and, the Corporation
may indemnify and advance expenses to persons who are not or were not
Directors, officers, employees or agents of the Corporation but who are or were
serving at the request of the Corporation as director, officer, partner,
venturer, proprietor, trustee, employee, agent or similar functionary of
another foreign or domestic corporation, limited liability company,
partnership, joint venture, sole proprietorship, trust, employee benefit plan
or other enterprise against any liability asserted against him or her and
incurred by him or her in such a capacity or arising out of his or her status
as such a person to the same extent that it may indemnify and advance expenses
to Directors and officers of the Corporation under this Article VI.
ARTICLE VII
OFFICES
Section 7.1 Registered Office and Agent. The registered agent and office of the
Corporation in the State of Delaware shall be the Corporation Trust Company,
located at 1209 Orange Street in the City of Wilmington, County of New Castle
(19801) or such other agent and office (which need not be a place of business
of the company) as the Board of Directors may designate from time to time in
the manner provided by law.
Section 7.2 Other Offices. The Corporation may maintain offices or places of
business at such other locations within or without the State of Delaware as the
Board of Directors may from time to time determine or as the business of the
Corporation may require.
20
ARTICLE VIII
GENERAL PROVISIONS
Section 8.1 Dividends. Subject to any applicable provisions of law and the
Certificate of Incorporation, dividends upon the shares of the Corporation may
be declared by the Board of Directors at any regular or special meeting of the
Board of Directors and any such dividend may be paid in cash, property, or
shares of the Corporations capital stock.
Section 8.2 Reserves. There may be set aside out of any funds of the
Corporation available for dividends such sum or sums as the Board of Directors
from time to time, in its absolute discretion, thinks proper as a reserve or
reserves to meet contingencies, or for equalizing dividends, or for repairing
or maintaining any property of the Corporation or for such other purpose as the
Board of Directors shall think conducive to the interest of the Corporation,
and the Board of Directors may similarly modify or abolish any such reserve.
Section 8.3 Execution of Instruments. The Chief Executive Officer, the
President, any Vice President, the Secretary or the Treasurer may enter into
any contract or execute and deliver any instrument in the name and on behalf of
the Corporation. The Board of Directors, the Chief Executive Officer or the
President may authorize any other officer or agent to enter into any contract
or execute and deliver any instrument in the name and on behalf of the
Corporation. Any such authorization may be general or limited to specific
contracts or instruments.
Section 8.4 Deposits. Any funds of the Corporation may be deposited from time
to time in such banks, trust companies or other depositories as may be
determined by the Board of Directors, the Chief Executive Officer or the
President, or by such officers or agents as may be authorized by the Board of
Directors, the Chief Executive Officer or the President to make such
determination.
Section 8.5 Checks. All checks or demands for money and notes of the
Corporation shall be signed by such officer or officers or such agent or agents
of the Corporation, and in such manner, as the Board of Directors or the Chief
Executive Officer or President from time to time may determine.
Section 8.6 Sale, Transfer, etc. of Securities. To the extent authorized by the
Board of Directors or by the Chief Executive Officer, the President, any Vice
President, the Secretary or the Treasurer or any other officers designated by
the Board of Directors, the Chief Executive Officer or the President may sell,
transfer, endorse, and assign any shares of stock, bonds or other securities
owned by or held in the name of the Corporation, and may make, execute and
deliver in the name of the Corporation, under its corporate seal, any
instruments that may be appropriate to effect any such sale, transfer,
endorsement or assignment.
Section 8.7 Voting as Stockholder. Unless otherwise determined by resolution of
the Board of Directors, the Chief Executive Officer or the President or any
Vice President shall have full power and authority on behalf of the Corporation
to attend any meeting of stockholders of
21
any corporation in which the Corporation may hold stock and to act, vote (or
execute proxies to vote) and exercise in person or by proxy all other rights,
powers and privileges incident to the ownership of such stock. Such officers
acting on behalf of the Corporation shall have full power and authority to
execute any instrument expressing consent to or dissent from any action of any
such corporation without a meeting. The Board of Directors may by resolution
from time to time confer such power and authority upon any other person or
persons.
Section 8.8 Fiscal Year. The fiscal year of the Corporation shall commence on
the first day of January of each year (except for the Corporations first
fiscal year which shall commence on the date of incorporation) and shall
terminate in each case on December 31.
Section 8.9 Seal. The seal of the Corporation shall be circular in
form, and shall contain the name of the Corporation, the year of its
incorporation and the words Corporate Seal and Delaware. The form of such seal
shall be subject to alteration by the Board of Directors. The seal may be used
by causing it or a facsimile thereof to be impressed, affixed or reproduced, or
may be used in any other lawful manner.
Section 8.10 Books and Records; Inspection. Except to the extent otherwise
required by law, the books and records of the Corporation shall be kept at such
place or places within or without the State of Delaware as may be determined
from time to time by the Board of Directors.
ARTICLE IX
AMENDMENT OF BYLAWS
Section 9.1 Amendment. Subject to any express provision in the Certificate of
Incorporation to the contrary, these Bylaws may be amended, altered or
repealed:
(a) by resolution adopted by a majority of the Board of Directors at any
special or regular meeting of the Board of Directors without the assent or vote
of the stockholders of the Corporation if, in the case of such special meeting
only, notice of such amendment, alteration or repeal is contained in the notice
or waiver of notice of such meeting; or
(b) at any regular or special meeting of the stockholders upon the affirmative
vote of not less than two-thirds (66-2/3% of the holders of the combined voting
power of the outstanding shares of the Corporation entitled to vote generally
in the election of Directors if, in the case of such special meeting only,
notice of such amendment, alteration or repeal is contained in the notice or
waiver of notice of such meeting.
ARTICLE X
CONSTRUCTION
Section 10.1 Construction. In the event of any conflict between the provisions
of these Bylaws as in effect from time to time and the provisions of the
Certificate of Incorporation of the
22
Corporation as in effect from time to time, the provisions of such Certificate
of Incorporation shall be controlling.
1
1
1
1
2
2
2
2
3
3
5
5
6
6
7
7
7
7
7
8
8
8
8
9
9
9
9
10
10
10
10
10
11
11
11
11
11
11
11
12
12
12
12
12
13
13
13
13
13
14
14
14
14
15
15
15
15
15
16
16
16
16
16
17
18
18
18
19
19
19
20
20
20
20
20
20
21
21
21
21
21
21
21
21
22
22
22
22
22
22
22
23
Exhibit 3.3
AMENDMENT No. 1 TO THE
AMENDED AND RESTATED BYLAWS OF
SELECT MEDICAL CORPORATION
This is an Amendment, dated September 17, 2001 (the Amendment) to the Amended and Restated Bylaws of SELECT MEDICAL CORPORATION, a Delaware corporation (the Company), which were adopted on March 23, 2001 (the Bylaws).
Background
The Board of Directors of the Company wishes to designate the Chairman of the Board of Directors as the Executive Chairman of the Company, and wishes to amend the Bylaws to allow for such designation.
Amendment
1. Section 4.1 of the Bylaws is hereby amended by inserting in the third line thereof the parenthetical (who may be designated as an Executive Chairman) immediately prior to the phrase, a Vice Chairman of the Board.
2. Section 4.6 of the Bylaws is hereby amended and restated in its entirety as follows:
Section 4.6. Chairman of the Board. The Chairman of the Board shall, if one is designated by the Board of Directors and if present, preside at all meetings of the stockholders and of the Board of Directors and exercise and perform such other powers and duties as may be from time to time assigned by the Board of Directors. In addition, if designated by the Board as Executive Chairman, the Chairman shall also assist the Directors and the senior officers of the Corporation in the formulation of the strategy and policies of the Corporation, shall be available to other officers for consultation and advice, and may execute documents on behalf of the Corporation, subject at all times to the authority of the Board of Directors.
3. Except as amended hereby, the Bylaws shall continue in effect in accordance with their terms.
Exhibit 3.4
AMENDMENT No. 2 TO THE
AMENDED AND RESTATED BYLAWS OF
SELECT MEDICAL CORPORATION
This is an Amendment, dated December 31, 2001 (the Amendment) to the Amended and Restated Bylaws of SELECT MEDICAL CORPORATION, a Delaware corporation (the Company), which were adopted on March 23, 2001 and were amended on September 17, 2001 (the Bylaws).
Background
The Board of Directors of the Company wishes to increase the authorized number of members of the Board of Directors, and wishes to amend the Bylaws to allow for such an increase.
Amendment
1. Section 2.2 of the Bylaws is hereby amended by replacing the phrase nine (9) in its entirety in the third line thereof with the phrase ten (10).
2. Except as amended hereby, the Bylaws shall continue in effect in accordance with their terms.
Exhibit 10.52
AMENDMENT NO. 4 TO
EMPLOYMENT AGREEMENT
This is an Amendment, dated September 17, 2001 (the Amendment) to the Employment Agreement made as of the 1st day of March, 2000 by and between SELECT MEDICAL CORPORATION, a Delaware corporation (the Employer), and ROCCO A. ORTENZIO, an individual (the Employee).
Background
A. The Employer and the Employee executed and delivered that certain Employment Agreement dated as of March 1, 2000, that certain Amendment No. 1 to Employment Agreement dated as of August 8, 2000, that certain Amendment No. 2 to Employment Agreement dated as of February 23, 2001, and that certain Amendment No. 3 to Employment Agreement dated as of April 24, 2001 (as amended, the Employment Agreement). The Employer and the Employee now desire to further amend the Employment Agreement as hereinafter provided.
B. Accordingly, and intended to be legally bound hereby, the Employer and the Employee agree as follows:
Agreement
1. Section 1.02 of the Employment Agreement is hereby amended and restated as follows:
1.02 Capacity. The Employee shall serve as Chairman of the Board of Directors of the Employer. The Employee shall also serve as Chief Executive Officer of the Employer until September 17, 2001. From and after September 17, 2001, the Employee shall serve as Executive Chairman of the Employer.
2. Except as amended hereby, the Employment Agreement shall continue in effect in accordance with its terms.
IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.
SELECT MEDICAL CORPORATION | ||
By: /s/ Michael E. Tarvin | ||
|
||
Michael E. Tarvin, | ||
Senior Vice President | ||
/s/ Rocco A. Ortenzio | ||
|
||
Rocco A. Ortenzio |
Exhibit 10.53
AMENDMENT NO. 3 TO
EMPLOYMENT AGREEMENT
This is an Amendment dated September 17, 2001 (the Amendment) to the Employment Agreement (as hereinafter defined) by and between SELECT MEDICAL CORPORATION, a Delaware corporation (the Employer), and ROBERT A. ORTENZIO, an individual (the Employee).
Background
A. The Employer and the Employee executed and delivered that certain Employment Agreement dated as of March 1, 2000, that certain Amendment No. 1 to Employment Agreement dated as of August 8, 2000, and that certain Amendment No. 2 to Employment Agreement dated as of February 23, 2001 (as amended, the Employment Agreement). The Employer and the Employee now desire to further amend the Employment Agreement as hereinafter provided.
B. Accordingly, and intended to be legally bound hereby, the Employer and the Employee agree as follows:
Agreement
1. Section 1.02 of the Employment Agreement is hereby amended and restated as follows:
1.02 Capacity. The Employee shall serve as President and Chief Operating Officer of the Employer until September 17, 2001. From and after September 17, 2001, the Employee shall serve as the Chief Executive Officer, President and Chief Operating Officer of the Employer.
2. Effective as of the first of the Companys payroll periods beginning after September 17, 2001, the Employees base salary under Section 3.01 of the Employment Agreement shall be increased to $800,000.
3. Except as amended hereby, the Employment Agreement shall continue in effect in accordance with its terms.
IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.
SELECT MEDICAL CORPORATION | ||||
By: | /s/ Michael E. Tarvin | |||
|
||||
Michael E. Tarvin, | ||||
Senior Vice President | ||||
/s/ Robert A. Ortenzio | ||||
|
||||
Robert A. Ortenzio |
Exhibit 10.54
Old Gettysburg Associates
4718 Old Gettysburg Road
Mechanicsburg, PA 17055
Fourth Addendum to Lease Agreement
THIS FOURTH AMENDMENT (this Fourth Amendment) is made as of the 1st day of September, 2001, by and between OLD GETTYSBURG ASSOCIATES, a Pennsylvania general partnership (Landlord), and SELECT MEDICAL CORPORATION, a Delaware corporation (Tenant).
BACKGROUND:
A. Landlord and Tenant are parties to that certain Office Lease Agreement dated June 15, 1999 (as amended by the First, Second and Third Addenda thereto, the Lease), pursuant to which Landlord leased to Tenant, and Tenant hired from Landlord, approximately 12,400 rentable square feet of space in the building located at 4718 Old Gettysburg Road, Mechanicsburg, Pennsylvania. All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Lease.
B. On August 31, 2001, Tenant desires to surrender possession of 175 square feet of space which is located on the 4th floor of the Premises, and Landlord desires to accept possession of such space. Therefore, Tenant and Landlord now desire to amend the Lease to reflect a reduction in the size of the Premises by 175 square feet.
NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and intending to be legally bound hereby, Landlord and Tenant agree as follows:
1. From and after September 1, 2001, the Premises will consist of 12,225 square feet of space rather than 12,400 square feet of space. Monthly rent will be $19,184.62 payable on September 1, 2001 and October 1, 2001. Monthly rent will be $18,372.37 (i.e., to provide a credit of $541.50 for over-payments during September and October 2001) payable on November 1, 2001. Monthly rent will be $18,913.87 payable on December 1, 2001 and thereafter until it is increased as provided in the Lease.
2. All other terms and conditions contained in the Lease not amended hereby remain in full force and effect.
IN WITNESS WHEREOF, Landlord and Tenant have caused this Fourth Amendment to be duly executed as of the day and year first above written.
Landlord:
OLD GETTYSBURG ASSOCIATES
a Pennsylvania general partnership
By: /s/ Michael E. Salerno | ||
|
||
Michael E. Salerno | ||
Agent for Owner |
Tenant:
SELECT MEDICAL CORPORATION,
a Delaware corporation
By: /s/ Michael E. Tarvin | ||
|
||
Michael E. Tarvin, | ||
Senior Vice President |
Exhibit 10.56
SELECT MEDICAL CORPORATION
4716 Old Gettysburg Road P.O. Box 2034
Mechanicsburg, Pennsylvania 17055
March 1, 2000
Mr. Scott A. Romberger
Select Medical Corporation
4716 Old Gettysburg Road
P.O. Box 2034
Mechanicsburg, PA 17055
Re: Agreement in the Event of a Change of Control of SMC
Dear Mr. Romberger:
The following will confirm the agreement of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.
In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this letter (this Letter Agreement), the Company and you hereby agree, intending to be legally bound hereby, as follows:
1. Covered Termination. A Covered Termination shall be deemed to occur if your employment with the Company terminates under any one of the following circumstances: (i) within the two-year period immediately following a Change of Control (as defined below), your employment with the Company (a) is terminated by the Company without Cause (as defined below), (ii) within the six-month period immediately following a Change of Control, you terminate your employment with the Company for Good Reason (as defined below), or (iii) within the six-month period preceding a Change of Control, your employment is terminated by the Company other than for Cause, and you reasonably demonstrate that such termination of employment was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control.
2. Payments Upon a Covered Termination. If a Covered Termination occurs, then (i) the Company agrees that such termination is not a voluntary termination or a termination for cause as contemplated by any of the Companys stock option or other incentive plans and any stock option or other award agreements entered into between you and the Company (including agreements that may be entered into in the future in connection with additional awards granted pursuant to any Company plan, the Award Agreements) and the Company agrees that all unvested, unexercised stock options held by you which were granted to you by the Company shall become fully vested and exercisable as of the date of the Covered Termination and you will have the right to exercise, at any time prior to the earlier of three months after the date of termination or the expiration date of such option, all such options to purchase the Companys stock notwithstanding any contrary vesting
schedule that may be contained in the applicable plan or Award Agreement, and
(ii) the Company will, on or before your last day as an employee of the Company, pay to you, in lieu of any other rights to cash compensation other than the payment of your salary for services performed before the date of termination and as a severance benefit, a lump sum cash payment equal to your total base salary plus bonus compensation from the Company for the preceding three years (or, if you shall have been employed for less than three years, an amount equal to three times your average total annual cash compensation for base salary and bonus for your years of service to the Company).
3. Definitions. | |
(a) Change of Control. |
(i) Prior to a Public Offering(as defined below), a Change of Control shall be deemed to have occurred, subject to Section 3(a)(iii) below, upon (i) any sale, lease, exchange or other transfer of all or substantially all of the property and assets of the Company (on a consolidated basis) to an entity, other than an entity at least 75% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale or other transfer, (ii) any merger or consolidation to which the Company is a party and as a result of which the holders of the voting securities of the Company immediately prior thereto own less than a majority of the outstanding voting securities of the surviving entity immediately following such transaction, or (iii) any persons (excluding WCAS, GTCR and Thoma Cressey Partners, the financial sponsors of the Company as of the date hereof), including a groups, becoming the beneficial owner of securities representing more than 50% of the voting securities of the Company then outstanding.
(ii) Following a Public Offering, a Change of Control shall be deemed to have occurred if, subject to Section 3(a)(iii) below, (i) any person including a group, but excluding any stockholder of the Company who immediately prior to the Public Offering beneficially owned 12% or more of the Companys outstanding shares, becomes the beneficial owner of shares of the Company having more than 50% of the total number of votes that may be cast for the election of directors of the Company, (ii) any person including a group, other than you or any group of which you are a party, increases its beneficial ownership of shares of the Company beyond such persons ownership immediately after the Public Offering by a number of shares equal to or greater than 33% of the total number of votes that may be cast for the election of directors; (iii) the individuals who serve on the Board of Directors of the Company as of the effective date hereof (the Incumbent Directors) cease for any reason to constitute at least a majority of the Board of Directors of the Company; provided, however, any person who becomes a director subsequent to the effective date hereof, whose election or nomination for election was approved by a vote of at least a majority of the directors then constituting the Incumbent Directors, shall for purposes of this clause (iii) be considered an Incumbent Director; (iv) the consummation of a merger or consolidation of the Company in which the stockholders of the Company immediately prior to such merger or consolidation, would not, immediately after the merger or consolidation, beneficially own, directly or indirectly, shares representing in the aggregate more than 50% of the combined voting power of the
-2-
voting securities of the corporation issuing cash or securities in the merger or consolidation (or of its ultimate parent corporation, if any); or (v) there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Companys assets (on a consolidated basis), other than a sale or disposition by the Company of all or substantially all of the Companys assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale.
(iii) Notwithstanding the foregoing, in no event shall a Change of Control be deemed to occur for purposes of this Letter Agreement, whether prior to or following a Public Offering, unless the total consideration for the transaction or transactions which would, absent this clause (iii), constitute a Change of Control, has a value that is equal to or greater than $3.75 per share of common stock of the Company (the Minimum Value); provided that such Minimum Value shall be adjusted to reflect changes to such common stock in the event of a stock dividend, stock split, reverse stock split, stock combination, reclassification, recapitalization, or other similar change in the structure or capitalization of the Company, or any other event which in the discretion of the Board of Directors of the Company necessitates such an adjustment.
(iv) For purposes of this Section 3(a), (A) the terms person, group, beneficial owner, and beneficially own have the same meanings as such terms under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, (B) the term Public Offering shall mean the consummation of the first public offering of shares of common stock of the Company in a firm commitment underwritten offering registered under the Securities Act of 1933, as amended, on Form S-1 or its successor forms, and (C) the term voting securities shall mean securities, the holders of which are ordinarily, in the absence of contingencies, entitled to elect the corporate directors (or persons performing similar functions).
(b) Cause. For purposes of this Letter Agreement, Cause shall mean
(i) your willful and continued failure to substantially perform your duties hereunder (other than any such failure resulting from incapacity due to physical or mental illness); (ii) your engaging in willful or reckless misconduct which is demonstrably and materially injurious to the Company, monetarily or otherwise; or (iii) your conviction of a felony involving moral turpitude; provided that an act, or failure to act, on your part shall be considered willful or reckless only if done, or omitted to be done, by you not in good faith and without a reasonable belief that his action or omission was in the best interest of the Company. Your employment shall not be deemed to have been terminated for Cause unless the Company shall have given or delivered to you (i) reasonable notice setting forth the reasons for the Companys intention to terminate your employment for Cause; (ii) an opportunity to cure any such breach during the 30-day period after your receipt of such notice; (iii) a reasonable opportunity, at any time during the 30-day period after your receipt of such notice, together with your counsel, to be heard before the Board of Directors; and (iv) a notice of termination stating that, in the good faith opinion of not less than a majority of the entire membership of the Board of Directors of the Company, you are guilty of the conduct set forth in any of clauses (i), (ii) or (iii) of the definition of Cause above.
(c) Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, (x) you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control, (y) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (z) you are required to be based anywhere other than the Companys principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania (except for required travel on the Companys business to an extent substantially consistent with your business travel obligations prior to the Change of Control).
-3-
4. Additional Payments.
(a) If all, or any portion, of the payments or other benefits provided under any section of this Agreement, either alone or together with other payments and benefits that you receive or are entitled to receive from the Company or its affiliates, (whether or not under an existing plan, arrangement or other agreement) (collectively the Payments) would constitute an excess parachute payment within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the Code) and would result in the imposition on you of an excise tax under Section 4999 of the Code, (such excise tax, together with any interest and penalties related thereto, are hereinafter collectively referred to as the Excise Tax) then, in addition to any other benefits to which you are entitled under this Agreement, you will be entitled to receive an additional payment (a Gross-Up Payment) in cash, in an amount such that after you pay all taxes including, without limitation, (i) any income taxes (and any interest and penalties imposed with respect thereto) and (ii) any Excise Tax, imposed upon the Gross-Up Payment, you will retain an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Unless you and the Company otherwise agree in writing, any determination required under this Section 4, including without limitation, the amount of payments under this Article 6 (the Parachute Gross-up) shall be computed and made in writing by the Employers then independent public accountants (the Accountants), whose determination shall be, subject to the Employees reasonable approval of the calculations required under this Article 6, conclusive and binding upon the Employee and the Employer for all purposes. For purposes of making the calculations required by this Section 4, the Accountants may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999 of the Code. You and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 4.
(b) As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accountants hereunder, it is possible that (i) Gross-Up Payments which will not have been made by the Company should have been made (an Underpayment), consistent with the calculations required to be made hereunder or that (ii) Gross-Up Payments that have been made will be determined to have been in excess of the Gross-Up Payments actually required (an Overpayment). In the event that you are required to make a payment of any Excise Tax, the Accountants shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for your benefit. In the event that it is finally determined that an Overpayment has occurred, you will promptly, and in any event within 30 days of such determination, refund the amount of the Overpayment, plus any interest actually paid to you with respect to the Overpayment, to the Company. The Company shall have the right with respect to the determination of either an Underpayment or an Overpayment to you to appeal the assertion of any Underpayment or to claim, and sue for, a refund of any Excise Tax paid by you upon any Payment or Gross-Up Payment, provided that the Company shall promptly reimburse you for all expenses, including counsel and accounting fees, incurred in connection with any such proceeding. Alternatively, the Company may undertake any such proceeding, and you shall cooperate with the Company in any such proceeding.
-4-
5. Miscellaneous.
(a) The Company will require any purchaser of all or substantially all of the assets of the Company, by agreement in form and substance reasonably satisfactory to you, to expressly assume and agree to perform this Letter Agreement in the same manner and to the same extent that the Company would be required to perform it if no such purchase had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Letter Agreement and shall entitle you to compensation from the Company in the same amount and on the same terms as you would be entitled hereunder if a Covered Termination had occurred. As used in this Letter Agreement, Company shall mean the Company as hereinbefore defined and any purchaser of its assets as aforesaid which executed and delivers the agreement provided for herein.
(b) This Letter Agreement shall remain in effect for so long as you are employed by the Company. This Letter Agreement may not be modified or waived except in writing and agreed to by the Company and you. This Letter Agreement shall be governed by the laws of the Commonwealth of Pennsylvania and shall inure to the benefit of your heirs.
(c) The Company represents that this Letter Agreement has been duly authorized and is binding on and enforceable against the Company. The invalidity or unenforceability of any provision of this Letter Agreement shall not affect the validity or enforceability of any other provision, which shall remain in full force and effect.
(d) Upon payment of the amount required under paragraph 1 hereof, you shall deliver to the Company a general release of liability of the Company and its officers and directors in a form reasonably satisfactory to the Company.
(e) All payments made pursuant to this Letter Agreement shall be subject to withholding of applicable deductions and income and employment taxes.
(f) Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by facsimile transmission or sent by certified, registered or express mail, postage prepaid. Any such notice shall be deemed given when so delivered personally or sent by facsimile transmission or, if mailed, five days after the date of deposit in the United States mails to the following addresses:
If to Employee:
Scott A. Romberger
440 Boyer Street
Halifax, PA 17032
If to the Company:
Select Medical Corporation
4716 Old Gettysburg Road
Mechanicsburg, PA 17055
Attention: General Counsel
-5-
6. Entire Agreement. This writing represents the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, written or oral, with respect thereto. This Agreement may not be altered or amended except by an agreement in writing.
Please indicate your acceptance of the above agreement by signing below in the space indicated.
Very truly yours, | ||||
SELECT MEDICAL CORPORATION, a Delaware
corporation |
||||
By: /s/ Robert A. Ortenzio, | ||||
|
||||
Robert A. Ortenzio, | ||||
President |
Agreed to and accepted: |
/s/ Scott A. Romberger
Scott A. Romberger |
-6-
Exhibit 10.57
SELECT MEDICAL CORPORATION
P.O. Box 2034, 4716 Old Gettysburg Road
Mechanicsburg, Pennsylvania 17055
February 23, 2001
Mr. Scott A. Romberger
Select Medical Corporation
P.O. Box 2034
4716 Old Gettysburg Road
Mechanicsburg, PA 17055
Re: Amendment to Agreement in the Event of a Change of Control of SMC
Dear Mr. Romberger:
The following will confirm our desire to amend the Letter Agreement dated as of March 1, 2000 (the Letter Agreement) of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.
In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this Amendment to the Letter Agreement (the Amendment), the Company and you hereby agree, intending to be legally bound hereby, as follows:
1. The portion of Section 1 of the Letter Agreement which appears before clause (ii) is hereby amended and restated as follows:
A Covered Termination shall be deemed to occur if (i) within the five-year period immediately following a Change of Control (as defined below), (a) your employment with the Company is terminated by the Company without Cause (as defined below), (b) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (c) you are required to be based anywhere other than the Companys principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania (except for required travel on the Companys business to an extent substantially consistent with your business travel obligations prior to the Change of Control), | |
2. Section 3(c) of the Letter Agreement is hereby amended and restated as follows: |
(c) Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control. | |
3. The Letter Agreement is hereby amended by the addition of the following |
Section 7 in its entirety, to be inserted immediately after Section 6 in its entirety:
7. Claims Procedure. Any claim for benefits under this Letter Agreement by you shall be made in writing and sent to the Company at its principal offices in Mechanicsburg, Pennsylvania, or such other place as the Company shall hereafter designate in writing. If you, or any beneficiary following your death (collectively, the Claimant), believes he or she has been denied any benefits or payments under this Letter Agreement, either in total or in an amount less than the full benefit or payment to which the Claimant would normally be entitled, the Company shall advise the Claimant in writing of the amount of the benefit, or payment, if any, and the specific reasons for the denial within thirty (30) days of the receipt of the Claimants claim. The Company shall also furnish the Claimant at that time with a written notice containing:
(A) A specific reference to pertinent provisions of this Letter Agreement; | |
(B) A description of any additional material or information necessary for the Claimant to perfect the claim if possible, and an explanation of why such material or information is needed; and | |
(C) An explanation of the claim review procedure set forth in this Section 7. |
Within sixty (60) days of receipt of the information described above, the Claimant shall, if further review is desired, file a written request of reconsideration of the Companys decision with the Appeal Committee. The Appeal Committee shall consist of those individuals who were serving as the Compensation Committee of the Board of Directors of the Company immediately prior to the Change of Control. The Appeal Committee shall select from its membership a chairperson and a secretary and may adopt such rules and procedures as it deems necessary to carry out its functions. In the event any individual is unable to serve on the Appeal Committee, then the chairperson of the Appeal Committee shall appoint a successor provided such successor must have been a member of the Board of Directors of the Company prior to the Change of Control (Prior Board Member). So long as the Claimants request for review is pending with the Appeal Committee (including such 60-day period), the Claimant, or his duly authorized representative, may review pertinent documents and may submit issues and comments in writing to the Appeal Committee. A final and binding decision shall be made by the Appeal Committee within thirty (30) days of the filing by the Claimant of the request for reconsideration. The Appeal Committees decision shall be conveyed to the Claimant in writing and shall include specific reasons for the decision and specific references to the pertinent provisions of this Letter
-2-
Agreement on which the decision is based. The Appeal Committee shall discharge its duties under this claims procedure in accordance with the fiduciary standards of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and in doing so, to the extent permitted by law, shall be indemnified and held harmless by the Company (to the extent not indemnified or saved harmless under any liability insurance or other indemnification arrangement with the Company) for or against all liability to which the Appeal Committee may be subjected by reason of any act done in good faith with respect to the adjudication of any claim under this Letter Agreement, including reasonable expenses. Notwithstanding anything to the contrary herein contained, the Claimant shall be entitled to submit his or her claim for determination to any court having competent jurisdiction regardless of whether he or she has first exercised his or her right to have the Companys decision reconsidered by the Appeal Committee.
4. Except as amended hereby, the Letter Agreement shall continue in effect in accordance with its terms.
Please indicate your acceptance of the above Amendment by signing below in the space indicated.
Very truly yours, | ||
SELECT MEDICAL CORPORATION, a Delaware
Corporation |
||
By: | /s/ Robert A. Ortenzio, | |
|
||
Robert A. Ortenzio, | ||
President |
Agreed to and accepted: |
/s/ Scott A. Romberger
Scott A. Romberger |
-3-
Exhibit 10.58
SELECT MEDICAL CORPORATION
4716 Old Gettysburg Road P.O. Box 2034
Mechanicsburg, Pennsylvania 17055
March 1, 2000
Mr. James J. Talalai
Select Medical Corporation
4716 Old Gettysburg Road
P.O. Box 2034
Mechanicsburg, PA 17055
Re: Agreement in the Event of a Change of Control of SMC
Dear Mr. Talalai:
The following will confirm the agreement of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.
In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this letter (this Letter Agreement), the Company and you hereby agree, intending to be legally bound hereby, as follows:
1. Covered Termination. A Covered Termination shall be deemed to occur if your employment with the Company terminates under any one of the following circumstances: (i) within the two-year period immediately following a Change of Control (as defined below), your employment with the Company (a) is terminated by the Company without Cause (as defined below), (ii) within the six-month period immediately following a Change of Control, you terminate your employment with the Company for Good Reason (as defined below), or (iii) within the six-month period preceding a Change of Control, your employment is terminated by the Company other than for Cause, and you reasonably demonstrate that such termination of employment was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control.
2. Payments Upon a Covered Termination. If a Covered Termination occurs,
then (i) the Company agrees that such termination is not a voluntary
termination or a termination for cause as contemplated by any of the Companys
stock option or other incentive plans and any stock option or other award
agreements entered into between you and the Company (including agreements that
may be entered into in the future in connection with additional awards granted
pursuant to any Company plan, the Award Agreements) and the Company agrees that
all unvested, unexercised stock options held by you which were granted to you
by the Company shall become fully vested and exercisable as of the date of the
Covered Termination and you will have the right to exercise, at any time prior
to the earlier of three months after the date of termination or the expiration
date of such option, all such options to purchase the Companys stock
notwithstanding any contrary vesting
schedule that may be contained in the applicable plan or Award Agreement, and (ii) the Company will, on or before your last day as an employee of the Company, pay to you, in lieu of any other rights to cash compensation other than the payment of your salary for services performed before the date of termination and as a severance benefit, a lump sum cash payment equal to your total base salary plus bonus compensation from the Company for the preceding three years (or, if you shall have been employed for less than three years, an amount equal to three times your average total annual cash compensation for base salary and bonus for your years of service to the Company).
3. Definitions.
(a) Change of Control.
(i) Prior to a Public Offering(as defined below), a Change of Control shall be deemed to have occurred, subject to Section 3(a)(iii) below, upon (i) any sale, lease, exchange or other transfer of all or substantially all of the property and assets of the Company (on a consolidated basis) to an entity, other than an entity at least 75% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale or other transfer, (ii) any merger or consolidation to which the Company is a party and as a result of which the holders of the voting securities of the Company immediately prior thereto own less than a majority of the outstanding voting securities of the surviving entity immediately following such transaction, or (iii) any persons (excluding WCAS, GTCR and Thoma Cressey Partners, the financial sponsors of the Company as of the date hereof), including a groups, becoming the beneficial owner of securities representing more than 50% of the voting securities of the Company then outstanding.
(ii) Following a Public Offering, a Change of Control shall be deemed to
have occurred if, subject to Section 3(a)(iii) below, (i) any person including
a group, but excluding any stockholder of the Company who immediately prior to
the Public Offering beneficially owned 12% or more of the Companys outstanding
shares, becomes the beneficial owner of shares of the Company having more than
50% of the total number of votes that may be cast for the election of directors
of the Company, (ii) any person including a group, other than you or any group
of which you are a party, increases its beneficial ownership of shares of the
Company beyond such persons ownership immediately after the Public Offering by
a number of shares equal to or greater than 33% of the total number of votes
that may be cast for the election of directors; (iii) the individuals who serve
on the Board of Directors of the Company as of the effective date hereof (the
Incumbent Directors) cease for any reason to constitute at least a majority of
the Board of Directors of the Company; provided, however, any person who
becomes a director subsequent to the effective date hereof, whose election or
nomination for election was approved by a vote of at least a majority of the
directors then constituting the Incumbent Directors, shall for purposes of this
clause (iii) be considered an Incumbent Director; (iv) the consummation of a
merger or consolidation of the Company in which the stockholders of the Company
immediately prior to such merger or consolidation, would not, immediately after
the merger or consolidation, beneficially own, directly or indirectly, shares
representing in the aggregate more than 50% of the combined voting power of the
-2-
voting securities of the corporation issuing cash or securities in the merger or consolidation (or of its ultimate parent corporation, if any); or (v) there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Companys assets (on a consolidated basis), other than a sale or disposition by the Company of all or substantially all of the Companys assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale.
(iii) Notwithstanding the foregoing, in no event shall a Change of Control be deemed to occur for purposes of this Letter Agreement, whether prior to or following a Public Offering, unless the total consideration for the transaction or transactions which would, absent this clause (iii), constitute a Change of Control, has a value that is equal to or greater than $3.75 per share of common stock of the Company (the Minimum Value); provided that such Minimum Value shall be adjusted to reflect changes to such common stock in the event of a stock dividend, stock split, reverse stock split, stock combination, reclassification, recapitalization, or other similar change in the structure or capitalization of the Company, or any other event which in the discretion of the Board of Directors of the Company necessitates such an adjustment.
(iv) For purposes of this Section 3(a), (A) the terms person, group, beneficial owner, and beneficially own have the same meanings as such terms under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, (B) the term Public Offering shall mean the consummation of the first public offering of shares of common stock of the Company in a firm commitment underwritten offering registered under the Securities Act of 1933, as amended, on Form S-1 or its successor forms, and (C) the term voting securities shall mean securities, the holders of which are ordinarily, in the absence of contingencies, entitled to elect the corporate directors (or persons performing similar functions).
(b) Cause. For purposes of this Letter Agreement, Cause shall mean (i) your willful and continued failure to substantially perform your duties hereunder (other than any such failure resulting from incapacity due to physical or mental illness); (ii) your engaging in willful or reckless misconduct which is demonstrably and materially injurious to the Company, monetarily or otherwise; or (iii) your conviction of a felony involving moral turpitude; provided that an act, or failure to act, on your part shall be considered willful or reckless only if done, or omitted to be done, by you not in good faith and without a reasonable belief that his action or omission was in the best interest of the Company. Your employment shall not be deemed to have been terminated for Cause unless the Company shall have given or delivered to you (i) reasonable notice setting forth the reasons for the Companys intention to terminate your employment for Cause; (ii) an opportunity to cure any such breach during the 30-day period after your receipt of such notice; (iii) a reasonable opportunity, at any time during the 30-day period after your receipt of such notice, together with your counsel, to be heard before the Board of Directors; and (iv) a notice of termination stating that, in the good faith opinion of not less than a majority of the entire membership of the Board of Directors of the Company, you are guilty of the conduct set forth in any of clauses (i), (ii) or (iii) of the definition of Cause above.
(c) Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, (x) you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control, (y) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (z) you are required to be based anywhere other than the Companys principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania (except for required travel on the Companys business to an extent substantially consistent with your business travel obligations prior to the Change of Control).
-3-
4. Additional Payments.
(a) If all, or any portion, of the payments or other benefits provided under any section of this Agreement, either alone or together with other payments and benefits that you receive or are entitled to receive from the Company or its affiliates, (whether or not under an existing plan, arrangement or other agreement) (collectively the Payments) would constitute an excess parachute payment within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the Code) and would result in the imposition on you of an excise tax under Section 4999 of the Code, (such excise tax, together with any interest and penalties related thereto, are hereinafter collectively referred to as the Excise Tax) then, in addition to any other benefits to which you are entitled under this Agreement, you will be entitled to receive an additional payment (a Gross-Up Payment) in cash, in an amount such that after you pay all taxes including, without limitation, (i) any income taxes (and any interest and penalties imposed with respect thereto) and (ii) any Excise Tax, imposed upon the Gross-Up Payment, you will retain an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Unless you and the Company otherwise agree in writing, any determination required under this Section 4, including without limitation, the amount of payments under this Article 6 (the Parachute Gross-up) shall be computed and made in writing by the Employers then independent public accountants (the Accountants), whose determination shall be, subject to the Employees reasonable approval of the calculations required under this Article 6, conclusive and binding upon the Employee and the Employer for all purposes. For purposes of making the calculations required by this Section 4, the Accountants may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999 of the Code. You and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 4.
(b) As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accountants hereunder, it is possible that (i) Gross-Up Payments which will not have been made by the Company should have been made (an Underpayment), consistent with the calculations required to be made hereunder or that (ii) Gross-Up Payments that have been made will be determined to have been in excess of the Gross-Up Payments actually required (an Overpayment). In the event that you are required to make a payment of any Excise Tax, the Accountants shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for your benefit. In the event that it is finally determined that an Overpayment has occurred, you will promptly, and in any event within 30 days of such determination, refund the amount of the Overpayment, plus any interest actually paid to you with respect to the Overpayment, to the Company. The Company shall have the right with respect to the determination of either an Underpayment or an Overpayment to you to appeal the assertion of any Underpayment or to claim, and sue for, a refund of any Excise Tax paid by you upon any Payment or Gross-Up Payment, provided that the Company shall promptly reimburse you for all expenses, including counsel and accounting fees, incurred in connection with any such proceeding. Alternatively, the Company may undertake any such proceeding, and you shall cooperate with the Company in any such proceeding.
-4-
5. Miscellaneous.
(a) The Company will require any purchaser of all or substantially all of the assets of the Company, by agreement in form and substance reasonably satisfactory to you, to expressly assume and agree to perform this Letter Agreement in the same manner and to the same extent that the Company would be required to perform it if no such purchase had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Letter Agreement and shall entitle you to compensation from the Company in the same amount and on the same terms as you would be entitled hereunder if a Covered Termination had occurred. As used in this Letter Agreement, Company shall mean the Company as hereinbefore defined and any purchaser of its assets as aforesaid which executed and delivers the agreement provided for herein.
(b) This Letter Agreement shall remain in effect for so long as you are employed by the Company. This Letter Agreement may not be modified or waived except in writing and agreed to by the Company and you. This Letter Agreement shall be governed by the laws of the Commonwealth of Pennsylvania and shall inure to the benefit of your heirs.
(c) The Company represents that this Letter Agreement has been duly authorized and is binding on and enforceable against the Company. The invalidity or unenforceability of any provision of this Letter Agreement shall not affect the validity or enforceability of any other provision, which shall remain in full force and effect.
(d) Upon payment of the amount required under paragraph 1 hereof, you shall deliver to the Company a general release of liability of the Company and its officers and directors in a form reasonably satisfactory to the Company.
(e) All payments made pursuant to this Letter Agreement shall be subject to withholding of applicable deductions and income and employment taxes.
(f) Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by facsimile transmission or sent by certified, registered or express mail, postage prepaid. Any such notice shall be deemed given when so delivered personally or sent by facsimile transmission or, if mailed, five days after the date of deposit in the United States mails to the following addresses:
If to Employee:
James J. Talalai
5224 Meadowbrook Drive
Mechanicsburg, PA 17055
If to the Company:
Select Medical Corporation
4716 Old Gettysburg Road
Mechanicsburg, PA 17055
Attention: General Counsel
-5-
6. Entire Agreement. This writing represents the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, written or oral, with respect thereto. This Agreement may not be altered or amended except by an agreement in writing.
Please indicate your acceptance of the above agreement by signing below in the space indicated.
Very truly yours, |
SELECT MEDICAL CORPORATION, a Delaware
corporation |
||||
By: |
/s/ Robert A. Ortenzio,
Robert A. Ortenzio, President |
Agreed to and accepted:
/s/ James J. Talalai
| |
James J. Talalai |
-6-
Exhibit 10.59
SELECT MEDICAL CORPORATION
P.O. Box 2034, 4716 Old Gettysburg Road
Mechanicsburg, Pennsylvania 17055
February 23, 2001
Mr. James J. Talalai
Select Medical Corporation
P.O. Box 2034
4716 Old Gettysburg Road
Mechanicsburg, PA 17055
Re: Amendment to Agreement in the Event of a Change of Control of SMC
Dear Mr. Talalai:
The following will confirm our desire to amend the Letter Agreement dated as of March 1, 2000 (the Letter Agreement) of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.
In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this Amendment to the Letter Agreement (the Amendment), the Company and you hereby agree, intending to be legally bound hereby, as follows:
1. The portion of Section 1 of the Letter Agreement which appears before clause (ii) is hereby amended and restated as follows:
A Covered Termination shall be deemed to occur if (i) within the five-year period immediately following a Change of Control (as defined below), (a) your employment with the Company is terminated by the Company without Cause (as defined below), (b) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (c) you are required to be based anywhere other than the Companys principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania (except for required travel on the Companys business to an extent substantially consistent with your business travel obligations prior to the Change of Control), |
2. Section 3(c) of the Letter Agreement is hereby amended and restated as
follows:
(c) Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control.
3. The Letter Agreement is hereby amended by the addition of the following Section 7 in its entirety, to be inserted immediately after Section 6 in its entirety:
7. Claims Procedure. Any claim for benefits under this Letter Agreement by you shall be made in writing and sent to the Company at its principal offices in Mechanicsburg, Pennsylvania, or such other place as the Company shall hereafter designate in writing. If you, or any beneficiary following your death (collectively, the Claimant), believes he or she has been denied any benefits or payments under this Letter Agreement, either in total or in an amount less than the full benefit or payment to which the Claimant would normally be entitled, the Company shall advise the Claimant in writing of the amount of the benefit, or payment, if any, and the specific reasons for the denial within thirty (30) days of the receipt of the Claimants claim. The Company shall also furnish the Claimant at that time with a written notice containing:
(A) A specific reference to pertinent provisions of this Letter Agreement;
(B) A description of any additional material or information necessary for the Claimant to perfect the claim if possible, and an explanation of why such material or information is needed; and
(C) An explanation of the claim review procedure set forth in this Section 7.
Within sixty (60) days of receipt of the information described above, the Claimant shall, if further review is desired, file a written request of reconsideration of the Companys decision with the Appeal Committee. The Appeal Committee shall consist of those individuals who were serving as the Compensation Committee of the Board of Directors of the Company immediately prior to the Change of Control. The Appeal Committee shall select from its membership a chairperson and a secretary and may adopt such rules and procedures as it deems necessary to carry out its functions. In the event any individual is unable to serve on the Appeal Committee, then the chairperson of the Appeal Committee shall appoint a successor provided such successor must have been a member of the Board of Directors of the Company prior to the Change of Control (Prior Board Member). So long as the Claimants request for review is pending with the Appeal Committee (including such 60-day period), the Claimant, or his duly authorized representative, may review pertinent documents and may submit issues and comments in writing to the Appeal Committee. A final and binding decision shall be made by the Appeal Committee within thirty (30) days of the filing by the Claimant of the request for reconsideration. The Appeal Committees decision shall be conveyed to the Claimant in writing and shall include specific reasons for the decision and specific references to the pertinent provisions of this Letter
-2-
Agreement on which the decision is based. The Appeal Committee shall discharge its duties under this claims procedure in accordance with the fiduciary standards of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and in doing so, to the extent permitted by law, shall be indemnified and held harmless by the Company (to the extent not indemnified or saved harmless under any liability insurance or other indemnification arrangement with the Company) for or against all liability to which the Appeal Committee may be subjected by reason of any act done in good faith with respect to the adjudication of any claim under this Letter Agreement, including reasonable expenses. Notwithstanding anything to the contrary herein contained, the Claimant shall be entitled to submit his or her claim for determination to any court having competent jurisdiction regardless of whether he or she has first exercised his or her right to have the Companys decision reconsidered by the Appeal Committee.
4. Except as amended hereby, the Letter Agreement shall continue in effect in accordance with its terms.
Please indicate your acceptance of the above Amendment by signing below in the space indicated.
Very truly yours, |
SELECT MEDICAL CORPORATION, a Delaware
Corporation |
||||
By: |
/s/ Robert A. Ortenzio,
Robert A. Ortenzio, President |
Agreed to and accepted:
/s/ James J. Talalai
| |
James J. Talalai |
Exhibit 10.60
CONFORMED COPY
FOURTH AMENDMENT dated as of October 5, 2001 (this Amendment) to the Credit Agreement dated as of September 22, 2000 (the Credit Agreement) as heretofore amended, among Select Medical Corporation, a Delaware corporation (the Company), Canadian Back Institute Limited, an Ontario corporation and a wholly owned subsidiary of the Company (CBIL and, together with the Company, the Borrowers), the Lenders party thereto, The Chase Manhattan Bank, as US Agent and US Collateral Agent, The Chase Manhattan Bank of Canada, as Canadian Agent and Canadian Collateral Agent, Banc of America Securities, LLC, as Syndication Agent, and CIBC, Inc., as Documentation Agent. |
WHEREAS, the Borrowers have requested that the Lenders (such term and each other capitalized term used but not otherwise defined herein having the meaning assigned to it in the Credit Agreement) approve amendments to certain provisions of the Credit Agreement;
WHEREAS, the undersigned Lenders are willing, on the terms and subject to the conditions set forth herein, to approve such amendments to the Credit Agreement;
NOW, THEREFORE, in consideration of these premises, the Borrowers and the undersigned Lenders hereby agree as follows:
SECTION 1. Amendments. Effective as of the Amendment Effective Date (as defined in Section 4 hereof):
(a) Paragraph (g) of Section 6.04 of the Credit Agreement is hereby amended by inserting at the end thereof, immediately prior to the semicolon, the words and Investments in connection with the repurchase of common stock of the Company permitted under subsection 6.11(g).
(b) Section 6.11 of the Credit Agreement is hereby amended by deleting the word and at the end of paragraph (e), replacing the period at the end of paragraph (f) with ; and and adding a new paragraph (g) as follows:
"(g) so long as no Default shall have occurred and be continuing or would result therefrom, purchase, redeem or otherwise acquire shares of its common stock in an aggregate amount not to exceed US$10,000,000 for all such purchases, redemptions or other acquisitions. |
2
SECTION 2. Representations and Warranties. Each of the Borrowers represents and warrants to each of the Lenders that, after giving effect to the amendments contemplated hereby, (a) the representations and warranties of such Borrower set forth in the Credit Agreement are true and correct in all material respects on and as of the date of this Amendment, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties shall be true and correct in all material respects as of the earlier date) and (b) no Default has occurred and is continuing.
SECTION 3. Effectiveness. This Amendment shall become effective as of the date (the Amendment Effective Date) when the Administrative Agent (or its counsel) shall have received copies hereof that, when taken together, bear the signatures of the Borrowers and the Required Lenders.
SECTION 4. Applicable Law. THIS AMENDMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.
SECTION 5. No Other Amendments. Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of, or otherwise affect the rights and remedies of any party under, the Credit Agreement, nor alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect. This Amendment shall apply and be effective only with respect to the provisions of the Credit Agreement specifically referred to herein. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents.
SECTION 6. Counterparts. This Amendment may be executed in two or more counterparts, each of which shall constitute an original, but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart of a signature page of this Amendment by facsimile transmission shall be as effective as delivery of a manually executed counterpart of this Amendment.
SECTION 7. Headings. Section headings used herein are for convenience of reference only, are not part of this Amendment and are not to affect the construction of, or to be taken into consideration in interpreting, this Amendment.
3
IN WITNESS WHEREOF, the Borrower and the undersigned Lenders have caused this Amendment to be duly executed by their duly authorized officers, all as of the date first above written.
SELECT MEDICAL CORPORATION, | ||||||
by:
|
/s/ Michael E. Tarvin
Name: Michael E. Tarvin Title: Senior Vice President |
|||||
CANADIAN BACK INSTITUTE
LIMITED, |
||||||
by:
|
/S/ Michael E. Tarvin
Name: Michael E. Tarvin Title: Vice President |
|||||
THE CHASE MANHATTAN BANK,
individually and as US Agent and US Collateral Agent, |
||||||
by:
|
/s/ Dawn Lee Lum
Name: Dawn Lee Lum Title: Vice President |
|||||
THE CHASE MANHATTAN BANK OF
CANADA, individually and as Canadian Agent and Canadian Collateral Agent, |
||||||
by:
|
/s/ Christine Chan
Name: Christine Chan Title: Vice President |
|||||
by:
|
/s/ Drew McDonald
Name: Drew McDonald Title: Vice President |
4
To approve the Fourth Amendment
dated as of October 5, 2001 (the Amendment) to the Select Medical Corporation Credit Agreement dated as of September 22, 2000: |
||||
Name of Institution: | ||||
CIBC Inc.
|
||||
by |
/s/ Terence Moore
Name: Terence Moore Title: Executive Director |
5
To approve the Fourth Amendment
dated as of October 5, 2001 (the Amendment) to the Select Medical Corporation Credit Agreement dated as of September 22, 2000: |
||||
Name of Institution: | ||||
First Union National Bank
|
||||
by |
/s/ Jeanette A. Griffin
Name: Jeanette A. Griffin Title: Vice President |
6
To approve the Fourth Amendment
dated as of October 5, 2001 (the Amendment) to the Select Medical Corporation Credit Agreement dated as of September 22, 2000: |
||||
Name of Institution: | ||||
KZH Cypress Tree-1 LLC
|
||||
by |
/s/ Susan Lee
Name: Susan Lee Title: Authorized Agent |
7
To approve the Fourth Amendment
dated as of October 5, 2001 (the Amendment) to the Select Medical Corporation Credit Agreement dated as of September 22, 2000: |
||||
Name of Institution: |
||||
KZH Sterling LLC
|
||||
by |
/s/ Susan Lee
Name: Susan Lee Title: Authorized Agent |
8
To approve the Fourth Amendment
dated as of October 5, 2001 (the Amendment) to the Select Medical Corporation Credit Agreement dated as of September 22, 2000: |
||||
Name of Institution: | ||||
Merrill Lynch Capital Corp.
|
||||
by |
/s/ Carol J.E. Feeley
Name: Carol J.E. Feeley Title: Vice President |
9
To approve the Fourth Amendment
dated as of October 5, 2001 (the Amendment) to the Select Medical Corporation Credit Agreement dated as of September 22, 2000: |
||||
Name of Institution: | ||||
PNC Bank, National Association
|
||||
by |
/s/ Marie T. Boyer
Name: Marie T. Boyer Title: Vice President |
10
To approve the Fourth Amendment
dated as of October 5, 2001 (the Amendment) to the Select Medical Corporation Credit Agreement dated as of September 22, 2000: |
||||
Name of Institution: | ||||
Morgan Guaranty Trust Co.
|
||||
by |
/s/ Dawn Lee Lum
Name: Dawn Lee Lum Title: Vice President |
11
To approve the Fourth Amendment
dated as of October 5, 2001 (the Amendment) to the Select Medical Corporation Credit Agreement dated as of September 22, 2000: |
||||
Name of Institution: | ||||
Societe Generale
|
||||
by |
/s/ Richard Bernal
Name: Richard Bernal Title: Director Corporate Banking |
Exhibit 10.61
SELECT MEDICAL CORPORATION
4716 Old Gettysburg Road P.O. Box 2034
Mechanicsburg, Pennsylvania 17055
November 21, 2001
Mr. David W. Cross
Select Medical Corporation
7733 Forsyth Boulevard
Suite 800
St. Louis, MO 63105
Re: Agreement in the Event of a Change of Control of SMC
Dear Mr. Cross:
The following will confirm the agreement of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.
In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this letter (this Letter Agreement), the Company and you hereby agree, intending to be legally bound hereby, as follows:
1. Covered Termination. A Covered Termination shall be deemed to occur if (i) within the five-year period immediately following a Change of Control (as defined below), (a) your employment with the Company is terminated by the Company without Cause (as defined below), (b) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (c) you are required to be based anywhere other than the Companys executive offices in (or within 25 miles of) St. Louis, Missouri (except for required travel on the Companys business to an extent substantially consistent with your business travel obligations prior to the Change of Control), (ii) within the six-month period immediately following a Change of Control, you terminate your employment with the Company for Good Reason (as defined below), or (iii) within the six-month period preceding a Change of Control, your employment is terminated by the Company other than for Cause, and you reasonably demonstrate that such termination of employment was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control.
2. Payments Upon a Covered Termination. If a Covered Termination occurs, then (i) the Company agrees that such termination is not a voluntary termination or a termination for cause as contemplated by any of the Companys stock option or other incentive plans and any stock option or other award agreements entered into between you and the Company (including agreements that may be entered into in the future in connection with additional awards granted pursuant to any
Company plan, the Award Agreements) and the Company agrees that all unvested, unexercised stock options held by you which were granted to you by the Company shall become fully vested and exercisable as of the date of the Covered Termination and you will have the right to exercise, at any time prior to the earlier of three months after the date of termination or the expiration date of such option, all such options to purchase the Companys stock notwithstanding any contrary vesting schedule that may be contained in the applicable plan or Award Agreement, and (ii) the Company will, on or before your last day as an employee of the Company, pay to you, in lieu of any other rights to cash compensation other than the payment of your salary for services performed before the date of termination and as a severance benefit, a lump sum cash payment equal to your total base salary plus bonus compensation from the Company for the preceding three years (or, if you shall have been employed for less than three years, an amount equal to three times your average total annual cash compensation for base salary and bonus for your years of service to the Company).
3. Definitions.
(a) Change of Control.
(i) A Change of Control shall be deemed to have occurred if, subject to Section 3(a)(ii) below, (i) any person including a group, but excluding any stockholder of the Company who immediately prior to the Public Offering (as defined below) beneficially owned 12% or more of the Companys outstanding shares, becomes the beneficial owner of shares of the Company having more than 50% of the total number of votes that may be cast for the election of directors of the Company, (ii) any person including a group, other than you or any group of which you are a party, increases its beneficial ownership of shares of the Company beyond such persons ownership immediately after the Public Offering by a number of shares equal to or greater than 33% of the total number of votes that may be cast for the election of directors; (iii) the individuals who serve on the Board of Directors of the Company as of the effective date hereof (the Incumbent Directors) cease for any reason to constitute at least a majority of the Board of Directors of the Company; provided, however, any person who becomes a director subsequent to the effective date hereof, whose election or nomination for election was approved by a vote of at least a majority of the directors then constituting the Incumbent Directors, shall for purposes of this clause (iii) be considered an Incumbent Director; (iv) the consummation of a merger or consolidation of the Company in which the stockholders of the Company immediately prior to such merger or consolidation, would not, immediately after the merger or consolidation, beneficially own, directly or indirectly, shares representing in the aggregate more than 50% of the combined voting power of the voting securities of the corporation issuing cash or securities in the merger or consolidation (or of its ultimate parent corporation, if any); or (v) there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Companys assets (on a consolidated basis), other than a sale or disposition by the Company of all or substantially all of the Companys assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale.
(ii) Notwithstanding the foregoing, in no event shall a Change of Control be deemed to occur for purposes of this Letter Agreement unless the total consideration for the transaction or transactions which would, absent this clause (iii), constitute a Change of Control, has a value that is equal to or greater than $6.51 per share of common stock of the Company (the Minimum Value); provided that such Minimum Value shall be adjusted to reflect changes to such common
-2-
stock in the event of a stock dividend, stock split, reverse stock split, stock combination, reclassification, recapitalization, or other similar change in the structure or capitalization of the Company, or any other event which in the discretion of the Board of Directors of the Company necessitates such an adjustment.
(iii) For purposes of this Section 3(a), (A) the terms person, group, beneficial owner, and beneficially own have the same meanings as such terms under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, (B) the term Public Offering shall mean the consummation of the first public offering of shares of common stock of the Company in a firm commitment underwritten offering registered under the Securities Act of 1933, as amended, on Form S-1 or its successor forms, and (C) the term voting securities shall mean securities, the holders of which are ordinarily, in the absence of contingencies, entitled to elect the corporate directors (or persons performing similar functions).
(b) Cause. For purposes of this Letter Agreement, Cause shall mean (i) your willful and continued failure to substantially perform your duties hereunder (other than any such failure resulting from incapacity due to physical or mental illness); (ii) your engaging in willful or reckless misconduct which is demonstrably and materially injurious to the Company, monetarily or otherwise; or (iii) your conviction of a felony involving moral turpitude; provided that an act, or failure to act, on your part shall be considered willful or reckless only if done, or omitted to be done, by you not in good faith and without a reasonable belief that his action or omission was in the best interest of the Company. Your employment shall not be deemed to have been terminated for Cause unless the Company shall have given or delivered to you (i) reasonable notice setting forth the reasons for the Companys intention to terminate your employment for Cause; (ii) an opportunity to cure any such breach during the 30-day period after your receipt of such notice; (iii) a reasonable opportunity, at any time during the 30-day period after your receipt of such notice, together with your counsel, to be heard before the Board of Directors; and (iv) a notice of termination stating that, in the good faith opinion of not less than a majority of the entire membership of the Board of Directors of the Company, you are guilty of the conduct set forth in any of clauses (i), (ii) or (iii) of the definition of Cause above.
(c) Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control.
4. Additional Payments.
(a) If all, or any portion, of the payments or other benefits provided under any section of this Agreement, either alone or together with other payments and benefits that you receive or are entitled to receive from the Company or its affiliates, (whether or not under an existing plan, arrangement or other agreement) (collectively the Payments) would constitute an excess parachute payment within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the Code) and would result in the imposition on you of an excise tax under Section 4999 of the Code, (such excise tax, together with any interest and penalties related thereto, are hereinafter collectively referred to as the Excise Tax) then, in addition to any other benefits to which you are entitled under this Agreement, you will be entitled to receive an additional payment (a Gross-Up Payment) in cash,
-3-
in an amount such that after you pay all taxes including, without limitation, (i) any income taxes (and any interest and penalties imposed with respect thereto) and (ii) any Excise Tax, imposed upon the Gross-Up Payment, you will retain an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Unless you and the Company otherwise agree in writing, any determination required under this Section 4, including without limitation, the amount of payments under this Article 6 (the Parachute Gross-up) shall be computed and made in writing by the Employers then independent public accountants (the Accountants), whose determination shall be, subject to the Employees reasonable approval of the calculations required under this Article 6, conclusive and binding upon the Employee and the Employer for all purposes. For purposes of making the calculations required by this Section 4, the Accountants may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999 of the Code. You and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 4.
(b) As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accountants hereunder, it is possible that (i) Gross-Up Payments which will not have been made by the Company should have been made (an Underpayment), consistent with the calculations required to be made hereunder or that (ii) Gross-Up Payments that have been made will be determined to have been in excess of the Gross-Up Payments actually required (an Overpayment). In the event that you are required to make a payment of any Excise Tax, the Accountants shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for your benefit. In the event that it is finally determined that an Overpayment has occurred, you will promptly, and in any event within 30 days of such determination, refund the amount of the Overpayment, plus any interest actually paid to you with respect to the Overpayment, to the Company. The Company shall have the right with respect to the determination of either an Underpayment or an Overpayment to you to appeal the assertion of any Underpayment or to claim, and sue for, a refund of any Excise Tax paid by you upon any Payment or Gross-Up Payment, provided that the Company shall promptly reimburse you for all expenses, including counsel and accounting fees, incurred in connection with any such proceeding. Alternatively, the Company may undertake any such proceeding, and you shall cooperate with the Company in any such proceeding.
5. Miscellaneous.
(a) The Company will require any purchaser of all or substantially all of the assets of the Company, by agreement in form and substance reasonably satisfactory to you, to expressly assume and agree to perform this Letter Agreement in the same manner and to the same extent that the Company would be required to perform it if no such purchase had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Letter Agreement and shall entitle you to compensation from the Company in the same amount and on the same terms as you would be entitled hereunder if a Covered Termination had occurred. As used in this Letter Agreement, Company shall mean the Company as hereinbefore defined and any purchaser of its assets as aforesaid which executed and delivers the agreement provided for herein.
-4-
(b) This Letter Agreement shall remain in effect for so long as you are employed by the Company. This Letter Agreement may not be modified or waived except in writing and agreed to by the Company and you. This Letter Agreement shall be governed by the laws of the Commonwealth of Pennsylvania and shall inure to the benefit of your heirs.
(c) The Company represents that this Letter Agreement has been duly authorized and is binding on and enforceable against the Company. The invalidity or unenforceability of any provision of this Letter Agreement shall not affect the validity or enforceability of any other provision, which shall remain in full force and effect.
(d) Upon payment of the amount required under paragraph 1 hereof, you shall deliver to the Company a general release of liability of the Company and its officers and directors in a form reasonably satisfactory to the Company.
(e) All payments made pursuant to this Letter Agreement shall be subject to withholding of applicable deductions and income and employment taxes.
(f) Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by facsimile transmission or sent by certified, registered or express mail, postage prepaid. Any such notice shall be deemed given when so delivered personally or sent by facsimile transmission or, if mailed, five days after the date of deposit in the United States mails to the following addresses:
If to Employee:
David W. Cross
10 Lindworth Drive
St. Louis, MO 63124
If to the Company:
Select Medical Corporation
4716 Old Gettysburg Road
Mechanicsburg, PA 17055
Attention: General Counsel
6. Claims Procedure. Any claim for benefits under this Letter Agreement by you shall be made in writing and sent to the Company at its principal offices in Mechanicsburg, Pennsylvania, or such other place as the Company shall hereafter designate in writing. If you, or any beneficiary following your death (collectively, the Claimant), believes he or she has been denied any benefits or payments under this Letter Agreement, either in total or in an amount less than the full benefit or payment to which the Claimant would normally be entitled, the Company shall advise the Claimant in writing of the amount of the benefit, or payment, if any, and the specific reasons for the denial within thirty (30) days of the receipt of the Claimants claim. The Company shall also furnish the Claimant at that time with a written notice containing:
-5-
(a) A specific reference to pertinent provisions of this Letter Agreement;
(b) A description of any additional material or information
necessary for the Claimant to perfect the claim if possible, and
an explanation of why such material or information is needed; and
(c) An explanation of the claim review procedure set forth in this Section 6.
Within sixty (60) days of receipt of the information described above, the Claimant shall, if further review is desired, file a written request of reconsideration of the Companys decision with the Appeal Committee. The Appeal Committee shall consist of those individuals who were serving as the Compensation Committee of the Board of Directors of the Company immediately prior to the Change of Control. The Appeal Committee shall select from its membership a chairperson and a secretary and may adopt such rules and procedures as it deems necessary to carry out its functions. In the event any individual is unable to serve on the Appeal Committee, then the chairperson of the Appeal Committee shall appoint a successor provided such successor must have been a member of the Board of Directors of the Company prior to the Change of Control (Prior Board Member). So long as the Claimants request for review is pending with the Appeal Committee (including such 60-day period), the Claimant, or his duly authorized representative, may review pertinent documents and may submit issues and comments in writing to the Appeal Committee. A final and binding decision shall be made by the Appeal Committee within thirty (30) days of the filing by the Claimant of the request for reconsideration. The Appeal Committees decision shall be conveyed to the Claimant in writing and shall include specific reasons for the decision and specific references to the pertinent provisions of this Letter Agreement on which the decision is based. The Appeal Committee shall discharge its duties under this claims procedure in accordance with the fiduciary standards of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and in doing so, to the extent permitted by law, shall be indemnified and held harmless by the Company (to the extent not indemnified or saved harmless under any liability insurance or other indemnification arrangement with the Company) for or against all liability to which the Appeal Committee may be subjected by reason of any act done in good faith with respect to the adjudication of any claim under this Letter Agreement, including reasonable expenses. Notwithstanding anything to the contrary herein contained, the Claimant shall be entitled to submit his or her claim for determination to any court having competent jurisdiction regardless of whether he or she has first exercised his or her right to have the Companys decision reconsidered by the Appeal Committee.
7. Entire Agreement. This writing represents the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, written or oral, with respect thereto. This Agreement may not be altered or amended except by an agreement in writing.
-6-
Please indicate your acceptance of the above agreement by signing below in the space indicated.
Very truly yours, | ||||
SELECT MEDICAL CORPORATION
, a Delaware
corporation |
||||
By:
|
/s/ Robert A. Ortenzio | |||
|
Robert A. Ortenzio, President |
|||
Agreed to and accepted: | ||||
/s/ David W. Cross | ||||
|
||||
David W. Cross |
-7-
Exhibit 12.1
Ratio of Earnings to Fixed Charges
Year Ended December 31,
2001
2000
1999
1998
1997
(dollars in
thousands)
$
50,519
$
26,082
$
(819
)
$
(16,482
)
$
3,255
29,716
36,126
21,461
5,382
183
19,810
18,394
8,899
2,865
450
5,397
4,516
3,428
1,094
74
4,120
16,110
13,874
2,515
445
$
59,043
$
75,146
$
47,662
$
11,856
$
1,152
$
105,442
$
85,118
$
32,969
$
(7,141
)
$
3,962
1.79
1.13
(B)(C
)
(B)(C
)
3.44
(A) | The preferred stock dividend requirements of consolidated subsidiaries is included in fixed charges (i.e., the denominator of the ratio calculation) but excluded from the numerator of the ratio calculation because such amount was not deducted in arriving at the pre-tax income (loss) from continuing operations, as defined. | |
(B) | Due to the Company's losses in 1998 and 1999, the ratio coverage was less than 1:1. The Company would have had to generate additional earnings of approximately $19.0 million and $14.7 million in 1998 and 1999, respectively, to achieve a coverage ratio of 1:1. | |
(C) | Included in earnings for 1998 and 1999 were special charges of $10.2 million and $5.2 million, respectively, relating to asset impairments and litigation settlement costs. If such charges were not taken the Company would have needed to generate additional earnings of $8.8 million and $9.5 million in 1998 and 1999, respectively, to achieve a coverage ratio of 1:1. |
Exhibit 21.1
Subsidiaries
U.S. Subsidiaries
State of Incorporation
Abel Center for Rehabilitation Therapies, Inc.
Oregon
Affiliated Physical Therapists, Ltd.
Arizona
Allegany Hearing and Speech, Inc.
Maryland
American Transitional Hospitals, Inc.
Delaware
Athens Sport Medicine Clinic, Inc.
Georgia
Ather Sports Injury Clinic, Inc.
California
Atlantic Health Group, Inc.
Delaware
Atlantic Rehabilitation Services, Inc.
New Jersey
Boca Rehab Agency, Inc.
Delaware
Buendel Physical Therapy, Inc.
Florida
C.E.R. West, Inc.
Michigan
CCISUB, Inc.
North Carolina
CMC Center Corporation
California
Cenla Physical Therapy & Rehabilitation Agency, Inc.
Louisiana
Center for Evaluation & Rehabilitation, Inc.
Michigan
Center for Physical Therapy and Sports Rehabilitation, Inc.
New Mexico
CenterTherapy, Inc.
Minnesota
Champion Physical Therapy, Inc.
Pennsylvania
C.O.A.S.T. Institute Physical Therapy, Inc.
California
Connecticut NovaCare Ventures, Inc.
Connecticut
Coplin Physical Therapy Associates, Inc.
Minnesota
Crowley Physical Therapy Clinic, Inc.
Louisiana
Douglas Avery & Associates, Ltd.
Virginia
Elk County Physical Therapy, Inc.
Pennsylvania
Fine, Bryant & Wah, Inc.
Maryland
Francis Naselli, Jr. & Stewart Rich Physical Therapists, Inc.
Pennsylvania
Gallery Physical Therapy Center, Inc.
Minnesota
Georgia NovaCare Ventures, Inc.
Georgia
Georgia Physical Therapy of West Georgia, Inc.
Georgia
Georgia Physical Therapy, Inc.
Georgia
Greater Sacramento Physical Therapy Associates, Inc.
California
Grove City Physical Therapy and Sports Medicine, Inc.
Pennsylvania
Gulf Breeze Physical Therapy, Inc.
Florida
Gulf Coast Hand Specialists, Inc.
Florida
Hand Therapy and Rehabilitation Associates, Inc.
California
Hand Therapy Associates, Inc.
Arizona
Hangtown Physical Therapy, Inc.
California
-1-
U.S. Subsidiaries
State of Incorporation
Hawley Physical Therapy, Inc.
California
Hudson Physical Therapy
Services, Inc.
New Jersey
Human Performance and Fitness, Inc.
California
Indianapolis Physical Therapy and Sports Medicine, Inc.
Indiana
Intensiva Healthcare Corporation
Delaware
Intensiva Hospital of Greater St. Louis, Inc.
Missouri
Joyner Sports Science Institute, Inc.
Pennsylvania
Joyner Sportsmedicine Institute, Inc.
Pennsylvania
Kentucky Rehabilitation Services, Inc.
Kentucky
Lynn M. Carlson, Inc.
Arizona
Mark Butler Physical Therapy Center, Inc.
New Jersey
Metro Rehabilitation Services, Inc.
Michigan
Metro Therapy, Inc.
New York
Michigan Therapy Centre, Inc.
Michigan
MidAtlantic Health Group, Inc.
Delaware
Monmouth Rehabilitation, Inc.
New Jersey
New England Health Group, Inc.
Massachusetts
New Mexico Physical Therapists, Inc.
New Mexico
Northside Physical Therapy, Inc.
Ohio
NovaCare Occupational Health Services, Inc.
Delaware
NovaCare Outpatient Rehabilitation East, Inc.
Delaware
NovaCare Outpatient Rehabilitation of California
California
NovaCare Outpatient Rehabilitation, Inc.
Kansas
NovaCare Outpatient Rehabilitation West, Inc.
Delaware
NovaCare Rehabilitation, Inc.
Minnesota
Ortho Rehab Associates, Inc.
Florida
P.T. Services Company
Ohio
P.T. Services, Inc.
Ohio
P.T. Services Rehabilitation,
Inc.
Ohio
Peter Trailov R.P.T. Physical
Therapy Clinic, Orthopedic Rehabilitation & Sports Medicine,
Ltd.
Illinois
Physical Rehabilitation Partners, Inc.
Louisiana
Physical Therapy Enterprises, Inc.
Arizona
Physical Therapy Institute, Inc.
Louisiana
Physical Therapy Services of the Jersey Cape, Inc.
New Jersey
Physio-Associates, Inc.
Pennsylvania
Pro Active Therapy of Ahoskie, Inc.
North Carolina
Pro Active Therapy of Gaffney, Inc.
South Carolina
-2-
U.S. Subsidiaries
State of Incorporation
Pro Active Therapy of Greenville, Inc.
North Carolina
Pro Active Therapy of North Carolina, Inc.
North Carolina
Pro Active Therapy of Rocky Mount, Inc.
North Carolina
Pro Active Therapy of South Carolina, Inc.
South Carolina
Pro Active Therapy of Virginia, Inc.
Virginia
Pro Active Therapy, Inc.
North Carolina
Professional Therapeutic Services, Inc.
Ohio
Quad City Management, Inc.
Iowa
RCI (Colorado), Inc.
Delaware
RCI (Exertec), Inc.
Delaware
RCI (Michigan), Inc.
Delaware
RCI (S.P.O.R.T.), Inc.
Delaware
RCI (WRS), Inc.
Delaware
RCI Nevada, Inc.
Delaware
Rebound Oklahoma, Inc.
Oklahoma
Redwood Pacific Therapies, Inc.
California
Rehab Advantage, Inc.
Delaware
Rehab Managed Care of Arizona, Inc.
Delaware
Rehab Provider Network California, Inc.
California
Rehab Provider Network East I, Inc.
Delaware
Rehab Provider Network East II, Inc.
Maryland
Rehab Provider Network Georgia, Inc.
Georgia
Rehab Provider Network Indiana, Inc.
Indiana
Rehab Provider Network Michigan, Inc.
Michigan
Rehab Provider Network New Jersey, Inc.
New Jersey
Rehab Provider Network Ohio, Inc.
Ohio
Rehab Provider Network Oklahoma, Inc.
Oklahoma
Rehab Provider Network Pennsylvania, Inc.
Pennsylvania
Rehab Provider Network Virginia, Inc.
Virginia
Rehab Provider Network Washington, D.C., Inc.
District of Columbia
Rehab Provider Network of Colorado, Inc.
Colorado
Rehab Provider Network of Florida, Inc.
Florida
Rehab Provider Network of Nevada, Inc.
Nevada
Rehab Provider Network of New Mexico, Inc.
New Mexico
Rehab Provider Network of North Carolina, Inc.
North Carolina
Rehab Provider Network of Texas, Inc.
Texas
Rehab Provider Network of Wisconsin, Inc.
Wisconsin
Rehab World, Inc.
Delaware
Rehab/Work Hardening Management Associates, Ltd.
Pennsylvania
RehabClinics (GALAXY), Inc.
Illinois
RehabClinics (New Jersey), Inc.
Delaware
RehabClinics (PTA), Inc.
Delaware
RehabClinics (SPT), Inc.
Delaware
-3-
U.S. Subsidiaries
State of Incorporation
RehabClinics Abilene, Inc.
Delaware
RehabClinics Dallas, Inc.
Delaware
RehabClinics Pennsylvania, Inc.
Pennsylvania
RehabClinics, Inc.
Delaware
S.T.A.R.T., Inc.
Massachusetts
Select Air Corporation
Delaware
Select Employment Services, Inc.
Delaware
Select Hospital Investors, Inc.
Delaware
SelectMark, Inc.
Delaware
Select Medical of Kentucky, Inc.
Delaware
Select Medical of Maryland, Inc.
Delaware
Select Medical of New Jersey, Inc.
Delaware
Select Medical of New York, Inc.
Delaware
Select Medical of Ohio, Inc.
Delaware
Select Medical of Pennsylvania, Inc.
Delaware
Select Rehabilitation
Management Services, Inc.
Delaware
Select Specialty Hospital Akron, Inc.
Missouri
Select Specialty Hospital Akron II, Inc.
Delaware
Select Specialty Hospital Ann Arbor, Inc.
Missouri
Select Specialty Hospital Battle Creek, Inc.
Missouri
Select Specialty Hospital Beech Grove, Inc.
Missouri
Select Specialty Hospital Biloxi, Inc.
Mississippi
Select Specialty Hospital Bloomington, Inc.
Delaware
Select Specialty Hospital Central Detroit, Inc.
Delaware
Select Specialty Hospital Charleston, Inc.
Delaware
Select Specialty Hospital Cincinnati, Inc.
Missouri
Select Specialty Hospital Columbus, Inc.
Delaware
Select Specialty Hospital Columbus/University, Inc.
Missouri
Select Specialty Hospital Dallas, Inc.
Delaware
Select Specialty Hospital Denver, Inc.
Delaware
Select Specialty Hospital Durham, Inc.
Delaware
Select Specialty Hospital Erie, Inc.
Delaware
Select Specialty Hospital Evansville, Inc.
Missouri
Select Specialty Hospital Flint, Inc.
Missouri
Select Specialty Hospital Fort Smith, Inc.
Missouri
Select Specialty Hospital Fort Wayne, Inc.
Missouri
Select Specialty Hospital Greensburg, Inc.
Delaware
Select Specialty Hospital Houston, Inc.
Delaware
Select Specialty Hospital Indianapolis, Inc.
Delaware
Select Specialty Hospital Jackson, Inc.
Delaware
Select Specialty Hospital Johnstown, Inc.
Missouri
Select Specialty Hospital Kansas City, Inc.
Missouri
Select Specialty Hospital Knoxville, Inc.
Delaware
Select Specialty Hospital Little Rock, Inc.
Delaware
Select Specialty Hospital Louisville, Inc.
Delaware
-4-
U.S. Subsidiaries
State of Incorporation
Select Specialty Hospital Macomb County, Inc.
Missouri
Select Specialty Hospital Memphis, Inc.
Delaware
Select Specialty Hospital Mesa, Inc.
Delaware
Select Specialty Hospital Milwaukee, Inc.
Delaware
Select Specialty Hospital Morgantown, Inc.
Delaware
Select Specialty Hospital Nashville, Inc.
Delaware
Select Specialty Hospital New Orleans, Inc.
Delaware
Select Specialty Hospital North Knoxville, Inc.
Missouri
Select Specialty Hospital Northwest Detroit, Inc.
Delaware
Select Specialty Hospital Northwest Indiana, Inc.
Missouri
Select Specialty Hospital Oklahoma City/East Campus, Inc.
Missouri
Select Specialty Hospital Oklahoma City, Inc.
Delaware
Select Specialty Hospital Omaha, Inc.
Missouri
Select Specialty Hospital Philadelphia/AEMC, Inc.
Missouri
Select Specialty Hospital Phoenix, Inc.
Delaware
Select Specialty Hospital Pittsburgh, Inc.
Missouri
Select Specialty Hospital Pontiac, Inc.
Missouri
Select Specialty Hospital Reno, Inc.
Missouri
Select Specialty Hospital Saginaw, Inc.
Delaware
Select Specialty Hospital San Antonio, Inc.
Delaware
Select Specialty Hospital Sarasota, Inc.
Delaware
Select Specialty Hospital Sioux Falls, Inc.
Missouri
Select Specialty Hospital
South Dallas, Inc.
Delaware
Select Specialty Hospital Topeka, Inc.
Missouri
Select Specialty Hospital TriCities, Inc.
Delaware
Select Specialty Hospital Tulsa, Inc.
Delaware
Select Specialty Hospital West Columbus, Inc.
Delaware
Select Specialty Hospital Western Michigan, Inc.
Missouri
Select Specialty Hospital Wichita, Inc.
Missouri
Select Specialty Hospital Wilmington, Inc.
Missouri
Select Specialty Hospital Wyandotte, Inc.
Delaware
Select Specialty Hospital Youngstown, Inc.
Missouri
Select Specialty Hospitals, Inc.
Delaware
Select Synergos, Inc.
Delaware
Select Unit Management, Inc.
Delaware
SLMC Finance Corporation
Delaware
SMC of Florida, Inc.
Delaware
South Jersey Physical Therapy Associates, Inc.
New Jersey
South Jersey Rehabilitation and Sports Medicine Center, Inc.
New Jersey
South Philadelphia
Occupational Health, Inc.
Pennsylvania
Southpointe Fitness Center, Inc.
Pennsylvania
Southwest Emergency Associates, Inc.
Arizona
Southwest Physical Therapy, Inc.
New Mexico
Southwest Therapists, Inc.
New Mexico
Sports & Orthopedic Rehabilitation Services, Inc.
Florida
Sports Therapy and Arthritis Rehabilitation, Inc.
Delaware
-5-
U.S. Subsidiaries
State of Incorporation
Star Physical Therapy, Inc.
Florida
Stephenson-Holtz, Inc.
California
The Center for Physical Therapy and Rehabilitation, Inc.
New Mexico
The Orthopedic Sports and
Industrial Rehabilitation Network, Inc.
Pennsylvania
Treister, Inc.
Ohio
Valley Group Physical Therapists, Inc.
Pennsylvania
Vanguard Rehabilitation, Inc.
Arizona
Victoria Healthcare, Inc.
Florida
Wayzata Physical Therapy Center, Inc.
Minnesota
West Penn Rehabilitation Services, Inc.
Pennsylvania
West Side Physical Therapy, Inc.
Ohio
West Suburban Health Partners, Inc.
Minnesota
Yuma Rehabilitation Center, Inc.
Arizona
-6-
Canadian Subsidiaries
Province of Incorporation
Canadian Back Institute Limited
Ontario
1263568 Ontario Limited
Ontario
Dynamic Rehabilitation, Inc.
Ontario
Eastern Rehabilitation, Inc.
Ontario
Rehab Health, Inc.
Ontario
S.T.A.R. Rehab, Inc.
Saskatchewan
S.T.A.R. Rehab (North Battleford), Inc.
Saskatchewan
U.S. Partnerships and Limited Liability Companies
State of Formation
Avalon Rehabilitation & Healthcare, LLC
Delaware
G.P. Therapy L.L.C.
Georgia
Kentucky Orthopedic Rehabilitation, LLC
Delaware
Medical Information Management Systems, LLC
Delaware
Millennium Rehab Services,
L.L.C.
Delaware
NovaCare Health Group, LLC
Delaware
NW Rehabilitation Associates, L.P.
Delaware
Rehab Advantage Therapy Services, LLC
Delaware
Select Management Services, LLC
Delaware
Select Houston Partners, L.P.
Delaware
Select Software Ventures, LLC
Delaware
Select Specialty Hospital Camp Hill, L.P.
Delaware
TJ Corporation I, L.L.C.
Delaware
TJ Partnership I
Florida
Canadian Limited Partnerships
Province of Declaration of Partnership
CBI Barrie Limited Partnership
Ontario
CBI Burnaby Limited Partnership
Ontario
CBI Cambridge Limited Partnership
Ontario
CBI Edmonton Limited Partnership
Ontario
CBI Gatineau Limited Partnership
Ontario
CBI Kitchener Limited Partnership
Ontario
CBI Lethbridge Limited Partnership
Ontario
CBI London East Limited Partnership
Ontario
CBI London Limited Partnership
Ontario
CBI Mississauga Limited Partnership
Ontario
CBI Montreal Limited Partnership
Ontario
CBI Niagara Limited Partnership
Ontario
CBI Ottawa Limited Partnership
Ontario
CBI Ottawa West Limited Partnership
Ontario
CBI Port Coquitlam Limited Partnership
Ontario
CBI Regina Limited Partnership
Ontario
CBI Richmond Limited Partnership
Ontario
-7-
CBI Sarnia Limited Partnership
Ontario
CBI St. Clair West Limited Partnership
Ontario
CBI Sudbury Limited Partnership
Ontario
Surrey Limited Partnership
Ontario
CBI Windsor Limited Partnership
Ontario
-8-
Exhibit 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in the
Registration Statement on Form S-8 (No. 333-58424) of
Select Medical Corporation of our report dated February 15,
2002 relating to the financial statements, which appears in this
Annual Report on Form 10-K. We also consent to the
incorporation by reference of our report dated February 15,
2002 relating to the financial statement schedule, which appears
in this Form 10-K.
PricewaterhouseCoopers LLP
Harrisburg, Pennsylvania